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ABSTRACT

Roles of endothelin 1 in follicular and luteal function
Fernando P. Perea-Ganchou., M.S.
Reproductive activity in mammals is characterized by the recurrent presence of follicles and
corpora lutea (CL) in the ovaries. In addition to the roles of follicles and corpora lutea in
regulating the activity of the hypothalamic–hypophyseal–ovarian axis, those ovarian structures
are responsible to generate a viable female gamete and to provide the appropriate uterine
physiological conditions to sustain the embryo/fetus development during pregnancy. If
fertilization of the oocyte does not occur or pregnancy fails, a new ovarian cycle starts a few
days later, assuring further opportunity for onset of a new gestation. Numerous locally
produced ovarian factors modulate function of follicles and CL. Endothelin 1, a 21-amino acid
peptide produced in the ovary, modulates steroid production by granulosal cells and mediates
luteolytic actions of PGF2 . Three experiments were carried out in order to examine the role of
endothelin in follicular steroid secretion in vitro and in spontaneous and PGF2 -induced
luteolysis in sheep.
In experiment 1, it was hypothesized that endothelin 1 (END1) acting through its receptors
ENDRA and/or ENDRB, on granulosal cells of ovine preovulatory follicles would inhibit
steroid production, and therefore, prevent the premature luteinization of granulosal cells of
those follicles. On day 14 of the estrous cycle (standing estrus = day 0), 17 nonpregnant Suffolk
ewes were injected with 2 doses of PGF2 (5 mg) 3 h apart. Thirty six to 40 hours after the
second dose of PGF2 , ovaries were removed by mid-ventral laparotomy. The 2 or 3 largest
follicles in the ovaries were dissected and granulosal cells were harvested under sterile
conditions. Aliquots of 15 L of granulosal cell suspension from each presumed preovulatory
follicle were cultured in 96-well plates containing a solution of 185 L of Ham’s F12
supplemented medium and treatments (single and combined effects of LH, END1, ENDRA
and ENDRB). Data from estrogen-inactive 20 follicles collected from 13 ewes were analyzed.
Accumulation of E2 and P4 by cultured granulosal cells was not affected by either LH or END1
or the END receptor blockers. Granulosal cells from follicles with the greatest concentration of
E2 in FF produced on the average significantly more E2 and P4 than follicles with lower
concentrations of E2 in FF. In conclusion, END1 did not affect steroid production by granulosal
cells from preovulatory follicles in sheep, and therefore the working hypothesis was not
supported.
In the second experiment, the ENDRA antagonist BQ-610 was delivered into the CL via an
osmotic minipump to examine the expression of genes related with P4 production and
structural luteolysis at 6 and 24 h after exogenous PGF2 . It was hypothesized that sustained
blockade of ENDRA would prevent upregulation of genes stimulated by PGF2 during
structural luteolysis. Minipumps loaded with either vehicle (2:1 methanol/saline solution) or
2.5 mg of BQ-610, were implanted in the mesovarium, with a catheter into a CL, on day 7.5 to
9 of the estrous cycle. A dose of PGF2 (25 mg) or saline was injected 48 h after surgery in all
animals, respectively. Six or 24 h later ewes were euthanized, ovaries were collected and CL
were dissected and stored for later determinations of hormones and gene expression. Data for
luteal weight, and concentrations of serum and luteal P4, mostly at 24 h after PGF2 , indicated

that in 9 of 10 treated ewes, BQ-610 did not prevent luteolysis, and the pattern of gene
expression confirmed this finding. Exogenous PGF2 downregulated expression of StAR,
3 HSD, VEGF, TIMP-1 and eNOS (P ≤ 0.02), whereas it upregulated 20 HSD, MMP-14 Bcl2 (P ≤ 0.03). Expression of Bcl-2 and Bax were reduced and Fas-R was increased from 6 to 24
h after PGF2 . In BQ-610-treated ewes, mRNA expression was upregulated more for 20 HSD,
and caspases 3 and 8 than in vehicle-treated and control ewes. In conclusion, PGF2 induced
luteolysis in both vehicle-treated and BQ-610-treated ewes. Given that in BQ-610-treated ewes,
certain genes related with P4 metabolism and apoptosis were differentially upregulated, the
greater dosage of BQ-610 used in this study, or its combination with methanol may have
activated ENDRA. If so, these findings would confirm that END1 via ENDRA in luteal cells is
associated with structural luteolysis as previously reported.
In the third experiment, it was hypothesized that chronic delivery of BQ-610 into the CL
would prevent luteal regression induced by endogenous PGF2 , thereby increasing length of the
estrous cycle and maintaining functional and structural characteristics of the CL. Ewes were
assigned receive an osmotic mini-pump containing 2 mg of BQ-610 (n = 12) or vehicle (n = 9),
implanted surgically on d 9 of the estrous cycle. Corpora lutea were collected 12 h after onset
of estrus, or on the afternoon of d 21 in ewes that had not returned to estrus, and from untreated
ewes on d 10 to 12 of the estrous cycle (mid-phase CL). Three of 12 BQ-610-treated ewes did
not show estrus before d 21 compared to 0 of 9 vehicle-treated ewes (P = 0.33); CL of the
remaining nine ewes treated with BQ-610 were excluded from further analysis. Estrous cycles
in vehicle-treated ewes averaged 15.5 ± 0.2 d. In the three BQ-610-treated ewes, luteal weights
on d 21were greater than in vehicle-treated ewes on the day of estrus (0.62 ± 0.05 versus 0.39 ±
0.03 g, respectively; P < 0.001), as were luteal contents of P4 (20.9 ± 1.8 versus 1.3 ± 1.0 g/g,
respectively; P < 0.0001). Serum concentrations of P4 in the three BQ-610-treated ewes
remained above 1.5 ng/ml through d 21 (P < 0.01). Their luteal tissue appeared normal with
53.3 ± 5.8% of apoptotic cells, whereas luteal tissue in vehicle-treated ewes was markedly
disorganized and in an advanced stage of structural regression. Expression of mRNA was lower
[3 HDS (P < 0.01), and TIMP-1 (P < 0.01)]; greater [preproEND1 (P < 0.01), END receptor A
(P < 0.01)]; or similar (Bax, Bcl-2, Fas-R) in CL from vehicle-treated than in CL of BQ-610treated ewes or in mid-phase CL. Caspase 3 expression was grater in CL of vehicle-treated an
BQ-610-treated ewes than mid-phase CL. In conclusion, chronic infusion of BQ-610 blocked
luteolysis and lengthened the estrous cycle in 3 of 12 ewes. Furthermore, functional features of
CL of those 3 ewes were similar to mid-phase CL. Overall, these results supported a role for
END1 in luteal regression in sheep.
Key words: luteolysis, progesterone, END1, endothelin receptor type A, BQ-610, gene
expression, sheep
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REVIEW OF LITERATURE

Physiologic aspects of follicular growth

Ovarian follicles are structural and functional entities that play essential physiological roles,
modulating activity of the hypothalamic–pituitary–ovarian (HPO) axis and providing an
appropriate metabolic and endocrine milieu to support the development and maturation of the
oocyte. Eventually they facilitate the release of the oocyte into the oviduct, where fertilization
takes place. Ovarian follicles develop from primordial follicles throughout different
morphological stages that are conducive to attainment of the functional competence to ovulate,
and thus, provide the female gamete required to assure survival of the species. Two follicular
populations of steroidogenic cells (granulosa and theca) interact with each other to produce
estradiol and other hormones necessary to modulate reproductive function (Mann et al., 1992).
Once ovulation occurs, the remnant collapsed follicle gives rise to another essential ovarian
structure, the corpus luteum. If fertilization of the oocyte does not occur, the corpus luteum
undergoes functional demise, and a new group of follicles begins to mature a few days later.
Thus, ovarian follicles are an essential component of reproductive cyclicity.

Preantral follicular development
Primordial follicles are the most elemental follicular structures and consist of an oocyte
surrounded by a single layer of flattened granulosal cells. In domestic animals and primates,
primordial follicles are formed during the embryonic/fetal period, and most of them will
undergo atresia during the first years after birth (Driancourt et al., 1993). For instance, in
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newborn human females, only 400,000 follicles remain in the ovary from 6 to 7 million
follicles present at mid gestation (Gougeon, 1996). The large pool of primordial follicles in the
ovary constitutes a follicular store from which they are activated progressively and grow
through different developmental stages. Most primordial follicles are in a resting stage as a
consequence of local and systemic inhibitory stimuli. Accordingly, in superficial pieces of
ovarian cortex cultured in serum-free conditions, healthy primordial follicles decreased by
88%, 90% and 94% after 2, 4 and 7 days in culture, respectively, whereas healthy primary
follicles increased by 260%, 209% and 197%, respectively, compared with the numbers present
on d 0 (Wandji et al., 1996a). These findings indicated that certain components of the ovarian
stroma may exert inhibitory control in the onset of growth of the primordial follicles (Wandji et
al., 1996a). The initiation of growth of primordial follicles and subsequent development to the
secondary stages can occur in absence of gonadotropins (Wandji et al., 1997). Moreover, the
transition from primordial to primary follicular stage is apparently dependent upon
communication

exchanged

between

the

follicle

and

the

adjacent

cells,

mostly

stromal/interstitial and endothelial cells, which provide both stimulatory and inhibitory signals
(Skinner, 2005). Thus, once stimulatory factors prevail over the inhibitory influences,
primordial follicles start to grow toward subsequent follicular stages (McGee and Hsueh, 2000;
Durlinger et al., 2002; Kezele et al., 2002; 2003; Holt et al., 2006; McNatty et al, 2007).
The transition from primordial to primary follicular stage is a process by which a primordial
follicle increases in size (Wandji et al., 1996a), as granulosal cells proliferate and change in
morphology from flattened to cuboidal (Lundy et al., 1999). As the follicle develops new layers
of granulosa, the size of the follicle cells increase, concomitant with the increment of oocyte
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diameter (Lundy et al., 1999). Numerous factors from local or systemic origin modulate growth
of primary follicles and successive preantral follicular stages (Wandji et al., 1996b; Fortune;
2003; McNatty et al, 2007). Although FSH did not appear to be essential for development of
preantral follicles (Halpin et al., 1996; McNatty et al., 1990), evidence indicated the presence
of FSH receptors in granulosal cells from primary and secondary follicles in ruminants (Wandji
et al., 1992; Tisdall et al., 1995; Xu et al., 1995a; Bao et al., 1997a). FSH and bFGF stimulated
a greater increment of the diameter of bovine preantral follicles than EGF (Wandji et al.,
1996b). Moreover, granulosal cells from preantral follicles treated with FSH produced more
progesterone than control or bFGF- and EGF-treated cells (Wandji et al., 1996b). Thus, it was
evident that FSH as well as other locally produced factors such as insulin, IGF1, GDF9,
BMP15, EGF, activin, and steroids, can modulate the rate of preantral follicle development
(Hulshof et al., 1995; 1997; Gutierrez et al., 2000; Juengel et al., 2002; Souza et al., 2002; Zhao
et al., 2003). In addition, granulosa-oocyte communication appears to be essential for normal
preantral follicular development (McGee and Hsueh, 2000). During the development of
preantral stages, growing oocytes synthesize the zona pellucida, and epithelial cells adjacent to
the follicle differentiate into thecal cells (Driancourt et al., 1993). Although mRNA for LH
receptor has been detected after formation of the theca interna, its role in these early stages of
follicular development has not been elucidated (Bao and Garverick, 1998).

Antral follicular development
At the end of the preantral stage, following formation of the theca interna around the
granulosal cells, thecal cells express mRNA for LH receptor and important steroidogenic
enzymes such as P450scc, P450c17 and 3 HSD as well (Xu et al., 1995a; Xu et al., 1995b; Bao
3

et al., 1997a; Bao et al., 1997b). Around the beginning of the antral stage, granulosal cells start
to express mRNA for 450arom (Xu et al., 1995b). Moreover, P450c17 mRNA was identified
exclusively in thecal cells, while 450arom mRNA was expressed solely in granulosal cells,
while both cell types expressed mRNA for P450scc and 3 HSD (Xu et al., 1995b; Bao et al.,
1997b). So, it was clear that thecal cells had the capacity to synthesize progestins and
androstenedione, whereas granulosal cells from antral follicles synthesized progestins and
estradiol. Therefore, it was suggested that thecal cells under LH stimulus synthesize androgens
and granulosal cells under FSH influence actively aromatize exogenous androgens to estrogens
(Fortune and Armstrong, 1978; Fortune, 1986). Furthermore, granulosal cells produced
considerable amounts of pregnenolone that were used by thecal cells as a precursor of androgen
production (Fortune, 1986), and androgens produced by the theca interna increased the ability
of granulosal cells to synthesize pregnenolone (Fortune, 1986).
Once follicles become progressively gonadotropin-dependent and the metabolic machinery
is expressed completely in steroidogenic cells, follicles start to form a fluid filled cavity or
antrum. According to Webb and Campbell (2007), “antrum formation marks the transition from
a proliferative to a differentiative phenotype for the follicular somatic cells”, which occurs
concomitant with a manifest increase in the rate of follicular atresia and significant changes in
gene expression (Webb et al., 2003). At the beginning of the antral stage, follicular fluid is
synthesized exclusively by thecal cells, and in later stages granulosal cells acquire the
metabolic capacity to synthesize both progestins and estradiol (Bao et al., 1997a; Bao et al.,
1997b).
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Although during the antral developmental stage, gonadotropic stimulus is essential for
normal development of the follicles; other locally produced factors originated from the oocyte
and somatic cells are important autocrine/paracrine modulators of the follicular growth.
Several members of BMP family (BMP 2, 4 and 6) increased FSH-stimulated production of
estradiol and inhibin A by ovine granulosal cells (Souza et al., 2002; Campbell et al., 2006).
Also, BMP 4, 6 and 7 stimulated estradiol, inhibin A, activin A, and follistatin production by
granulosal cells without presence of FSH in the culture media (Gliser et al., 2004). Moreover,
BMP 4, 6 and 7 increased the ability of IGF-I to stimulate secretion of estradiol, inhibin A,
activin A, and follistatin by granulosal cells (Gliser et al., 2004) and suppressed basal and LHstimulated androgen and progesterone production by bovine thecal cells (Gliser et al., 2005).
Also, GDF9, an oocyte derived factor, stimulated proliferation of granulosal and thecal cells
and decreased FSH-/IGF-I- and LH-stimulated steroid production in both cell types,
respectively (Spicer et al., 2006; 2008). The inhibitory effect of GDF9 on androgen production
by thecal cells was associated with a reduction of LH receptor and P450ssc mRNA (Spicer et
al., 2008); whereas, the ability of GDF9 to stimulate thecal cell proliferation was more evident
in small than in large follicles (Spicer et al., 2008). Apparently, the role of GDF9 was to
prevent premature differentiation of both thecal and granulosal cells (Spicer et al., 2006; 2008).
In addition to the previously described factors, estradiol and inhibin are important
modulators of follicular function. Estradiol decreased progesterone production induced by LH,
LH and insulin or LH and IGF-I in thecal cells. In contrast, estradiol had a potent stimulatory
effect on production of androstenedione by thecal cells in either absence or presence of LH, LH
and insulin, or LH and IGF-I (Spicer et al., 2005). So, estrogen synthesized in granulosal cells
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appeared to form part of a paracrine positive feedback mechanism that stimulated further
production of follicular estradiol by increasing androgen production by thecal cells (Spicer et
al., 2005). On the other hand, inhibin, which is produced primarily by granulosal cells, plays
important autocrine and paracrine roles in follicular physiology. Apparently, inhibin limits
follicular estradiol production, because treatment of granulosal cells with an inhibin antibody
increased estradiol production by 2 to 15 fold, compared with controls (Jimenez-Krassel et al.,
2003). Moreover, treatment of granulosal cells isolated from estrogen-active and estrogeninactive dominant follicles and subordinate follicles with anti-inhibin significantly increased
estradiol production, indicating that inhibin was suppressing estradiol production by estrogeninactive and subordinate follicles (Jimenez-Krassel et al., 2003).
In addition to the stimulatory role of FSH and LH in follicular development, two circulating
substances, insulin and IGF-I, play important roles in modulating follicular growth (Spicer et
al., 2002). Insulin and IGF-I increased FSH-stimulated estradiol production by granulosal cells
from either small or large follicles. Likewise, individual or combined treatment of insulin and
IGF-I stimulated basal and FSH-induced proliferation of granulosal cells from small and large
follicles in a dose dependent manner (Spicer et al., 2002). Both IGF-I and IGF-II were locally
identified in granulosa and theca, respectively, from follicles of different morphologic and
functional characteristics (Yuan et al., 1998). Although IGF-II mRNA was detected in bovine
thecal cells from diverse follicular developmental stages, no evidence for IGF-I mRNA
expression was observed at any stage of development (Armstrong et al., 2000). It seems that
IGF-II plays an autocrine role because IGF-II stimulated androstenedione and progesterone
production by thecal cells, and this effect was mediated by IGF type I receptors (Spicer et al.,
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2004). Hence, both IGF-II and IGF-I play significant roles in steroidogenesis during follicular
development.

Follicular selection and dominance
Ruminants have been used intensively in studies of ovarian follicular development.
Particularly in cattle, morphological changes of the follicles during the estrous cycle have been
associated with circulating hormones and functional characteristics of the follicles at different
developmental stages. In addition to the feasibility to perform interesting in vivo studies, sheep
represented a useful model to study aspects of follicular physiology in vitro.
In ruminants, the later stages of antral follicle development occur in waves of follicular
growth. During each reproductive cycle, follicular development was characterized by
recruitment of several small follicles that grew progressively until the stage in which one or
more were selected and continued their development; while the remaining follicles became
smaller and progressively disappeared from the ovarian cortex (Ireland et al., 2000). In
ruminants and other domestic species, emergence of each follicular wave is preceded or
accompanied by a small increment of FSH concentration (Evans, 2003a) followed by
upregulation of P450scc and P450arom in granulosal cells and gonadotropin receptors in
steroidogenic cells (Bao and Garverick, 1998). Thus, the resultant greater steroidogenic
capacity is an important physiological fact that influences the subsequent stages of follicular
development.
Follicular selection is the mechanism by which one or two follicles become morphologically
(greater size) and functionally (greater steroidogenic capacity) dominant (Xu et al., 1995b; Bao
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et al., 1997b) and continue growing toward ovulation. The remaining follicles decreased in size
and underwent atresia, most likely due to down regulation of LH receptor, StAR and
steroidogenic enzymes (Xu et al., 1995a; Xu et al., 1995b; Bao et al., 1998), with the
consequent reduction in estradiol synthesis that preceded apoptosis of granulosal cells (Austin
et al., 2001; Clark et al., 2004). Follicular dominance was associated with greater expression of
mRNA for LH receptor, P450scc, P450c17 and 3 HSD in thecal cells, and P450arom in
granulosal cells, as compared with previous follicular stages (Xu et al., 1995b; Bao et al.,
1997a; Bao et al., 1997b). Dominant follicles (DF) had lower concentrations of IGF binding
proteins (IGFBP) 2, 4, and 5 and greater concentrations of IGF-I than follicles prior to selection
(Mihm et al., 1997; Austin et al., 2001). Likewise, onset of expression of LH receptor and
3 HSD in granulosal cells was a remarkable indicator of the greater steroidogenic capacity of
selected follicles (Bao et al., 1997a; Bao et al., 1997b; Beg et al., 2001), which apparently
switch in gonadotropin dependence from FSH to LH (Mihm et al., 2006). Moreover, follicular
size was highly correlated with concentrations of mRNA for P450arom (r = 0.77) and LH
receptors in theca (r = 0.71) and granulosa (r = 0.54; Bao et al., 1997a). Expression of StAR,
that was observed only in thecal cells, progressively increased as the dominant follicle grew
(Bao et al., 1998), indicating that increasing synthesis of estradiol may require an increment of
cholesterol transport in thecal cells to produce greater amounts of androgen, the substrate
utilized by granulosal cells to synthesize estradiol.
After the transient increase of FSH that precedes the emergence of each follicular wave,
circulating concentrations of FSH decreased progressively within the following 24 h (Mihm et
al., 1997; Austin et al., 2001), probably due to negative feedback exerted by increasing
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amounts of estradiol and inhibin secreted by selected follicles (Kaneko et al., 1997; Ginther et
al., 2000a; Bergfelt et al., 2000). It was suggested that the decrease in circulating
concentrations of FSH after the transient rise is associated with selection or deviation of the DF
and atresia of the remaining subordinate follicles (Adams et al., 1993; Mihm et al., 1997; Beg
et al., 2001). Administration of physiological concentrations of FSH delayed selection of the
DF and subordinate follicles (Mihm et al., 1997). Apparently, follicles with greater amounts of
gonadotropin receptors and steroidogenic capacity (Xu et al., 1995a; Xu et al., 1995b; Bao et
al., 1998a; Bao et al., 1998b; Bao et al., 1998; Beg et al., 2001) were more competent to grow
in an endocrine milieu low in FSH (Mihm et al., 1997; Ginther et al., 1999; Ginther et al.,
2000b). In contrast, subordinate follicles depended on FSH support and the reduced FSH
concentration was a critical event that conferred them with metabolic disadvantages to grow at
the same rate as the DF (Adams et al., 1993). However, subordinated follicles continued
growing if adequate FSH was provided (Adams et al., 1993) or became dominant if the DF was
removed (Ko et al., 1991; Ginther et al., 2001), indicating that they maintained the metabolic
capacity to grow and were able to reach ovulatory status under appropriate endocrine influence.
Evidence indicates that the IGF system is involved in follicular selection and dominance.
The IGF system consists of two ligands (IGF-I and IGF-II), two receptors (IGFR1 and IGFR2),
several IGF binding proteins (IGFBP) and IGFBP proteases (Spicer and Echternkamp, 1995;
Monget et al., 1996). As documented above, IGF ligands play relevant functions in ovarian
follicular development by stimulating granulosal cell proliferation and steroidogenesis (Spicer
et al., 2002). The role of the IGF system in follicular deviation and subsequent dominance has
been described. Using an in situ hybridization approach, IGF-I and IGF-II were detected in
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granulosa and theca, respectively, with a significantly greater abundance in DF than
subordinate follicles in both early- and mid-dominance (Yuan et al., 1998). Also, amounts of
IGFBP2 were lower in DF than subordinate follicles in both follicular stages (Yuan et al.,
1998) and treatment of granulosal cells with FSH decreased IGFBP2 mRNA expression
(Armstrong et al., 1998). In agreement with the previous findings, concentrations of IGF-I in
follicular fluid were greater in the largest than in the smaller follicles (Echternkamp et al.,
1994; Beg et al., 2001). The IGFBP2 concentrations were significantly greater in the largest
compared with the smaller follicles (Beg et al., 2001), coincident with the finding that
proteolytic activity on IGFBP was greater in follicular fluid of estrogen-active than estrogeninactive follicles (Echternkamp et al., 1994; Rivera et al., 2001). Samples of follicular fluid
from the two or three largest follicles collected on d 3 of the estrous cycle indicated that
estradiol was greater and IGFBP4 was lower in the presumptive DF compared with
subordinated follicles (Mihm et al., 2000). Apparently, an increment in the proteolytic activity
on IGFBP and the consequent reduction of IGFBP concentrations in follicular fluid is a
functional feature that distinguishes DF from subordinate follicles. Thus, the increased
bioavailability of IGF-I under an appropriate gonadotropin stimulus mediates the greater
capacity of DF to produce estradiol.
In the ewe, as in the cow, emergence of each follicular wave is preceded by a transient
increase of FSH (Souza et al., 1997; Evans, 2003b). During the estrous cycle, 2 to 4 groups of
follicles grow in a wave-like pattern (Souza et al., 1998; Bartlewski 1999; Evans et al., 2000;
Duggavathi et al., 2003). In the ewe, follicular dominance appears to be less evident than in the
cow (Duggavathi et al., 2004; 2005; Barrett et al., 2006). Although follicular dominance was
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documented in sheep (Lopez-Sebastian et al., 1997; Gonzalez-Bulnes et al., 2001; 2004), recent
authors have questioned the concept of follicular dominance as it occurs in cattle. The presence
of a large estrogen-active growing follicle in the ovary did not prevent the emergence of a new
follicular wave induced by exogenous FSH during the inter-wave FSH nadir (Duggavathi et al.,
2004). In addition, induction of physiological peaks of circulating FSH by exogenous
administration of FSH every 2 to 2.5 d, stimulated the emergence of an extra follicular wave,
but modified neither the occurrence of endogenous FSH peaks nor the subsequent follicular
wave emergence (Duggavathi et al., 2004). Moreover, emergence and development of the
induced follicular wave was not inhibited by the presence of the largest growing follicles
belonging to the preceding endogenous FSH-induced follicular wave (Duggavathi et al., 2005).
Using a different experimental approach, the peak and the amplitude of endogenous FSH was
altered by elevated concentrations of estradiol released from implants placed on d 4 of estrous
cycle (Barrett et al., 2006); as a consequence, emergence of a new follicular wave was
prevented. However, despite supra-physiological concentrations of estradiol, administration of
a physiological dose of FSH restored the emergence of follicles (Barrett et al., 2006). To
support further the previous data, 2 or more large follicles from ultimate and penultimate waves
of the estrous cycle may reach ovulatory status and eventually ovulate simultaneously (Souza et
al., 1997; Bartlewski 1999).
After luteolysis is initiated by uterine PGF2 , concentrations of progesterone drop rapidly
and the negative feedback exerted by this steroid in the hypothalamus and pituitary decline.
The subsequent increased frequency of LH pulses during proestrus stimulates greater secretion
of estradiol by the DF that acts in a positive feedback loop to enhance LH and further estradiol
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secretion (Goodman and Inskeep, 2006). Thus, elevated concentrations of estradiol trigger an
LH/FSH surge (Karsch et al., 1983). Greater mRNA concentrations for P450scc and 3 HSD in
both granulosa and theca and P450-17 -hydroxylase in thecal cells were responsible for the
elevated steroidogenic capacity of preovulatory follicles, mostly by providing substrate for the
aromatization of androgen to estradiol in granulosal cells (Tian et al., 1995). Nevertheless, after
an LH surge, the pattern of steroid secretion from the preovulatory follicle changed abruptly
(Murdoch and Dunn, 1982; Fortune and Hansel, 1985). In the ewe and cow, a remarkable
reduction of estradiol and androgen production followed the LH surge. Likewise, an abrupt
increment in progesterone concentrations and the switch in pregnenolone/progesterone ratio
from 1.6 h prior to LH to 0.18 h after the LH surge was indicated (Murdoch and Dunn, 1982;
Fortune and Hansel, 1985). In addition, the transition in steroid production by preovulatory
follicles from estrogen to progesterone dominance was associated with downregulation of
P450-17 -hydroxylase and P450arom in thecal and granulosal cells, respectively, and
upregulation of progesterone receptor (PR) in the two types of steroidogenic cells (Voss and
Fortune, 1993a; Komar et al., 2001; Jo et al., 2002). Thus, the switch in steroid production by
steroidogenic cells after the LH surge is part of the mechanism of differentiation of granulosal
and thecal cells into large and small luteal cells of the insipient corpus luteum. Moreover, the
amount of PR mRNA increased markedly and transiently in follicular cells of bovine
periovulatory follicles within a few hours after the LH surge, followed by a second increase
near the time of ovulation (Jo et al., 2002). Therefore, the first rise in PR mRNA may be
associated with the sudden and simultaneous increases in follicular production of oxytocin,
prostaglandins, and other important substances for ovulation during the periovulatory period;
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whereas the second rise in progesterone and PR mRNA may play an important role in the
subsequent formation of the CL (Murdoch et al., 1986; Voss and Fortune, 1993a; Voss and
Fortune, 1993b).
The events that characterize follicular growth from the pool of primordial follicles
throughout different developmental stages are summarized in Figure 1. Under appropriate
stimuli by local and systemic hormones and growth factors, one or more large follicles become
morphologically and functionally dominant while others undergo atresia. Ovulation occurs at
the end of the follicular phase, once progesterone declines and increasing amounts of estradiol
produced by the preovulatory follicle trigger the LH/FSH surge.
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Gonadotropin responsive
(FSH); no essential

Gonadotropin
independent

Primordial follicle
(+)
Result of communication between
follicles and adjacent stromal and
interstitial and endothelial cells

(−)

Primary follicle
Constitutive
receptor.

expression

of

FSH

(+)

anti Mullerian hormone (AMH); stroma derived factor 1 (SDF-1)

Intraovarian factors: GDF-9, BMP-15, bFGF, EGF, activin,
inhibin
Extraovarian factors: IGF system, FSH

Preantral follicle
FSH accelerates the rate at which
these follicles grow, but FSH is not
essential.

(+)

Intraovarian factors: GDF-9, BMP-15, bFGF, EGF, activin,
inhibin

Extraovarian factors: IGF system, FSH

Small antral follicle
FSH stimulates E2 production by GC.

Increases mRNA expression of FSH
receptors and P450arom in GC and
LH receptors and P450c17 in TC.

Gonadotropin dependent

bFGF, insulin, BMP-4 and BMP-7, Leukemia inhibitory factor (LIF)

(+)

Intraovarian factors: BMP system, estradiol, inhibin A,
activin A, follistatin, TGF , EGF, IGFI
Extraovarian factors: FSH, insulin and IGF ( number and
quality of gonadotropin responsive follicles)

Large antral follicle
Granulosal cells express LH receptors
and TC increase expression of LH
receptors .

(+)

Subordinate follicle
Intraovarian factors: BMP system, estradiol,
activin A, follistatin, TGF , EGF
Extraovarian factors: FSH, insulin and IGF

Selection

Expression of LHR in GC (Webb and
Campbell, 2007) and/or IGF system
(Fortune et al., 2004) is determinant
for selection of dominant follicle

Dominant follicle
Expression of LH receptors in GC
switch gonadotropin dependence
from FSH to LH. Appropriate pulsatil
LH support appears to be required
to maintain ovulatory competence.

(+)

Ovulatory follicle

LH, insulin and IGF

Atretic follicles

Lack of appropriate LH support switches steroid
production from estrogen and testosterone to
progesterone. The follicle become estrogenically
inactive and apoptosis is initiated in all cellular
compartments of the follicle. Decrease of
intrafollicular estradiol has been shown to precede
apoptosis of GC that activates the controlled
degradation of ECM proteins by of MMPs and of
TIMPs. A reduction of estradiol also increases IGFBP.

Figure 1. Summary of the events that characterize follicular development throughout different
developmental stages in the cow.
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Physiologic aspects of luteal function

After ovulation, the collapsed ovulatory follicle undergoes dramatic cellular and structural
changes that confer to the new ovarian structure, the corpus luteum (CL), endocrine
characteristics aimed to create physiological conditions that favor early embryonic
development, implantation, placentation, and in general, assure success of gestation and
survival of the specie. Thus, the CL constitutes the primary source of circulating progesterone.
However, if fertilization of the oocyte does not occur, CL function decreases and a new
reproductive cycle is initiatea a few days later. This physiological process is known as “corpus
luteum regression” or “luteolysis”. Therefore, CL function is essential in all mammals for
implantation and early maintenance of pregnancy and in the event of an infertile cycle its
disappearance assures further opportunity for onset of a new gestation (Hoyer, 1998).

Morphological characteristics of the corpus luteum
The corpus luteum is a transient, highly vascularized, ovarian tissue that develops in a few
days from a “corpus hemorrhagicus” to a mature CL, producing progressively greater amounts
of progesterone (P4). From morphological and functional points of view, the CL has two
different populations of cells: endocrine and non-endocrine cells that vary in proportion and
number throughout the luteal phase (Rodgers and O'Shea, 1982; O’Shea et al., 1984; Rogers et
al., 1984; Farin et al., 1986). Steroidogenic cells (SC) represent 55% of the cellular volume of
the CL and consist of large (LLC) and small (SLC) luteal cells originated from granulosal and
thecal cells of the ovulatory follicle (Hansel and Dowd, 1986), respectively. Nonsteroidogenic
cells have been identified as fibroblastic, endothelial and immune cells (O’Shea et al., 1984;
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Rogers et al., 1984) and represent around 16% of the volume of the CL, considering that
cellular matrix occupies 27% (Farin et al., 1986). Non-steroidogenic cells provide the structural
architecture of the CL and synthesize several products that interact with steroidogenic cells and
regulate steroid production (Girsh et al., 1996b; Juengel et al., 1998a; Korzekwa et al., 2008).
Irregular shaped SLC, with a diameter < 20

m, produce low basal concentrations of

progesterone (P4) under the influence of LH (Rodgers and O'Shea, 1982; Hoyer et al., 1984;
Mamluk et al., 1998; Wiltbank, 1994), whereas round or polyhedral shaped LLC, whose
diameter varies between 20 and 40 m in different mammalian species, secrete considerably
greater amounts of P4 without pituitary luteotropic stimulus (Rodgers and O'Shea, 1982; Fitz et
al., 1982; Bourdage et al., 1984; Wiltbank, 1994). Although number of LLC did not appear to
change through different stages of luteal phase, including early periods of regressed CL, SLC
significantly increased from Day 4 to 8 of the estrous cycle and maintained stable numbers
until time of luteal regression when they began to decline (Farin et al., 1986). Apparently,
hypertrophy of LLC and hyperplasia of SLC, fibroblasts and endothelial cells account for the
dramatic increase in size and weight of the CL, often compared with tumor tissues (Juengel et
al., 1998a). During CL development, a vast network of capillaries is established assuring
sufficient blood flow to sustain the high metabolic rate of a completely mature CL (Bruce and
Moor, 1976).

Functional characteristics of the corpus luteum
In most mammalian species, a luteotropic stimulus is partially or totally required to maintain
luteal secretion of P4, particularly during the estrous cycle and in some species during early
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stages of gestation. However, the influence of a specific pulsatile pattern of LH secretion
appears to differ among species. In primates, for instance, luteolysis (Dubourdieu et al., 1991;
Webley et al., 1991) or inhibition of luteal angiogenesis and progesterone production (Dickson
and Fraser, 2000) were consequences of interruption of pulsatile LH secretion by using GnRH
antagonists. In ruminants, lack of an appropriate pattern of LH secretion disrupted function of
developing CL in heifers (Peters et al., 1994) but did not affect substantially any stage of luteal
development in sheep (McNeilly et al., 1992). In other mammalian species, like the rabbit,
estrogen is the main luteotropic hormone, while in the rat prolactin is primary and LH and
estrogen play secondary roles (Holt, 1989; Freeman, 2006; Stouffer, 2006).
Lifespan of the cyclic CL varies in different mammalian species. In primates and farm
animals, cyclic CL persist between 12 and 16 days, whereas in rodents luteal phase is shorter (4
or 5 day cycle) and is extended for about 1 to 2 or 3 weeks only in the event of
pseudopregnancy or a fertile cycle, respectively (Leymarie and Martal, 1993; Freeman, 2006).
In other animals like carnivores (dogs, wolves, foxes, cats, etc), the length of the luteal phase in
pregnant or nonpregnant females does not differ appreciably (Stouffer, 2006). On the other
hand, while in many mammals the CL is not absolutely indispensable throughout gestation
(sheep, horse, rat, human, monkey) because luteal P4 is replaced by placental secretion of P4,
some animals such as cow, pig, goat and rabbit require luteal function during the entire
gestation period (Tanabe, 1966; McDonald et al., 1952; Allen, 2001).
At the end of the ovarian cycle, the absence of viable embryos in the uterus allows luteolysis
to take place. In many species, including domestic farm animals (such as the ewe, cow, goat,
mare, sow) and laboratory animals (the rat, mouse, hamster, guinea, pig and and rabbit), an
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endogenous luteolytic substance, prostaglandin F2

(PGF2 ), released from the uterine

endometrium, restrains P4 production and induces CL regression (Wiltbank and Casida, 1956;
Malven and Hansel, 1964; McCracken et al., 1970; Hilliard, 1973; Currie and Thorburn, 1974;
Gleeson et al., 1974; Douglas and Ginther, 1976; Douglas et al., 1976). In most of these
species, transfer of PGF2

from utero-ovarian vein toward ovarian artery appears to be an

important component of the mechanism by which this hormone reaches the luteal tissue
(Ginther, 1974); given that close anatomical relationship between uterine vein and ovarian
artery (Del Campo and Ginther, 1972; 1973a; 1973b; Ginther and Del Campo, 1974), and
functional connection among uterus and CL (Wiltbank and Casida, 1956; Malven and Hansel,
1964; Inskeep and Butcher, 1966; Barley et al., 1966; Currie and Thorburn, 1974; Gleeson et
al., 1974; Gleeson, 1974; Pexton et al., 1975a) were demonstrated. In contrast, in the mare,
uterine and ovarian vasculature seems to be anatomically more independent (Ginther et al.,
1972; Del Campo and Ginther, 1973a) and plays a less significant role in luteolysis (Douglas
and Ginther, 1975). Although in primates an extensive area of contact between utero-ovarian
vein and ovarian artery exists (Ginther et al 1974), raising the possibility that a local diffusion
mechanism takes place, no functional association among uterus and CL has been indicated
(Neill et al., 1969; Castracane et al., 1979), and even, the role of PGF2 as a luteolytic agent in
these species has been controversial and several substances have proposed as luteotropic factors
(Zeleznik and Clifford, 2006). However, a cumulative bulk of evidence indicates that luteal
PGF2 mediates luteolysis in primates (Auletta et al, 1984; Johnson et al., 1988; Houmards et
al., 1989; Zelinski-Wooten, et al., 1990; Bennegard et al., 1991; Bogan et al., 2008; Priyancka
et al., 2009).
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Factors affecting lifespan of the corpus luteum
The events conducive to secretion of PGF2 from the uterus have been described in detail in
ruminants. Luteolysis during the estrous cycle was believed to occur as consequence of a
reciprocal positive feedback mechanism between luteal oxytocin and uterine PGF2
(McCracken et al., 1984; Lafrance and Goff, 1988; Lamsa et al., 1989). This mechanism was
proposed to be responsible for the episodic secretion of PGF2 necessary to complete luteal
regression (Flint et al., 1990); furthermore, this process occurs at a specific time of the estrous
cycle (Lafrance and Goff, 1988; Silvia et al., 1991; Kieborz-Loos et al., 2003). Progesterone
suppressed secretion of PGF2 when more P4 receptors were present, presumably by inhibition
of synthesis of oxytocin receptors early in the estrous cycle when the uterus was more
responsive to P4 (McCracken et al., 1984; Hazzard et al., 1998; Kieborz-Loss et al., 2003).
However, as the estrous cycle progressed, concentrations of P4 receptors decreased, which in
turn allowed the synthesis of estrogen and oxytocin receptors (McCracken et al., 1984). As a
result, the uterus became more responsive to luteal oxytocin and a positive feedback
mechanism was apparently established between oxytocin and endometrial PGF2 .
A period of progestational influence appears to be important in the timing of luteal
regression. Treatment with exogenous P4 on day 0 or 1 after estrus advanced the occurrence of
the first peak of PGF2 and shortened the length of the estrous cycle in sheep (days 8 and 11 for
P4-treated ewes and days 12.3 and 17 for control ewes, respectively; Ottobre et al., 1980). In
addition, the blockade of P4 receptors by mifepristone (RU 486) during the early to mid-luteal
phase inhibited luteolysis and preserved a functional corpus luteum beyond day 20, presumably
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due to delayed PGF2 secretion from the endometrium (Morgan et al., 1993). Abolition of P4
source on days 12 or 14 by removal of either ovaries or CL in sheep, resulted in a temporal
increase of PGF2 followed by a gradual decline (Ottobre et al., 1984; Vincent et al., 1986); it
was suggested that continued secretion of P4 is necessary for secretion of PGF2 to continue
beyond day 14 of the estrous cycle. Apparently, P4 regulates secretion of PGF2 early in the
estrous cycle by timing the initial peaks of secretion, and thereafter, by modulating secretion of
PGF2 until luteal regression is completed. However, in postpartum cows and anestrous ewes
the absence of a previous exposure of the uterus to P4 followed by estrogen prior to first
ovulation alters the physiological conditions of the uterus and as a consequence, the timing of
luteolysis is premature (Inskeep, 2004).
At the time when PGF2 was identified as the luteolytic agent (McCracken et al., 1970), and
the anatomical and functional relationship between uterus and CL were pointed out (Ginther,
1974), suppression of PGF2 secretion was the most likely mechanism to prevent luteolysis in
pregnant animals. However, secretion patterns of PGF2 in pregnant and nonpregnant sheep in
the late luteal phase were similar (Pexton et al., 1975b), indicating that in pregnant females
luteolysis is prevented by mechanisms other than suppression of PGF2 secretion, for example
amounts of PGF2 transported or metabolized, or amount of PGF2 assimilated by luteal tissue
(Pexton et al., 1975c; Lewis et al., 1977). Beside the luteoprotective effect of the embryos in
the uterus (Inskeep et al., 1975; Pratt et al., 1977; Thatcher et al., 1986), uterine PGE2 appears
to be important to prevent luteolysis in pregnant sheep (Lewis et al., 1978; Pratt et al., 1979;
Silvia et al., 1984).
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Physiological and molecular aspects of luteal regression

Luteal regression involves two consecutive and complementary mechanisms whereby the
CL loses steroidogenic capacity (functional luteolysis) without apparent changes in cellular
structure and undergoes subsequent degradation of all cellular and structural components
(structural luteolysis). The latter mechanism implies a concomitant reduction of luteal weight
and size; and finally, the CL becomes a fibrotic nonfunctional tissue named “corpus albicans”.
These mechanisms are triggered at the end of the luteal phase after uterine PGF2 activates its
receptors in different luteal cell types. Hence, luteolysis is a complex and orchestrated
physiologic processes involving not only steroid secreting cells but also endothelial and
immune cells that through autocrine and paracrine mechanisms drive a sequence of cellular and
vascular events conducive to demise of the CL (reviewed by Hoyer, 1998; McCracken et al.,
1999; Niswender et al., 2000; Stocco et al., 2007).

PGF2 reduces essential enzymes for progesterone synthesis during functional luteolysis
An abrupt increase in the amplitude, duration and number of pulses of PGF2 at the end of
the luteal phase (Pexton et al., 1976; Nett et al., 1976a; Zarco et al., 1988a) marks the onset of
luteal regression. A few hours later, concentrations of peripheral P4 are minimum and size and
weight of the CL are smaller (Zarco et al., 1988b; Tsai et al., 2001). Furthermore, reduction in
P4 secretion after exogenous PGF2

administration was accompanied by a simultaneous

decrease in blood flow (McCracken et al., 1970; Nett et al., 1976b; Niswender et al., 1975),
which implies less nutrient and luteotropic stimuli to sustain steroid production by large and
small luteal cells (Niswender et al., 1976).
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After PGF2

binds to its luteal receptor, it triggers changes in expression of genes and

activity of proteins associated with P4 synthesis. Apparently, P450ssc mRNA and protein
activity are not down regulated by PGF2

before plasma P4 declines below functional

concentrations (Tian et al., 1994; Rogers et al., 1995; Diaz and Wiltbank, 2005). Although 3 HDS mRNA decreased concurrently with P4 concentration (r = 0.76, p < 0.005) during the first
12 h after a luteolytic dose of PGF2 (Tian et al., 1994; Tsai et al., 2001), neither the amount of
protein nor enzyme activity decreased within 24 h following PGF2 (Rogers et al., 1995;
Juengel et al., 1998b). Tubulin, a component of the cytoskeleton associated with transport of
cholesterol to the outer mitochondrial membrane, decreased markedly before decline of P4 in
PGF2 -induced luteolysis in sheep (Murdoch, 1996). Moreover, mRNA encoding steroidogenic
acute regulatory protein (StAR), a protein involved in transport of cholesterol from the outer to
the inner mitochondrial membrane, was down regulated a few hours after exogenous PGF2 in
sheep, sows and cows (Juengel et al., 2000; Tsai et al., 2001; Diaz and Wiltbank, 2005). In
addition, transcript concentration for LH receptor in luteal tissue decreased significantly in a
lapse of 4 to 9 h after PGF2 -induced luteolysis in cows and sheep (Juengel et al., 2000; Tsai et
al., 2001) but not in sows (Diaz and Wiltbank, 2005). Thus, abolition of luteotropic stimulus
and transport of cholesterol through cytoplasm and the mitochondrial membrane appears to be
the target of PGF2 to reduce steroidogenic capacity of CL during functional luteolysis.
However, reduction of P4 production and oligonucleosome formation after a subluteolytic dose
of PGF2 was reversed a few hours later (Juengel et al., 2000). Apparently a continuous pattern
of episodic PGF2 secretion is necessary to induce irreversible changes in the functional and
structural characteristics of CL.
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Role of blood flow in luteolysis
The effect of endogenous and exogenous PGF2

on reduction of luteal blood flow

concurrently with diminution of P4 concentrations during the estrous cycle has been described
as a normal physiological event in the ewe (McCracken et al., 1970; Niswender et al., 1975;
Niswender et al., 1976; Nett et al., 1976). Whether PGF2 has a direct effect on ovarian blood
flow or blood flow declines as a consequence of the reduction of P4 production by luteal cells
(or vice versa) has been uncertain. However, in recent years evidence has accumulated
indicating a role of PGF2 in the hemodynamic changes associated with luteolysis. The
presence of PGF2 receptors (FP) in endothelial cells was reported in the cow and sow
(Mamluk et al., 1998; Zanoni et al., 2007). Also, acute increases in blood flow followed by a
progressive reduction at the end of the luteal phase and after administration of PGF2 in midphase bovine CL were associated as a component of the luteolytic cascade (Acosta et al., 2002;
Shirasuna et al., 2008). Moreover, this acute increase in luteal blood flow during spontaneous
luteolysis was accompanied by an increase in plasma PGFM (15-keto, 13,14dihydro-PGF2 ,
inactive metabolite of PGF2 ) (Shirasuna et al., 2008).
Endothelin 1 (END1), a vasoactive peptide produced by luteal endothelial cells, increased at
the end of the luteal phase or after an exogenous dose of PGF2 (Girsh et al., 1996b; Ohtani et
al., 1998; Wright et al., 2001; Choundhary et al., 2004; Shirasuna et al., 2008). END1, whose
potent vasoconstrictor effect has been demonstrated in many tissues, activates receptors in
luteal endothelial cells (Mamluk et al., 1999; Klipper et al., 2004) and may be responsible for
reducing blood supply to the CL during structural luteolysis. In addition to the previous
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physiological effects, END1 decreased P4 concentrations in vitro and in vivo and is involved in
PGF2 -induced luteolysis in sheep and cows (Hinckley and Milvae, 2001; Doerr et al., 2008;
Keator et al., 2008), as will be described in detail later in this review.
Nitric oxide (NO), another vasoactive substance synthesized by luteal endothelial cells) was
reported to modulate luteal production of P4 in vivo and in vitro (Jaroszewski and Hansel,
2000; Jaroszewski et al., 2002; Jaroszewski et al., 2003; Skarzynski et al., 2003; Korzekwa et
al., 2004) and may play a role acting as a component of autocrine and paracrine actions during
luteolysis (Jaroszewski et al., 2003). Nitric oxide, a gas synthesized by deamination of the
amino acid L-arginine through catalytic action of NO synthase (NOS), is secreted from
endothelial cells causing relaxation of vascular smooth muscular cells by binding and activating
guanylyl cyclase to produce cyclic GMP (Alberts et al., 2002); and is an important modulator
of local blood flow in the tissues (Moncada and Higgs, 2006). Luteal endothelial NOS (eNOS)
mRNA and protein increased at the end of the luteal phase (coincident with the time of onset of
luteolysis) or after exogenous PGF2 in cows and sheep, respectively (Skarzynski et al., 2003;
Vonnahme et al., 2006; Shirasuna et al., 2008), whereas only eNOS protein increased after
PGF2 in the rabbit (Boiti et al., 2003).
Recently, it was reported that administration of NO donor into the CL induced an acute
increase in luteal blow flow within 30 min after injection and reduced the length of the estrous
cycle in cows (Shirasuna et al., 2008). In contrast, intraluteal injections of a NO inhibitor
suppressed the increase of luteal blood flow and delayed the onset of luteolysis in response to
exogenous PGF2 (Skarzynski et al., 2003; Shirasuna et al., 2008). In addition, partial pressure
of oxygen and concentrations of nitrite/nitrate (metabolites of NO) were augmented
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significantly in cows after a luteolytic dose of PGF2 during the mid-luteal phase (Skarzynski et
al., 2003; Acosta et al., 2008); and both events were temporally associated with the increase of
luteal blood flow and preceded the decline of P4 concentrations (Acosta et al., 2008). Moreover,
infusion of a NO inhibitor increased concentration of P4, decreased plasma concentration of
nitrite/nitrate and extended the lifespan of the CL (Skarzynski et al., 2003). Accordingly, the
increase in luteal blood flow caused by NO and the consequent enhancement of vascular
permeability may promote infiltration of immune cells and other substances into the CL,
contributing to the successive events involved in the mechanism of structural luteolysis (Acosta
et al., 2008). Whether the increase in blood supply to the CL within few minutes after PGF2
triggers the luteolytic cascade as was suggested (Acosta and Miyamoto, 2004) or is only a
component of the intricate mechanism of luteolysis have to be further confirmed.

Active participation of immune system in luteolysis
According to Pate and Keyes (2001), the role of immune cells in luteal regression may be
explained by their participation in the loss of steroidogenic capacity and destruction of the
luteal tissue, and by modulation of the potential inflammatory conditions originated by
degenerating luteal cells with the aim of preserving basic environmental conditions for those
cells that have not died. Population of immune cells in CL is represented by T-lymphocytes,
macrophages-monocytes and eosinophils (Bagavandoss et al., 1988; Pate, 1994; Bukovsky et
al., 1995; Best et al., 1996; Penny et al., 1999; Bauer et al., 2001 Townson et al., 2002), whose
number increased as the mid-luteal phase progressed (Bauer et al., 2001; Townson et al., 2002);
reaching a considerably greater number of cells during spontaneous luteolysis and after
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PGF2 -induced luteolysis (Penny et al., 1999; Bauer et al., 2001; Townson et al., 2002).
Leucocytes increased around 20% at the end of the luteal phase and 70% at late luteal
regression; this increment was due to infiltration of monocytes and local proliferation of
macrophages when capillaries were no longer present (Bauer et al., 2001). During structural
luteolysis macrophages play an important role by phagocytizing dead cells and cell debris
(Paavola and Boyd, 1979) as well as releasing cytokines, oxygen radicals and substances that
inhibit steroidogenesis (Hoyer, 1998; Pate and Keyes, 2001),
Infiltration of macrophages appears to be regulated by chemokines (Pate and Keyes, 2001),
particularly monocyte chemoattractant protein 1 (MCP-1), a cytokine detected in greater
quantity during luteal regression in coincidence with the influx of macrophages (Bowen et al.,
1996; Penny et al., 1998) or 4 to 8 h after PGF2 -induced luteolysis (Haworth et al., 1998; Tsai
et al., 1997; Penny et al., 1999). Analysis of MCP-1 mRNA expression in bovine CL revealed a
significant increment as early as 0.5 h after PGF2 -induced luteolysis and continued for at least
64 h (Kliem et al., 2009); whereas the expression of its receptor was greater from 12 until 64 h
after PGF2 . MCP-1 was detected in endothelial cells (Cavicchio et al., 2002). Once expressed
in vascular tissue, MCP-1 stimulated migration of immune cells, particularly monocytes,
macrophages and T-lymphocytes, from blood vessels into tissues undergoing inflammation
(Mukaida et al., 1998). Townson et al. (2002) documented that MPC-1 mRNA and protein
expression as well as immune cell accumulation in bovine CL preceded the onset of
spontaneous luteolysis by several days. If luteolysis was prevented between days 16 to 18 of
the cow estrous cycle, no increase in MCP-1 or macrophage infiltration was observed (Penny,
2000). In addition, in vitro studies have failed to demonstrate an effect of PGF2 on MCP-1
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secretion by endothelial cells (Cavicchio et al., 2002), indicating that this chemoattractant may
be released as an indirect action of PGF2 . According to the proposed model by Penny (2000),
at the end of the luteal phase PGF2 stimulated, directly or indirectly, secretion of MCP-1 and
other cytokines by several luteal cell types (lymphocytes, macrophages, fibroblasts, and
steroidogenic and endothelial cells) causing an influx of macrophages that play an essential role
during structural regression of the CL .
Once immune cells become activated within an inflamed tissue, they secrete cytokines, such
as tumor necrosis

(TNF- ), interferon

(IFN- ) and interleukin 1 (IL-1 ). In addition to

modulating the immune response during luteal regression, these cytokines directly affect luteal
steroidogenic cells, suppressing progesterone production and inducing apoptosis (Friedman et
al., 2000; Pate and Keyes, 2001; Petroff et al., 2001). A significant increase of mRNA
expression of TNF- , IFN- , and IL-1 was detected as early as 2 h after PGF2 -induced
luteolysis (Neuvians et al., 2004a). Moreover, this increment was simultaneous with a decline
of LHR and P450scc mRNA (Neuvians et al., 2004a); which supports the suppressive effect of
these immune mediators on P4 production by luteal tissue (Fairchild and Pate, 1991; Benyo and
Pate, 1992; Young et al., 1997). In another study, increases of TNF- and IFN- mRNA 0.5
and 2 h after PGF2 , respectively, were reported (Kliem et al., 2009), followed by increases in
TNF- receptor mRNA and protein at 2 and 12 h, respectively. TNF- receptor was identified
in endothelial cells from microvascular tissue of bovine CL (Okuda et al., 1999) as well as in
SLC and LLC (Friedman et al., 2000). In addition, expression of TNF-

receptor mRNA

increased significantly after a luteolytic dose of PGF2 (Friedman et al., 2000).
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Evidence indicates that both TNF- and IFN- are highly cytotoxic (Benyo and Pate, 1992;
Friedman et al., 2000; Petroff et al., 2001). Cultured luteal cells treated with TNF- and IFNhad less cell viability than untreated control cells and these cytokines induced DNA
fragmentation by 48 h after cytokine treatment (Petroff et al., 2001). Immune cytokines
stimulated greater secretion of luteal PGF2 in vitro than control untreated cells (Fairchild and
Pate, 1991; Benyo and Pate, 1992; Petroff et al., 2001). However, IFN- -induced elevation of
luteal PGF2 was reversed by P4 (Fairchild and Pate, 1991), indicating a protective effect of P 4
on luteal function that was also demonstrated by reducing TNF- -induced cytotoxicity in
endothelial cells treated with P4 (Friedman et al., 2000). In this regard, Juengel et al. (2000)
observed that a subluteolytic dose of PGF2 (3 mg/6 kg BW) in the ewe transiently suppressed
serum concentrations of P4 and caused formation of oligonucleosomes 9 h after treatment and
thereafter disappeared without any effect on CL weight.
In conclusion, after luteolysis is initiated by uterine PGF2 , secretion of MCP-1 by luteal
cells (Penny, 2000) induces infiltration of macrophages and T-lymphocytes into the CL (Penny
et al., 1999; Townson et al., 2002). These leukocytes secrete immune cytokines such as TNF- ,
IFN-

and IL-1

that stimulate luteal PGF2

secretion and suppress P4 production by

steroidogenic cells, reinforcing the cascade of luteolytic events (Pate and Keyes, 2001). In
addition, immune cytokines have a direct effect on viability of endothelial and steroidogenic
cells, inducing apoptosis (Petroff et al., 2001) and degradation of cellular matrix (Hagedorn et
al., 2001).
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Apoptosis during structural luteolysis
After uterine PGF2 disrupts synthesis and secretion of P4 from steroidogenic cells, luteal
PGF2 directly and/or through several luteolytic mediators (like NO, END1, TNF- , IFN- , IL1 ) triggers structural luteolysis that involves cellular apoptosis, phagocytosis of endothelial
and steroidogenic cells, and degradation of cellular matrix (Hoyer, 1998; Pate and Keyes, 2001;
Smith et al., 2002; Stocco et al., 2007).
Apoptosis or programmed cell death is a highly regulated physiological mechanism for
reducing non-necessary populations of cells for the normal function of the tissue, or during
specific developmental stages. Albert et al. (2002) described structural changes of the apoptotic
cell as follow: “the cell shrinks and condenses, the cytoskeleton collapses, the nuclear
membrane disassembles and the nuclear DNA breaks up into fragments”. As a final cellular
event of apoptosis, fragmentation of DNA occurs due to activation of Mg++/Ca++-dependent
endonucleases that cleave DNA into 185-bp DNA fragments (Tilly, 1996). So, degradation of
DNA and the consequent formation of oligonucleosomes is considered a hallmark of apoptosis
(Compton, 1992) and has been identified during luteal regression in human beings (Shikone et
al., 1995; Sugino et al., 2000a), sheep (Sawyer et al., 1990; Rueda et al., 1995a), cows
(Friedman et al., 2000; Petroff et al., 2001), sows (Bacci et al., 1996) and rats (Matsuyama et
al., 1996).
During functional luteolysis, the anti-apoptotic effect of P4 is suppressed and luteal PGF2 ,
directly or via autocrine and paracrine mediators, initiates progressive destruction of all cellular
populations of the CL. Juengel et al. (1993) reported that apoptotic signals appeared after P4
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concentrations declined and structural regression started; evidence that also was observed by
Murdoch (1995). Content of DNA in bovine CL decreased from about 9.5 mg/CL at the midluteal phase to 2.2 mg/CL at the time of luteolysis (days 18 to 21 of the estrous cycle) (Zheng et
al. 1994); whereas weight of CL and luteal content of P4 decreased 73% and 98% respectively,
and the number of cells dying during luteolysis was approximately 77.8×106 per day.
Fragmentation of DNA was first observed 12 h after exogenous PGF2 in the ewe (Sawyer et
al., 1990; Rueda et al., 1995) and by 6 h in the sow (Bacci et al., 1996). Endothelial cells
appeared to be the first population of cells targeted by PGF2 -induced apoptosis (Sawyer et al.,
1990; Rueda et al., 1995; Bacci et al., 1996; Gaytan et al., 1998). In the sow, loss of capillaries
increased progressively from 15% at 6 h after PGF2 -induced luteolysis to 49% 36 h later
(Bacci et al., 1996). However, new morphological signs of apoptosis in parenchymal cells were
not observed until 48 h after PGF2 (Bacci et al., 1996). In regressing ovine CL, endothelial
cells with normal nuclei declined significantly at 12 h after PGF2 , followed by steroidogenic
cells and fibroblasts at 24 and 36 h, respectively (Sawyer et al., 1990). Also, apoptotic cells in
buffalo cows increased 18 h after PGF2 (Yadav et al., 2005).
Apoptosis is mediated by a variety of proteins activated by stimuli originated inside
(intrinsic pathway) or outside (extrinsic pathway) the cell. In the first case, several factors (such
as hypoxia, hyperoxia, hormone deprivation, radiation, etc) can induce changes in the
permeability of the mitochondrial membrane that trigger a cascade of intracellular events that
involve several proteases named caspases. In the second case, an apoptotic cascade is
originated by activation of a membrane receptor (Fas receptor; FasR) by Fas ligands (FasL)
present in the surface of killer lymphocytes (Alberts et al., 2002). Also, intrinsic apoptosis
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during cellular stress is regulated by changes in the Bcl-2 family of proteins that have antiapoptotic (Bcl-2 and others) and pro-apoptotic (Bax, Bad, etc) activity (Tilly, 1996). The ratio
of Bax to Bcl-2 appears to be important to determine cell survival. Concentrations of Bax but
not Bcl-2 mRNA and protein increased within 4 h after PGF2 -induced luteolysis in buffalo
cows (Yadav et al., 2005); the Bax/Bcl-2 ratio was 4 fold greater compared with time 0
(PGF2

injection). Both caspases 3 and 9 proteins and activity increased after PGF2 , but

caspase 9 increased earlier (4-12 h) than caspase 3 (18 h) (Yadav et al., 2005). During induced
luteolysis in cows, mRNA expression of p53 (another apoptotic protein) and Bax increased
significantly from 24 to 64 h after PGF2 , whereas Bcl-XL showed a significant increase only
from 48 to 64 h (Kliem et al., 2009). In addition, caspases 3, 6 and 7 were greater at 12, 2 and 2
h after PGF2 , respectively, than at time 0.
In human CL, the expression of Bcl-2 and Bax mRNA was examined during the menstrual
cycle. Results revealed that Bcl-2 protein was lower in the regressing CL than in mid-luteal
phase and early pregnancy (Sugino et al., 2000a), whereas Bax protein was greater in the
regressing CL than during mid-luteal phase and early pregnancy. In addition, mRNA
expression during luteolysis followed the same pattern with greater expression level for Bax
and lower for BCL-2 (Sugino et al., 2000a). Interestingly, hCG incubated with luteal tissue
significantly decreased mRNA and protein of Bax and significantly increased those of Bcl-2
(Sugino et al., 2000a). In this regard, blockade of P4 receptor in cultured bovine luteal cells
increased FasR and caspase 3 mRNA expression and caspase 3 activity (Okuda et al., 2004),
supporting the concept that apoptosis is a hormone-regulated process in which luteotropic
stimuli inhibit and luteolytic stimuli promote apoptosis.
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Intrinsic apoptosis during luteal regression has been associated with an increase of reactive
oxygen species (ROS), and with the consequent oxidative stress (Hoyer, 1998). During
luteolysis, production of ROS was increased in the CL by several mechanisms involving
PGF2 , macrophages and hemodynamic changes (Sugino, 2006). As a consequence,
accumulation of ROS causes DNA and protein damage and cell membrane alterations that
trigger apoptosis (Sugino, 2006). In addition, the CL and other tissues have specific enzymes
that counteract superoxide radical accumulation (Sugino et al., 2000b). Copper-zinc and
manganese superoxide dismutase (SOD) mRNA and protein, and lipid peroxide concentrations
during the human menstrual cycle and early pregnancy were evaluated (Sugino et al., 2000b).
Copper-zinc SOD mRNA and activity reached the lowest amount during luteal regression and
the greatest amount during pregnancy. In contrast, manganese SOD mRNA and activity were
greater in regressing CL than at any other luteal stage (Sugino et al., 2000b), concurrently with
higher amounts of lipid peroxide concentration.
On other hand, FasL was significantly up-regulated 0.5 h after PGF2 and attained the
highest increment at 12 h; while FasR increased from 2 h until 64 h after PGF2 (Kliem et al.,
2009). Both proteins, FasL and FasR, have been implicated in the regulation of cellular
apoptosis during structural luteolysis (Taniguchi et al., 2002). FasR transcript was detected in
bovine CL with a significantly greater expression during luteal regression than in any other
stage (early, mid and late CL) (Taniguchi et al., 2002). Also, FasR mRNA expression increased
1.4 and 1.8 fold in cultured luteal cells treated with INF alone and INF combined with TNF ,
respectively (Taniguchi et al., 2002). Moreover, treatment of luteal cells with FasL combined
with INF or with INF and TNF

induced death of 60 and 85% of cultured luteal cells;
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whereas FasL alone was not cytotoxic. Although FasR was expressed in luteal cells in the
absence of cytokines, the presence of FasL in the culture did not induce apoptosis, supporting
the role of the immune cytokines in the sequence of events leading to luteal regression.

Cellular matrix degradation and structural luteolysis
In the ovary, as in other tissues, the space between cells is occupied by a network of
macromolecules, proteins and polysaccharides that constitute the structural support of the tissue
and interact with the cells, influencing their survival, development, migration, proliferation,
shape and function (Albert et al., 2002). This “substance around the cells” is named
extracellular matrix (ECM). In the ovary, ECM is object of continuous remodeling to provide
basic cellular conditions to each developmental stage and functional structure. Stability of
ECM is a consequence of differential expression of two important groups of proteins: matrix
metalloproteinases (MMP) that degrade certain components of ECM (Pitzel et al., 2000) and
tissue inhibitors of metalloproteinases (TIMP) that inhibit MMP activity (Ricke et al., 2002a).
MMP proteins are zinc- and calcium-dependent enzymes that degrade proteinaceous
components of the ECM and cleave signaling proteins. This group consists of more than 26
members synthesized as inactivated enzymes (pro-MMP) and classified in collagenases,
gelatinases, stromelysins and membrane type MMP (Smith et al., 2002). TIMP include a group
of 4 proteins (TIMP-1, -2, -3 and -4) that specifically inhibit MMP and can regulate cellular
functions by mechanisms different to MMP inhibitor activity (Smith et al., 2002). TIMP are
able to modulate proliferation of endothelial cells and fibroblasts (Rho et al., 2007; Seo et al.,
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2008), inhibit angiogenesis (Seo et al., 2003) and apoptosis (Guedez et al., 1998) and promote
steroidogenesis (Shores and Hunter, 2000) and other functions.
During its lifespan, a CL undergoes an intensive remodeling of the ECM that is hormonally
regulated by luteotropic, luteolytic and steroidogenic stimuli at the level of transcription,
secretion and activation of proenzymes (Smith et al., 2002; Vassilev et al., 2002).
Modifications of MMP and TIMP mRNA expression and protein activity were associated with
structural regression of the CL in rats (Liu et al., 1999), pigs (Pitzet el al., 2000) and sheep
(Ricke et al., 2002 a, b). Members of MMP and TIMP families have been identified and
monitored in luteal tissue of several species during the estrous cycle and luteolysis (Liu et al.,
1999; Pitzel el al., 2000; Ricke et al., 2002 a, b, c; Towle et al., 2002; Ribeiro et al., 2006 ,
2007; Kliem et al., 2007). Expression of TIMP-2 mRNA was demonstrated in ovine
preovulatory follicles and CL throughout the luteal phase (Smith et al., 1995). Concentrations
of TIMP-2 in luteal tissue were maximal during the early luteal phase (d 3 and 7 post estrus)
and minimal on d 16, when probably luteolysis was taking place. Also, TIMP-2 mRNA
concentration was 10 times greater in LLC than in SLL, indicating that probably LLC are the
primary source of TIMP-2 as reported elsewhere (Smith et al., 1994; Ricke et al., 2002b).
Amounts of MMP-2 and MMP-14 mRNA followed a different expression pattern during the
estrous cycle in sheep (Ricke et al., 2002c). At day 5, MMP-14 attained greater expression and
decreased in mid- and late-luteal phase; whereas MMP-2 was greater on day 10 compared with
earlier stages.
In ovine tissue of mid-luteal phase, TIMP-1 and TIMP-2 decreased abruptly (60% and 90%
from controls, respectively) as early as 1 h after PGF2 -induced luteolysis, remaining low until
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h 8. In contrast, MMP-2 and MMP-9 activities increased 165% at 8 h after PGF2 , coinciding
with the lowest concentration of P4 (Towle et al., 2002). In another report in sheep, TIMP-1
concentration significantly decreased 15 min after administration of PGF2 (time 0) and
remained at basal values through 48 h (Ricke et al., 2002a). In addition, TIMP-1 mRNA
decreased 1 h after PGF2 and increased at 4 and 6 h, whereas TIMP-2 and TIMP-3 mRNA
remained lower throughout the first 6-h period and then significantly increased (Ricke et al.,
2002a). The study of mRNA expression and activity of various members of the MMP family
(MMP-1, -2, -3 , -7 , -13 and -14) in the ewe CL after PGF2 -induced luteolysis revealed an
increase in mRNA of all MMP members (except MMP-2) 15 to 30 min post PGF2 (Ricke et
al., 2002b). All MMP mRNAs were greater than at time 0 (previous to PGF2 ) by 6 h after
PGF2 , and MMP activity increased significantly by 15 min and remained elevated through 48
h post- PGF2 (Ricke et al., 2002b). Thus, modification in the expression pattern and activity of
MMP and TIMP mRNA and protein may increase the MMP/TIMP ratio, facilitating ECM
degradation and consequently favoring structural luteolysis (Smith et al., 2002).
In mid-phase bovine CL, MMP-1 mRNA expression increased abruptly 2 h after PGF2 induced luteolysis, followed by MMP-9 (12 h), and MMP-2 and MMP-14 (24 h). TIMP-2
mRNA initially remained at same amounts of h 0 luteal tissue (previous to PGF2 ) and
decreased precipitously at h 48; whereas TIMP-1 increased at h 12 and declined 36 h later
(Kliem et al., 2007). In addition, mRNA expression of plasminogen activator system (PAS)
revealed an abrupt increase as early as 2 to 4 h after PGF2 . PAS is involved in ECM
degradation in the CL (Liu, 2004).

35

Roles of uterine and luteal PGF2 in luteal regression
As mentioned above, absence of viable embryos in the uterus at the end of each luteal cycle
allows increased secretion of PGF2 (Zarco et al., 1988) that through diffusion from venous to
arterial blood vessels reaches the ovary and binds to specific PGF2 receptors (FP) localized in
the surface of LLC (Fitz et al., 1984; Balapure et al., 1989; Gadsby et al., 1990). Activation of
FP triggers a cascade of molecular events conducive to the demise of the CL and the onset of a
new reproductive cycle.

Biochemical characteristics, synthesis, and transport of PGF2
Prostaglandins (PG) are members of a group of biomolecules containing 20-carbon
backbone structure known as eicosanoids, that play essential functions in the reproductive
physiology of mammals (Weems et al., 2006; Flores and Barlund, 2009). In addition to PG, the
eicosanoid family includes thromboxanes and leukotrienes. Biologically active prostaglandins
include 3 members: PGI2, PGE2 and PGF2 . Prostaglandins are synthesized from arachidonic
acid (an important polyunsaturated fatty acid of the cellular membrane) and hence have a lipid
nature (Marnett et al., 1999). Phospholipase A2 catalyzes release of arachidonic acid from
cellular membrane, followed by oxygenation and peroxidation of arachidonic acid in the
reticulum endoplasmic to yield PGG2 and PGH2 (Marnett et al., 1999). This step is comprised
of two successive reactions catalyzed by a single bifunctional enzyme: prostaglandin
endoperoxide synthase or prostaglandin G/H synthase (Cox). At least 2 forms of Cox have been
identified; Cox-1 is expressed constitutively and Cox-2 is an inducible isoform (Smith et al.,
2000). Formation of PGG2 and PGH2 is catalyzed by cyclooxygenase and peroxidase
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components of the enzyme, respectively (Smith et al., 2000); and is considered a rate-limiting
step in the biosynthesis of PG (Sirois et al., 2004). Conversion of PGH2 into the different
biological forms of PG is catalyzed by cell-specific terminal synthases (Flores and Barlund,
2009). For instance, PGES and PGFS synthesize PGE2 and PGF2 , respectively, whereas
prostaglandin dehydrogenase catabolizes PGF2 into 13, 14-dihydro-15-keto PGF2 (PGFM)
(Tai et al., 2002).
Although PG have a lipid nature, at physiological pH they behave as organic anions and do
not diffuse easily across cellular plasma membranes (Shuster, 1998). Instead, PG utilize carriermediated transport that includes three aspects: transport and metabolic clearance by the lung,
transport by non-lung tissues that metabolize PGs, and transport by tissues that do not
metabolize PGs (Shuster, 1998). Recently, PG transporter (PGT) in ovine endometrium was
cloned and characterized, and its participation in PGF2 -induced luteolysis was demonstrated
(Banu et al., 2008). Inhibition of PGT-mediated transport of PGF2 from the uterus prevented
luteolysis and extended lifespan of the CL and length of the estrous cycle. Moreover, inhibition
of PGT reduced the ability of the endometrium to secrete PGF2 in response to oxytocin (Banu
et al., 2008). Apparently, ERK1/2 pathways modulate efflux of PGF2 , whereas JNK/SAPK
pathways regulate both efflux and influx of PGF2 in ovine endometrial cells (Banu et al.,
2008). In ovine CL, expression of both PGT mRNA and protein was greater on d 7 to 21 than 1
to 6 of the estrous cycle with maximal expression values on d 13 to 15 (Arosh et al., 2003).
Also, PGT protein was expressed highly in LLC.
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Characteristics, variants, and localization of PGF2 receptor
PGF2 induces changes in intracellular functions by binding to a specific cellular membrane
receptor that was cloned and characterized in several mammalian species (Abramovitz et al.,
1994; Graves et al., 1994; Kitanaka et al., 1994; Lake et al., 1994; Sakamoto et al., 1994). FP
belongs to the family of G-protein-coupled receptors that, once activated, couples to Gq to
trigger the inositol trisphosphate (IP3) second-messenger pathway. In cattle and sheep, FP
protein has 362 amino acids, while human being and rat have 359 and 366, respectively.
Molecular weight of FP is similar among species, varying between 40060 and 40983 in human
beings and ruminants (Abramovitz et al., 1994; Graves et al., 1994; Kitanaka et al., 1994;
Sakamoto et al., 1994).
Two FP isoforms have been identified in the sheep CL (Graves et al., 1994; Pierce et al.,
1997). Both FPA and FPB have similar amino acid (AA) sequences through the seven
transmembrane domains, but differ in the carboxyl terminus site, in which FPA has 45 more
AA than FPB (Pierce et al., 1997). Thus, FPB isoform is a truncated version of the FPA
isoform. Activation of FP receptor variants leads to an increase in inositol phosphate
accumulation, protein kinase C (PKC) activation, and intracellular calcium release consistent
with activation of G-proteins of the Gq family (Abramovitz et al., 1994; Graves et al., 1994;
Sakamoto et al., 1994). However, FPA and FPB activation led to Rho-dependent changes in
cell morphology, formation of actin stress fibers, and tyrosine phosphorylation of p125 FAK
(Pierce et al., 1999).
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In cells transfected with either FPA or FPB, PGF2

elicited a similar maximum IP

accumulation; nevertheless, basal accumulation of IP was about 130% greater in cells
expressing FPA than in those expressing FPB isoforms (Pierce et al., 1997). Moreover, FP
isoforms are regulated differentially by PKC. In human embryonic kidney cells that steadily
expressed FPA and FPB, PKC inhibited PGF2 -stimulated IP formation by FPA but not by FPB
(Fujino et al., 2000a). Also, a stronger PKC-mediated agonist dependent phosphorylation was
observed in FPA, but not in FPB (Fujino et al., 2000a), indicating that under conditions of acute
activation or down-regulation of PKC, the FPA isoform might be more responsive to
submaximally stimulating concentrations of agonist than the FPB variant. In addition, agonistinduced stimulation of inositol phosphate formation, and mobilization of intracellular Ca2+
indicate that the FPB variant resensitizes more slowly than the FPA (Fujino et al., 2000b).
Apparently, the carboxyl terminus of the FPA isoform is critical for resensitization because the
absence of 45 of 46 AA in the carboxyl terminus of FPB slowed resensitization and prolonged
signaling (Fujino et al., 2000b). Overall, these findings demonstrated molecular and signaling
differences between variants of FP that may contribute to elucidation of physiological actions
of PGF2 in the CL. Possibly, differential expression of the two isoforms in response to
functional stages of the CL may alter intracellular responsiveness to PGF2 (Hoyer, 1998).
In ovine CL, northern blot analysis revealed similar expression of FP mRNA at mid-luteal
phase (d 10, 2.73 ± 0.17; d 12 2.47 ± 0.91) but greater on d 16 of pregnancy (Rueda et al.,
1995b). A subsequent study corroborated that concentrations of FP mRNA did not vary
throughout the estrous cycle (Juengel et al., 1996), although a significant reduction in FP
mRNA expression was observed as early as 4 h (Juengel et al., 1996; Tsai et al., 2001) or 12 h
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(Tsai et al., 1998a) during PGF2 -induced luteolysis in sheep, cow and pig (Rueda et al., 1995b;
Sakamoto et al., 1995; Estill et al., 1995; Mamluk et al., 1998). These findings are consistent
with the reduction of number of FP by the time of luteolysis (Wiepz et al., 1992), and the
decline of FP mRNA concentration in cultured LLC treated with a PKC activator or calcium
ionophore (Tsai et al., 2001). Thus, reduction of FP protein and mRNA concentrations were
associated with significantly lower concentrations of P4 and luteal weight (Juengel et al., 1996;
Tsai et al., 1998a). On the basis of the previous evidence, FP seems to be downregulated by a
mechanism of homologous ligand that could imply reduction of mRNA FP expression for
PGF2 at the same time that FP are downregulated by mechanisms of receptor internalization
and degradation (Tsai et al., 1998a).
Both FP mRNA and protein are considerably more abundant in luteal tissue than in any
other ovine tissue (Tsai et al., 1998a). Amounts of FP mRNA and proteins were approximately
26 and 148 times greater, respectively, in luteal tissue than in ovarian stroma, and this figure
was even greater when compared with other tissues. FP were localized primarily in LLC from
several mammalian species (Balapure et al., 1989; Gadsy et al., 1990; Juengel et al., 1996;
Mamluk et al., 1998; Boonyaprakob et al., 2001; Bogan et al., 2008). Using separated
populations of LLC and SLC purified by elutriation, high affinity binding sites (Kd = 19 to 64
nM in pigs and 17.4 ± 2.3 nM in ewes) were identified exclusively in LLC, whereas low
affinity binding sites (Kd = 262-3103 nM in pigs and 409 ± 166 nM in ewes) were present in
LLC and SLC (Balapure et al., 1989; Gadsby et al., 1990). Number of high affinity PGF2 binding sites was low during the early luteal phase of the pig (before d 12) but increased
thereafter (day 13, 14 and 16-17) (Gadsby et al., 1990). In bovine CL, in situ hybridization
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allowed detection of FP mainly in LLC (Sakamoto et al., 1995). However, in a subsequent
study using RT-PCR with elutriated SLC and LLC, FP mRNA was detected in both
steroidogenic cells, although FP mRNA expression in LLC was around 2.5 times greater than
in SLC (Mamluk et al., 1998). Immunohistochemical analysis (IHC) in primate CL revealed
expression of FP protein in LLC and vascular endothelial cells (Bogan et al., 2008). Amounts
of FP were lower during early and mid-luteal phase and increased in the following days of the
menstrual cycle.
Albeit evidence of FP in the vascular tissue of the CL has been controversial over the years,
presence of FP in endothelial cells was documented in pigs, cows and primates (Mamluk et al.,
1998; Zannoni et al., 2007; Bogan et al., 2008). Using in situ hybridization, Boonyaprakob et
al. (2003) did not identify FP in endothelial cells in pig CL. However, in a recent report,
microvascular endothelial cells were isolated from porcine CL by an immunomagnetic
separation protocol and FP protein and mRNA were identified and quantified by
immunofluorescence and RT-PCR (Zanoni et al., 2007); FP mRNA and protein expression
significantly increased from early- to mid-luteal phase, attaining maximum amounts during
pregnancy. FP mRNA was identified in luteal endothelial cells from bovine CL (Mamluk et al.,
1998), whereas in primates FP in vascular tissue was identified by IHC (Bogan et al., 2008).
Luteolysis is an intricate process in which substances locally produced by different cellular
components modulate luteal regression by paracrine and autocrine mechanisms (Korzekwa et
al., 2008). In luteal steroidogenic cells cultured in monolayer, PGF2

increased P4

accumulation after 24 h incubation. Nevertheless, PGF2 reduced production of P4 in culture of
luteal steroidogenic, endothelial and immune cells (Korzekwa et al., 2008). So, interactions
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among different cellular components appear to be necessary so that synthesis and secretion of
P4 is disrupted, and hence, subsequent steps of luteolysis take place. In addition, two important
vasoactive factors, NO and END1, produced by endothelial cells (Girsh et al., 1996a;
Skarzynski et al., 2003) appear to be involved in luteolysis. Moreover, they are regulated by
PGF2 (Manluk et al., 1999; Skarzynski et al., 2003; Shirasuna et al., 2008), and PGF2 itself is
involved in regulating blood flow in extraovarian tissues (Ogletree et al., 1982). Hence,
presence of FP in endothelial cells is consistent with experimental evidence about the role of
luteal vascular tissue in luteolysis.

Signal transduction pathways involved in PGF2 -mediated luteolysis
Activation of luteal FP by PGF2 during luteolysis modifies the molecular conformation of
the receptor allowing activation of G protein (Alberts et al., 2002). G protein (GTP-binding
protein) is a trimeric molecule composed of three subunits, , , and , which remain inactive
while receptor is not bound to its ligand. Once G-protein is stimulated, GDP in the

subunit is

exchanged by GTP, and as a consequence, the trimeric G-protein dissociates into two activated
components,

subunit and

the case of FP, activated
pathway. Briefly,

complex (Levitzki, 1987). In Gq-protein-coupled receptors, as is
subunit triggers the inositol phosphate (IP3) second-messenger

subunit activates the enzyme phospholipase C (PLC), which cleaves

phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] into two molecules, inositol 1,4,5trisphosphate (IP3) and diacylglycerol (DAG) (Berridge et al., 1983; Davis et al., 1987; Davis et
al., 1988). Both molecules act as intracellular messengers with different functions (Berridge et
al., 1987). The IP3 leaves the plasma membrane and diffuses through the cytosol to the
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endoplasmic reticulum (ER). In the ER membrane, IP3 binds and opens IP3-gated Ca2+-release
channels increasing concentrations of intracellular Ca2+ (Streb et al., 1984; Spat et al., 1986;
Davis et al., 1987a; Williamson and Monk, 1989). In the cellular membrane, DAG together
with the increased cytosolic Ca2+ activates the enzyme protein kinase C (PKC) (Berridge et al.,
1987). The PKC, via mitogen-activated protein kinase (MAP kinase) activates PLA, which in
turn stimulates release of AA from the membrane (Qiu and Leslie, 1994; Chen et al., 1998) and
promotes synthesis of PGF2 . Thus, uterine PGF2 induces synthesis of luteal PGF2 .
Recently, it was demonstrated that the interaction of PGF2 with FP receptor activates an
additional intracellular signaling pathway, the mitogen activated protein kinases (MAPKs), that
is involved in the transduction of extracellular signals into the nucleus to regulate gene
expression (Chen et al., 1998). This pathway has been widely described in the signaling of
receptor-linked tyrosine kinases activated by several growth factors, and involves
phosphorylation of numerous serine/threonine-selective protein kinases, such as RAF, MEK
and MAPK, that regulate the activities of several transcription factors (Alberts et al., 2002).
Apparently, the RAF/MEK/MAPK signaling cascade also mediates the cellular response to
various ligands that bind G protein-coupled receptors, including PGF2 (Chen et al., 1998; Tai
et al., 2001; Hou et al., 2008). Three isoforms of Raf family were detected in the bovine CL,
but only Raf-1 and B-Raf were activated by PGF2 and phorbol 12-mysristate 13-acetate
(PMA; a pharmacological PKC activator); and subsequently MEK1, p42mapk and p44mapk
kinases were activated. Activation of this protein kinase pathway by PGF2 may represent a
mechanism by which the intracellular signal initiated by FP is transmitted to the nucleus to
regulate transcriptional activity related with luteolysis (Chen et al., 1998). Moreover, PGF2 ,
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via MEK/ERK signaling pathway, stimulated mRNA and protein expression of early growth
response 1 (EGR1) both in vivo and in vitro (Hou et al., 2008). EGR1 has been associated to
various reproductive functions (Espey et al., 2000; Russell et al., 2003). During PGF2 stimulated luteal regression in cow, EGR1 induced expression of TGF 1, an important tissue
remodeling protein also involved in apoptosis (Hou et al., 2008).
The first attempts to understand the intracellular mechanisms by which PGF2 disrupts
synthesis and secretion of P4 were carried out in rat luteal cells. Treatment of rats with PGF2
down-regulated LH luteal receptors within 12-24 h in parallel with the decrease of P4;
nevertheless, reduction of P4 concentrations preceded a decrease in LH receptors by several
hours (Grinwich et al., 1976). Also, it was demonstrated that LH or PGF2 in absence of LH,
stimulated P4 production in a dose dependent manner in dissociated luteal cells (Thomas et al.,
1978). In addition, LH induced a significant increase of adenylate cyclase activity and
accumulation of cAMP; whereas adding PGF2 to LH-supplemented cultured luteal cells
reduced both adenylate cyclase activity and cAMP accumulation by about 50 to 70% (Thomas
et al., 1978; Dorflinger et al., 1983; Kenny and Robinson, 1986). Moreover, addition of
dibutyryl cyclic AMP (dbcAMP; analogue of cAMP) reversed PGF2 -induced inhibition of P4
(Thomas et al., 1978; Dorflinger et al., 1983 Kenny and Robinson, 1986).
From these early studies, it was evident that the PGF2 -induced block of LH-stimulated P4
secretion was not due to inhibition of specific binding activity of LH receptor, cAMP
degradation, direct action on adenylate cyclase or direct damage of luteal cells by PGF2
(Grinwich et al., 1976; Thomas et al., 1978; Dorflinger et al., 1983). Instead, PGF2 -induced
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inhibition of LH-stimulated P4 may be due to inhibition of activation of cAMP accumulation by
LH and inhibition of luteal cell response to cAMP (Thomas et al., 1978; Dorflinger et al.,
1983). However, when dbcAMP or LH was added to dispersed luteal cells from rats treated
with PGF2 in vivo, P4 production was reduced significantly, indicating that PGF2 -induced
inhibition of P4 production may occur at a site beyond cAMP formation in the steroidogenic
pathway (Jordan, 1981). Because PGF2 was more effective to inhibit dbcAMP-stimulated
steroidogenesis in vivo (Jordan, 1981) than in vitro (Thomas et al., 1978; Jordan, 1981) it was
suggested that PGF2 -induced inhibition of P4 may be the result of both direct and indirect
effects (Jordan, 1981). In addition, PGF2

was able to inhibit activity of 3 -HDS and

cholesterol esterase (Dwyer and Church, 1979), as well luteal adenylate cyclase activity
concomitant with the decrease of P4 concentrations in a 24-h period (Agudo and Smith, 1982).
Thus, on the basis of the experimental evidence it was likely that PGF2 may have multiple
sites of action and that its luteolytic actions involve other substances or mediators, indicating
the complex mechanism of luteolysis.
Luteal regression was associated to structural changes in cellular membranes (Carlson et al.,
1984) and hydrolysis of phosphoinositides with the concomitant increment of radiolabeled
inositol phosphates (Raymond et al., 1983; Leung et al., 1986). At that time, increasing
evidence from other tissues strengthened the idea that inositol polyphosphates may function as
a second messenger for mobilizing Ca2+ from intracellular stores (Burguess et al., 1984); and
this mechanism may be responsible for inhibition of gonadotropin-induced cAMP and
progesterone production (Leung et al., 1986; Davis et al., 1987). In this regard, incubation of
luteal cells in Ca2+ free medium increased cAMP accumulation in response to LH. Also, the
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Ca2+ ionophore A23187 inhibited LH-stimulated cAMP accumulation in a dose-dependent
manner, although the inhibition was dependent on presence of extracellular Ca2+ (Dorflinger et
al., 1984). In addition, Ca2+ directly inhibited LH-sensitive adenylate cyclase activity at
concentrations consistent with known (IC50, ~ 10 M) intracellular values (Dorflinger et al.,
1984). Moreover, the inhibitory effect of Ca2+ was not due to stimulation of an increase in
cAMP degradation because inhibition occurred in cells incubated in presence or absence of a
cAMP phosphodiesterase inhibitor (Dorflinger et al., 1984). On the other hand, the effect of
PGF2 on LH-stimulated cAMP accumulation was independent of the presence of Ca2+ in the
medium, and the blockade of Ca2+ channels by verapimil did not affect the magnitude of
inhibition induced by PGF2 as well. Thus, it appeared that the luteolytic effect of PGF2 was
not dependent on an influx of extracellular Ca2+, instead, it seemed to be dependent on an
increase in intracellular Ca2+ by other means (Dorflinger et al., 1984; Davis et al., 1987).
In bovine luteal cells, PGF2 increased turnover of inositol phospholipid inducing a rapid (10
sec) and sustained (up to 60 min) increment in the concentrations of inositol phosphates (IP),
that was greater in magnitude in IP3 than IP2 and IP1 and independent of extracellular Ca2+
(Davis et al., 1987a; Davis et al., 1988). Also, PGF2 augmented concentrations of Ca2+ by 2 to
3 fold, again independent of extracellular Ca2+. In cultured SLC, removal of Ca2+ from the
medium reduced hormone-stimulated but not basal P4 production, whereas in LLC both basal
and stimulated P4 production were dependent on Ca2+ (Alila et al., 1990). Interestingly, the
finding that LH was able to enhance accumulation of cAMP as well concentrations of IP3 and
Ca2+ in bovine luteal cells indicated that LH actions are mediated by at least two second
messenger systems (Davis et al., 1987b). Hence, this fact implies that both LH and PGF2 use
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the same second messenger systems to produce opposite effects on P4 production by luteal
steroidogenic cells (Wiltbank et al., 1991).
Measurements of free intracellular Ca2+ in ovine individual SLC and LLC demonstrated
differential response of both cell types to PGF2 and calcium ionophore (A23187). Although
A23187 increased free intracellular Ca2+ in the two cell types, SLC underwent an abrupt and
marked increase in free Ca2+ that was highest by 30 s and gradually returned to baseline in the
time course of 3 min. Instead, LLC reached the greatest free Ca2+ by 90 s and required more
than 30 min to return to baseline values (Wiltbank et al., 1989a). In addition, PGF2 induced a
remarkable increase of intracellular Ca2+ in LLC but not in SLC; whereas LH did not affect free
Ca2+ concentration in either luteal cell type (Wiltbank et al., 1989a). The increment of
intracellular Ca2+ in PGF2 -stimulated LLC was dependent upon influx of extracellular Ca2+,
because inclusion of a Ca2+ channel blocker decreased and removal of extracellular Ca2+
eliminated the response to PGF2 (Wiltbank et al., 1989a).
At this point, it is clear that the IP3 increase after FP activation by PGF2 is associated to an
abrupt and transient increment of intracellular Ca2+ released from endoplasmic reticulum, in
whose membrane IP3 binds specific receptors (Vermassen et al., 2004). Nevertheless, other
intracellular organelles, such as the Golgi apparatus and secretory vesicles, may act as IP 3sensitive Ca2+ stores (Vermassen et al., 2004). The IP3 receptor has been characterized as a
tetrameric intracellular ligand-gated Ca2+ channel (250-300 kDa), bearing a large cytosolic
domain in which several regulatory molecules can bind, including IP3 and Ca2+, and
cooperatively modulate channel gating (Dawson, 1997). Three of the 4 IP3-receptor subunits
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are encoded by different genes and determine three IP3 receptor isoforms (types 1, 2 and 3)
(Südhof et al., 1991; Blondel et al., 1993; Yamada et al., 1994; Yamamoto et al., 1994). The
structure of the type 1 IP3 receptor has been better characterized and consists of a ligandbinding domain in the NH2 terminal portion, a coupling or modulatory domain in the middle
portion and a Ca2+ channel domain in the COOH-terminal portion (Mignery and Südhof, 1990).
The three IP3 receptor isoforms were identified in mouse granulosal cells (Díaz-Muñoz et al.,
2008); but only IP3 receptor type 2 was observed in granulosal and thecal cells of growing
follicles and luteal cells of developing CL in pigs (Steffl et al., 2004).
As indicated above, protein kinase C (PKC) is associated to PGF2 -induced inhibition of P4
production by luteal steroidogenic cells (Wiltbank et al., 1991). In ovine luteal cells, activity of
PKC was 4 times greater in LLC than SLC. Activation of PKC by phorbol 12-myristate 13acetate (PMA) caused an abrupt and dose-dependent inhibition of P4 production in LLC and
LH-, forskolin- and dbcAMP-stimulated SLC (Wiltbank et al., 1989b). Moreover, PMA
reduced P4 production in LLC treated with 25-hydroxycholesterol but that effect was not
demonstrated in LH-stimulated SLC. Apparently, the inhibitory action of PKC in SLC occurs
after LH binding and cAMP production because in forskolin-, dbaAMP- and LH-stimulated
cells, SLC P4 production was similarly inhibited. It is likely that PKC inhibition occurs prior to
enzymatic cleavage of cholesterol because inclusion of 25-hydroxycholesterol in the culture
medium did not affect P4 production by SLC in response to PMA (Wiltbank et al., 1989b). The
presence of lipoproteins in the culture medium increased P4 production in both LLC and LHstimulated SLC with a greater effect of high density lipoproteins (HDL) than low density
lipoproteins (LDL). In LLC, PGF2 significantly reduced P4 production in the presence but not
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in the absence of HDL or LDL; whereas in SLC stimulated or not with LH and/or HDL or
LDL, PGF2 did not reduce P4 production (Wiltbank et al., 1990). To further demonstrate if
PKC was mediating the inhibition of P4 by PGF2 , PKC-deficient or normal LLC stimulated
with LDL or HDL were cultured in presence or absence of PGF2 . As was expected, PGF2
reduced P4 production in PKC-normal LLC with LDL or HDL, but had no effect in PKCdeficient LLC (Wiltbank et al., 1990).
It seems to be evident that PKC mediates the antisteroidogenic actions of PGF2 in luteal
cells; nevertheless, the locus at which PKC blocks P4 production in LLC and SLC is apparently
different. Consistent with the differences in the IP3−Ca2+−PKC second messenger system
indicated above, SLC and LLC have other morphological and functional differences. For
instance, Fitz et al. (1982) reported that SLC in the ewe had 11 times greater LH receptors than
LLC (33260 and 3074 for SLC and LLC, respectively), whereas LLC contained 32 times
greater PGF2 receptors than SLC (62143 and 2115 for LLC and SLC, respectively). In
contrast, a later study in sheep from the same group indicated no differences in the number of
LH receptors between both types of steroidogenic cells during the mid-luteal phase (Harrison et
al., 1987). Although SLC were considerably more responsive to LH stimulus, LLC produced 6
to 8 times more P4 than SLC (Ursely and Leymarie, 1979; Harrison et al., 1987). Moreover,
pharmacological or physiological activation of the cAMP second messenger pathway did not
increase P4 production by LLC (Hoyer and Niswender, 1984). It was suggested that this
signaling pathway is constitutively activated in these steroidogenic cells and for that reason
stimulation of LLC with LH did not cause a further increment in P4 output (Hoyer and
Niswender, 1984; Diaz et al., 2002; Niswender et al., 2007).
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From the numerous PKC isoenzymes described in the literature, five forms, , I, II, , and
were detected in bovine luteal tissue (Sen et al., 2004). Whereas

, I, II variants were

detected in both luteal steroidogenic and endothelial cells, PKC was located exclusively in
steroidogenic cells of the CL (Sen et al., 2006). PKC II and PKC were expressed more in day10 than day-4 CL (Sen et al., 2004). In addition, PGF2 induced a significantly lower increase
in intracellular Ca2+ concentration in 4-day than 10-day CL in both LLC and SLC (Sen et al.,
2005; Choudhary et al., 2005). A PKC inhibitor reduced the PGF2 -induced calcium increase
in both LLC and SLC on day 10 (Sen et al., 2005). The magnitude of P 4 reduction induced by a
pharmacological increase of Ca2+ concentrations was lower in day-10 than day-4 CL
(Goravanahally et al., 2007). Moreover, down-regulation of PKC expression by siRNA
technology or blocking PKC activation reduced the effectiveness of PGF2 in reducing LHstimulated production of P4 (Sen et al., 2005; Goravanahally et al., 2007). Hence, these findings
strongly indicate that differential expression of certain components associated to signal
transduction triggered by PGF2 may account for lack of responsiveness of CL during early
development. Previously it was demonstrated that the insensibility of early CL to PGF2 was
not due to the lack of FP (Wiltbank et al., 1995; Mamluk et al., 1999), or limited capacity of
PGF2 to stimulate END1 (Choudhary et al., 2004; Choudhary et al., 2005) as had been
suggested (Levi et al., 2000). Instead, a lower expression of PGT and a greater PGE 2
production in the early CL may contribute to explain its resistance to luteolytic actions of
PGF2 (Arosh et al., 2004). However, new findings about differential expression of signaling
mediators of PGF2 strengthen the thesis espoused above (Goravanahally et al., 2009).
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Luteal PGF2 and luteolysis: a proposed model to explain the intraluteal mechanism that
regulates luteal regression in ruminants
As indicated elsewhere (Diaz et al., 2002; Wiltbank and Ottobre, 2003; Niswender et al.,
2007), the corpus luteum of several mammalian species has the capacity to synthesize PGF2 .
Luteal PGF2 is synthesized and secreted by LLC, and by autocrine and paracrine mechanisms
this hormone coordinates and participates in the successive intracellular and intercellular events
that are conducive to the functional and structural disappearance of the CL. In the bovine CL,
LLC have the molecular and metabolic machinery related with the synthesis, transport, and
signaling of both PGF2 and PGE2 (Arosh et al., 2004). For instance, Cox-2, PGES, PGT, EP2,
EP3 and FP were greatly regulated, whereas Cox-1, PGFS and PGDH were expressed
uniformly throughout the luteal lifespan. Accordingly, synthesis of PG during the bovine
estrous cycle is directed selectively toward PGE2 in early luteal phase and toward PGF2 during
luteal regression, but it is nonselective during mid-luteal phase (Arosh et al., 2004). Likewise,
in sheep, exogenous PGF2 induced expression of Cox-2 but not Cox-1; Cox-2 mRNA
expression increased about 10 fold in less than 1 h after PGF2 was added to cultured LLC
(Tsai and Wiltbank, 1997). Also, Cox-2 mRNA was greater expressed in LLC than SLC (4507
vs 323 copies/cell). These findings indicate that LLC respond to uterine PGF2 by increasing
synthesis of luteal PGF2 within 1 h or less, and in that way intraluteal PGF2 signal is
amplified several times by a positive feedback loop (Tsai and Wiltbank, 1997), in which luteal
oxytocin and other mediators may be involved (Townson and Pate, 1994; 1996; Mann, 1999;
Kotwica, 1999; Shirasuna et al., 2007).
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The importance of intraluteal production of PGF2 during luteolysis was demonstrated by
applying a different experimental approach (Niswender et al., 2007). On day 10 of the ovine
estrous cycle, an implant with 0, 1 or 10 mg of indomethacin (inhibitor of PG synthesis) was
delivered into the CL. Progesterone production was significantly greater on days 13 through 16
of the cycle and CL were heavier in indomethacin(10 mg)-treated than in control ewes
(Niswender et al., 2007). Thus, it seems that luteal PGF2 is required in both functional
(decreasing steroidogenic capacity) and structural (inducing apoptosis and tissue degradation)
phases of luteolysis.
Recently, Niswender et al. (2007) proposed a model to explain the intraluteal mechanism
that regulates luteal regression in ruminants. In this model, the authors suggested that although
luteolysis is initiated from extra-luteal influence (endometrial PGF2 ), the mechanisms that
ultimately lead to the demise of the CL are orchestrated by the corpus luteum itself through
autocrine and paracrine actions of luteal PGF2 and oxytocin. Thus, once the uterine signal
initiates luteal regression, increased luteal secretion of PGF2

triggers mobilization of

intracellular Ca2+ in large luteal cells and secretion of oxytocin by these cells. Oxytocin in turn,
increases concentrations of Ca2+ in small luteal cells. Apoptosis follows Ca2+ mobilization in
both cell types. Likewise, as was indicated elsewhere in this review, several other factors
secreted from nonsteroidogenic cells of luteal origin (vascular smooth muscular cells,
endothelial cells, and immune cells) interact with steroidogenic cells to support luteolytic
actions of luteal PGF2 (Figure 2).
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Figure 2. Cellular interactions during luteal regression.
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Endothelin system: a modulator of ovarian function

Ovarian function is regulated mainly by the pituitary gonadotropins, follicle-stimulating
hormone (FSH) and luteinizing hormone (LH), through their receptors. However, numerous
factors such as steroid hormones, peptides and growth factors, produced locally or not, play
essential modulatory roles in follicular and luteal function (Tisdall et al., 1995; Schams and
Berisha, 2002; Webb et al., 2002; Lopez et al., 2005).
Endothelins (END), a family of 21-amino acid peptides constituted by three different
isoforms (END1, END2 and END3), are involved in a wide variety of biological functions in
diverse tissues (Kedezierski and Yanagisawa, 2001). The most relevant END family member
associated with female reproductive function, END1, has been identified in the ovary of several
mammalian species (Usuki et al., 1991; Iwai et al., 1991; Flores et al., 1992; Kamada et al.,
1993; Tedeschi et al., 1994; Mancina et al., 1997; Flores et al., 2000; Hinckley and Milvae,
2001; Schams et al., 2003; Boiti et al., 2005).
In the corpus luteum, END1 plays an important role in mediating PGF2 -induced luteal
regression. END1 reduced both basal and LH-stimulated progesterone secretion in a dosedependent manner, and its inhibitory effect was prevented by the addition of a selective
ENDRA receptor antagonist (Girsh et al., 1996a; Hinckley and Milvae, 2001; Doerr et al.,
2008). In antral follicles, END1 acts as a modulator of the steroidogenic function of granulosal
cells. Both LH- and FSH-stimulated progesterone and cAMP production in granulosal cells
were suppressed by END1 in a dose-dependent manner (Iwai et al., 1991; Flores et al., 1992;
Kamada et al., 1993; Flores et al., 1999). Thus it appears that END1, acting through autocrine
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and paracrine mechanisms, inhibits the luteinization of granulosal cells until near time to
ovulate, when its activity is abolished and all events conducive to ovulation take place.

Brief description of endothelin system
The endothelin system consists of a group of peptides (ligands) and proteins (enzymes and
receptors) involved in a wide variety of physiologic and pathologic roles in numerous
mammalian tissues (Nussdorfer et al., 1999; Kedezierski and Yanagisawa, 2001). These
molecules have been described as two G-protein-coupled receptors, three peptide ligands, and
two activating peptidases (Pinet et al., 2004).
Endothelin-1 (END1), a peptide constituted of 21 amino acids, originally was isolated from
porcine aortic endothelial cells as a potent vasoconstrictor (Yanagisawa et al., 1988).
Endothelin-2 (END2) and endothelin-3 (END3) were discovered later and constitute two
structurally-related peptides that differ from END1 by two and six amino acids, respectively
(Fig. 3; Inoue et al., 1989). Endothelins are synthesized as large molecules (~200 amino acids)
named preproendothelins (ppEND), which are cleaved into three physiologically active
endothelin peptides (Fig. 4) through two consecutive enzymatic steps (Rubanyi and Polokoff,
1994). The first step involves a furin-like protease that converts pp-ENDs into an inactive END
precursor (p-ENDs; ~37 to 41 amino acids). The second step is performed by a specific
endopeptidase (zinc metalloendoeptidase) known as endothelin-converting enzyme (ECE),
which consists of two isoforms: ECE1 and ECE2 (Xu et al., 1994; Emoto and Yanagisawa,
1995).
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Figure 3. Molecular structure of endothelin peptides. The unshaded circles illustrate the
variable amino acid sequence of human endothelins showing the amino acid substitution of
END2 and END3 with respect to END1 (Modified from Nussdorfer et al., 1999). Each END
peptide is encoded by a different gene. The three genes have different chromosomal
localization and are differentially regulated. END isoforms are molecularly similar to
cardiotoxic peptides isolated from the venom of Atractacpis engaddensis.
Two membrane receptors (ENDRA and ENDRB) have been identified as responsible for the
intracellular signals that cause the different biological effects of ENDs described in the
scientific literature (reviewed by Nussdorfer et al., 1999 and Kedezierski and Yanagisawa,
2001). ENDRA has a very high affinity for END1 and END2 and around 70 to 100% lower
affinity for END3, while ENDRB binds with high and similar affinity to all three END
peptides. Each END receptor is encoded by a different gene.
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Figure 4. Molecular components of endothelin pathway (Modified from Pinet et al., 2004).
Although END1 was described originally as a potent vasoconstrictor, currently innumerable
biological effects of this peptide family are known in a wide variety of tissue, taking part not
only in physiological but also in pathological functions in human beings and animals. ENDRA
receptor has around 100 fold more affinity for END1 and END2 than END3, while ENDRB
receptor interacts on a non-selective manner with three END peptides.

Molecular characteristics of endothelin receptor type A
Endothelin receptors have been isolated and cloned from mammalian tissues and the
structures of the mature receptors have been deduced from the nucleotide sequences of the
cDNA (Arai et al., 1990; Sakurai et al., 1990). ENDRA structure is consistent with a seventransmembrane domain (7TM), G protein-coupled receptor belonging to the rhodopsin-type
receptor family. Binding of END to ENDRA and ENDRB activate at least three classes of G
proteins (G s, G

1

and G q) (Miyauchi and Masaki, 1999). ENDRA has an extracellular NH2-

terminal domain, a seven transmembrane-spanning domain, and intracellular COOH-terminal
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domain. The transmembrane domains consist of seven amphipathic membrane-spanning helices
joined together by three intracellular and three extracellular loops. The ENDRA receptor has an
N-terminal signal sequence with a relatively long extracellular N-terminal portion preceding
the first transmembrane domain (Figure 5). There are two separate ligand-interaction subdomains, and the extracellular loops, particularly between transmembrane domains 4 to 6,
determine selectivity (Devenport and Maguire, 2006).

Figure 5. Structure of endothelin receptor type A

Activation of ENDRA receptors produces a range of biological effects in different tissues.
END1 is known as one of the most potent vasoconstrictors. In the ovary of Chinese hamster,
for example, END1 through ENDRA receptor induces the release of arachidonic acid (AA)
from the cell membrane (Trevesi et al., 2002). END1-induced vascular contraction is
accompanied by an increase in calcium (Ca2+) through its mobilization from intracellular stores
and as result of transmembrane Ca2+ influx. Also, extracellular Ca2+ influx plays a critical role
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in END1-induced arachidonic acid (AA) release from membrane lipids by activating ENDRA
receptor. In the ovary of hamsters, AA was released by activating two types of Ca2+ permeable
nonselective cation channels and a store-operated Ca2+ channel, which were activated by Gq
and G12 proteins coupled to ENDRA receptor (Kawanabe et al., 2003).
Binding of END1 to ENDRA changes its conformation and alters the conformation of the G
protein bound to the receptor. The alteration of

subunit of the G protein allows it to exchange

its GDP for GTP and causes the G protein to break up into two active components,
and

complex. Immediately

subunit or

subunit

complex activates phospholipase C (PLC) and

the IP3 and DAG pathway (Trevisi et al., 2002) described above for PGF2 . Alternatively, in
human vascular endothelium, PKC and non- receptor protein tyrosine kinase (PTK) activated
by END1 through its receptor ENDRA, regulate the expression of endothelial nitric oxide
synthase (eNOS) at the genomic level and stimulate NO production (Marsen et al., 1999).
In addition, in various cell types, ENDRA receptors activate PLC to produce IP3 as well as
DAG. The IP3 stimulates release of Ca2+ from IP3-sensitive stores (endoplasmic reticulum) and
subsequent activation of store-operated Ca2+ channels. After or concomitant with the release of
Ca2+ from intracellular stores, a second phase is initiated in which Ca2+ moves into the cell
from the extracellular compartment. The resulting Ca2+ influx is responsible for an additional
component of the END1-induced contraction of rat main pulmonary artery (Hyvelin et al.,
1998).
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Role of END1 in follicular function
END family members have been identified in ovarian antral follicles from pig (Iwai et al.,
1991; Kamada et al., 1993; Flores et al., 1995; Flores, 2000), rat (Iwai et al., 1993; Tedeschi et
al., 1994), cow (Acosta et al., 1998; Levy et al., 2003) and human being (Magini et al., 1996;
Mancina et al., 1997). Their general role appears to be to regulate steroid production by
granulosal and thecal cells of antral follicles (Iwai et al., 1991; Tedeschi et al., 1992; Flores et
al., 1992; Kamada et al., 1993) by acting as a local modulator of ovarian function.
Measurable amounts of END1 (Iwai et al., 1991) were lower in porcine follicular fluid of
small (1 to 2 mm) than medium (3 to 5 mm) or large (6 to 11 mm) follicles (9.4 ± 1.1 vs 12.2 ±
1.1 b and 14.2 ± 1.8 pg/ml, respectively; P<0.05); and greater in porcine granulosal cells
cultured with LH than FSH (56 ± 9.3 and 4.9 ± 1.8 pg/106 cells × h, respectively) (Iwai et al.,
1991). Also, cultured porcine granulosal cells collected from large antral follicles (9 to 10 mm)
had three fold greater (P<0.05) binding capacity for END1 than granulosal cells from small
follicles (2 to 5 mm; Flores et al., 1995). Studies in porcine ovaries have demonstrated that
greater binding capacity for END1 (Flores et al., 1995) and higher immunoreactivity of END1
(Flores, 2000) were restricted to vascular and granulosal cell compartments of antral follicles.
END1 gene expression in ovarian follicles started around the antral stage; it increased as
follicles developed toward the periovulatory stage, and it decreased immediately after ovulation
(Flores, 2000). Likewise, large antral follicles expressed higher immunoreactivity to END1
(66.7%) and underwent less atresia (20%) than small antral follicles (16.8 and 40%,
respectively).
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Multiple evidence has indicated that END can modulate steroidogenic function of GC in
several mammalian species (Iwai et al., 1991; Kamada et al., 1992; Flores et al., 1992;
Tedeschi et al., 1992; Kamada et al., 1993; Tedeschi et al., 1994; Magini et al., 1996; Calogero
et al., 1998; Plonowski et al., 1999; Denkova et al., 2000; Denkova et al., 2002; Yaneva et al.,
2003). Significantly less LH- (Iwai et al., 1991), hCG- (Kamada et al., 1993) and FSHstimulated (Flores et al., 1992; Kamada et al., 1993) accumulation of progesterone was
quantified in GC cultured in presence of END1. Both FSH- and LH-stimulated progesterone
accumulation decreased in a dose-dependent manner (Iwai et al., 1991; Kamada et al., 1993).
Similarly, LH- and FSH-stimulated cAMP production in granulosal cells was suppressed by
END1 in a dose-dependent manner (Iwai et al., 1991; Flores et al., 1992; Flores et al., 1999).
The cellular mechanism by which END1 reduced the FSH-stimulated progesterone production
in the rat, could be by inhibiting some progesterone-forming enzymes (Flores et al., 1999)
and/or by stimulating progesterone-degrading enzymes (Tedeschi et al., 1992). This mechanism
would imply the activation of phosphoinositide-calcium-PKC pathway and the obstruction of
FSH-stimulated steroidogenesis by inhibiting cAMP production (Flores et al., 1999).
Three END isoforms had similar inhibitory effects on progesterone production by porcine
(Iwai et al., 1991; Kamada et al., 1993) and murine (Tedeschi et al., 1994) granulosal cells.
Therefore, it has been suggested that the nonselective receptor, ENDRB, could be involved in
that action (Iwai et al., 1991; Tedeschi et al., 1994). Iwai et al. (1993) documented the presence
of abundant ENDRB mRNA on granulosal cells of developing follicles in rat. However,
competitive binding assays and receptor agonist competition experiments, performed in
cultured granulosal cells, indicated that type A is the most important END receptor in the
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porcine ovary (Flores et al., 1995). The latter authors suggested that such divergences could be
attributed to different methodologies and species used in these studies.

Role of END1 in luteolysis
Prostaglandin F2 has been documented as the main luteolytic factor in many mammalian
species (Niswender et al., 2000). However, it is currently known that numerous other factors
participate in luteolysis (McCracken et al., 1999), some of which act in a paracrine or/and
autocrine manner (Girsh et al., 1996a; Shirasuna et al., 2006). PGF2 suppressed the P4
secretion from large luteal cells only in the presence of endothelial cells, so Girsh et al. (1995)
suggested that one or more factors produced in the microvascular tissue of the CL could be
involved in that process. At that time, END1 was proposed as a possible mediator in PGF2 induced luteal regression, and subsequent evidence corroborated that hypothesis (Girsh et al.,
1996a; Miyamoto et al., 1997; Doerr et al., 2008).
Studies in ruminants confirmed that END1 reduces both basal and LH-stimulated P4
secretion in a dose-dependent manner (Girsh et al., 1996a; Hinckley and Milvae, 2001), and
that the inhibitory effect could be prevented by the addition of a selective ENDRA receptor
antagonist (Girsh et al., 1996a; Doerr et al., 2008). Apparently, END1 is synthesized and
secreted only by vascular endothelial cells, because END1 could not be detected in either
luteal-like cells or luteal cell extract (Girsh et al., 1996a). On the other hand, a significantly
greater content of ENDRA and expression of END1 mRNA were detected in CL collected on
day 18 of the bovine estrous cycle compared with those collected on day 5 and 10 of the cycle
(Girsh et al., 1996b). In concordance with the latter finding, greater amounts of ECE-1 mRNA
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expression were observed at middle (days 7 to 12) and late (days 13 to 16) stages of luteal
phase than at earlier stages (Levy et al., 2001, 2003). The greater END content and mRNA
expression coincided with high amounts of PGF2 present during luteolysis and concur with the
fact that END1 secretion increases in response to PGF2 in vitro (Girsh et al., 1996a; Miyamoto
et al., 1997) and in vivo in microdialysed CL (Ohtani et al., 1998). However, END1 is not
regulated by PGF2 early in the cycle and it is present in the natural CL (Wright et al., 2001;
Choudhary et al., 2004).
Peripheral plasma concentrations of END1 during the bovine estrous cycle remained low
from days 2 to 12, increased on days 13 to 19 and reached the greatest values on days 20 to 22
(Ohtani et al., 1998). Low expression of END1 peptide and mRNAs for END1, ECE1 and
ENDRA (Ohtani et al., 1998; Mamluk et al., 2001; Levy et al., 2001; Wright et al., 2001; Levy
et al., 2003; Choudhary et al., 2004) at early stages of the luteal phase are coincident with the
time when the CL is refractory to luteolytic doses of PGF2 (Braun et al., 1988; Levy et al.,
2000). However, CL has enough PGF2

receptors from day 2 of estrous cycle for initiating

luteolysis (Wiltbank et al., 1995). So, the lack of response of CL to the luteolytic action of
PGF2 may be because incomplete neovascularization of CL in that developmental stage limits
END1 synthesis (Levy et al., 2000). However, subsequent evidence indicated that endothelin
system in the bovine CL is regulated by PGF2 in a dependent or independent manner
according to the phase of the estrous cycle (Choudhary et al., 2004). Before day 10 of estrous
cycle, the amounts of mRNA encoding END1, ECE1, ENDRA and ENDRB increased
independently of PGF2 ; whereas PGF2 differentially affected expression of ppEND1 and
ENDRA after day 10 of estrous cycle (Choudhary et al., 2004). So, these findings do not
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support the involvement of END1 in the differential sensitivity of CL to PGF2 in early versus
later stages of luteal phase.
In recent years, data from various in vivo studies have confirmed and strengthened the
concept that END1 is an important mediator of PGF2 -induced luteal regression. Infusions of
BQ-610 (500 g), a highly specific ENDRA antagonist, every 12 h on d 16 through 18 of the
estrous cycle in heifers delayed luteolysis for about 2 days (Keator et al., 2008). Chronic
administration of BQ-610 into the CL through a minipump implanted in the ovary during the
mid-luteal phase in sheep, decreased serum P4 concentration throughout first 12 h after a single
injection of PGF2 . However, P4 progressively increased during the next 36 h, attaining a
concentration similar to the control group 48 h after PGF2 (Doerr et al., 2008). Apparently, a
direct action of PGF2

decreased serum P4 during early luteolysis, whereas END1 was

required in later stages as indicated by the rise of P4 in BQ-610-treated ewes beginning 12 h
after PGF2 ; this would imply that END1 may participate in structural rather than functional
luteolysis. In contrast, administration of an ENDRB antagonist (BQ-788) in the same
experiment did not reverse the reduction of P4 after PGF2 (Doerr et al., 2008). This finding
agreed with the fact that ENDRB mRNA expression was almost absent in mid-phase CL (Doerr
et al., 2008), indicating that END1 participates in the luteolytic cascade by activating ENDRA.
Intraluteal injections of ENDRA antagonists (BQ-610, BQ-123 and LU-13522) were less
effective to address the role of END1 PGF2 -induced luteolysis. A single injection of BQ-123
(100 g) on days 8 to 9 of the estrous cycle in sheep diminished, but did not completely block
peripheral P4 concentration during 24 h in response to a luteolytic dose of PGF2 (Hinckley and
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Milvae, 2001). The authors suggested that activation of ENDRB may have contributed to the
incomplete inhibition of END system or BQ-123 was less effective in blocking ENDRA than
other antagonists. Also, single or multiple intraluteal injections of ENDRA antagonists during
bovine mid-luteal phase were ineffective to prevent P4 decline as was reported in sheep. In both
heifers (Keator et al., 2008) and cows (Watanabe et al., 2006) P4 concentration after a
luteolytic dose of PGF2 decreased parallel to control females.
To test the role of END1 in PGF2 -induced luteolysis, sheep were injected (im) with saline,
7.5 mg of PGF2 , 100 g of END1, or 7.5 mg of PGF2 plus 100 g of END1 during midluteal phase (Hinckley and Milvae, 2001). END1 transiently increased plasma P4
concentrations that thereafter decreased progressively attaining minimal values simultaneously
with saline-treated group. Dosage of PGF2 first decreased concentrations of P4 for about 6 h
and then P4 increased to similar values as in saline-treated ewes. Interestingly, combination of
PGF2 and END1 reduced plasma P4 concentration from 0.25 h to 48 h post-treatment, time at
which P4 reached luteolytic concentrations (less than 0.5 ng/mL). The combination also
shortened the estrous cycle (10.3 d) compared with the rest of the groups (about 16 d each).
These findings support the role of END1 as a mediator of the intricate luteolytic cascade
initiated by uterine PGF2

and modulated by luteal PGF2

Apparently, presence of PGF2

and other local mediators.

is required so that END1 exerts its luteolytic effect as

demonstrated by Miyamoto et al. (1997) in an in vitro study.
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Role of END1 in steroid production by ovine granulosal cells collected from
large preovulatory follicles
Introduction
In sheep, follicular growth occurs in a wave-like pattern with typically 3 to 4 follicular
waves during every estrous cycle (Ginther et al., 1995; Bartlewski et al., 1999; Evans et al.,
2003). Follicular dominance is not as marked in sheep as is in the cow (Lopez-Sebastian et al.,
1997; Gonzalez-Bulnes et al., 2001; 2004). Neither the presence of a large follicle induced by
exogenous FSH nor supraphysiological concentrations of estradiol released from implants
prevented emergence of a new wave of follicles (Duggavathi et al., 2004; 2005; Barrett et al.,
2006). Likewise, more than 2 antral follicles from ultimate and penultimate waves of the cycle
may reach ovulatory status and eventually ovulate (Souza et al., 1997; Bartlewski et al., 1999).
Preovulatory follicles produce greater amounts of estradiol (Duggavathi et al., 2003); and
elevated concentrations of circulating estradiol trigger the LH/FSH surge and the consequent
ovulation process (Karsch et al., 1983). After the LH surge, the predominant pattern of steroid
production by the preovulatory follicles changes rapidly from estrogen to progesterone as the
main steroid secreted by granulosal and thecal cells (Murdoch and Dunn, 1982; Fortune and
Hansel, 1985). The downregulation of P450-17 -hydroxylase and P450arom in thecal and
granulosal cells, respectively, and upregulation of progesterone receptor in the two types of
steroidogenic cells appear to support this change (Voss and Fortune, 1993a; Komar et al., 2001;
Jo et al., 2002). Likewise, steroid production by granulosal and thecal cells of large follicles is
regulated by numerous factors through autocrine and paracrine actions: insulin (Spicer et al.,
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2002), BMPs (Gliser et al., 2004; Campbell et al., 2006), BMP15 (Juengel et al., 2002), GDF9
(Spicer et al., 2006; 2008), inhibin (Jimenez-Krassel et al., 2003), estradiol (Spicer et al., 2005),
IGFs (Spicer et al., 2002; 2004), and END1 (Flores et al., 1992; Kamada et al., 1993; Acosta et
al., 1998), modulate steroid production through autocrine and paracrine mechanisms, and might
prevent premature differentiation of granulosal and thecal cells of preovulatory follicles prior
to LH/FSH surge.
Endothelin 1, a 21-amino acid peptide, was described originally as a potent vasoconstrictor
(Yanagisawa et al., 1988) and later associated with modulation of steroidogenesis in follicular
and luteal tissue from rats (Tedeschi et al., 1992; 1994; Colagero et al., 1998), pigs (Iwai et al.,
1991; Flores et al., 1992; Kamada et al., 1992; 1993), cows (Girsh et al., 1996a; Miyamoto et
al., 1997), ewes (Hinckley and Milvae, 2001; Doerr et al., 2008) and human beings (Denkova
et al., 2000; Yaneva et al., 2003). Endothelin 1 is synthesized and secreted from ovarian
granulosal cells, and greater amounts of END1 were detected in larger than in smaller antral
follicles (Iwai et al., 1991; Flores et al., 2000). The antisteroidogenic effect on granulosal cells
appeared to be mediated via ENDRA in pigs (Flores et al., 1995) and ENDRB in rats (Iwai et
al., 1993). The END1 mRNA expression in pigs was detected first around the antral stage,
increased as the follicles grew, and decreased rapidly after ovulation (Flores, 2000). In the rat
ovary, inhibition of P4 production in granulosal cells by END1 was associated with
downregulation of P450scc and 3 -HSD and upregulation of 20 -HSD, 5 -reductase and 3 HSD (Tedeschi et al., 1992), enzymes implicated in synthesis and metabolism of P4,
respectively. Moreover, in bovine microdialyzed mature follicles, END1 inhibited P4 secretion
and stimulated E2 secretion (Acosta et al., 1998; 1999). Although there is no evidence of a role
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of END1 in regulating steroidogenesis in sheep follicles, on the basis of previous experimental
evidence, it is possible to speculate that END1 acting through autocrine and paracrine
mechanisms, might prevent premature luteinization of granulosal cells prior to the LH surge in
sheep as suggested in other species (Tedeschi et al., 1992; Flores, 2000).
The objective of this study was to examine the effect of blocking ENDRA and ENDRB on
follicular steroid production by granulosal cells from preovulatory follicles in sheep. The
hypothesis was that END1 acting through ENDRA and/or ENDRB would inhibit steroid
production, and therefore, prevent the premature luteinization of granulosal cells of ovine
preovulatory follicles.

Materials and methods

General experimental procedure
Seventeen nonpregnant cycling Suffolk ewes with at least one previous estrous cycle of
normal length (15 to 19 days) were used in the experiment, conducted in fall of 2006
(September-December) with ewes from the West Virginia University research flock. For
observation of estrus (12 h intervals), ewes were penned with a vasectomized ram bearing a
harness with a crayon in the area of the brisket; standing estrus was confirmed by teasing with
another vasectomized ram. Fourteen days after estrus (estrus = day 0) ewes were injected (i.m.)
with two doses (5 mg each) of PGF2 (Lutalyse®, Pfizer Animal Health, New York, NY) 3 h
apart (Hawk, 1973) to induce luteolysis. To verify that a surge of LH had not occurred before
collection of follicles, jugular blood samples (8 ml) were collected at h -3, 0, 6, 12, 18, 24, 30
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and 36 in relation to the second dose of PGF2 (Fig. 6). Blood samples were refrigerated for 24
h to allow them to clot, and then centrifuged for 20 minutes at 2500 rpm. Serum was collected
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Figure 6. Protocol for collection of preovulatory follicles in sheep

Thirty six to 40 hours after the second dose of PGF2 , ewes were anesthetized with 0.3
mg/kg diazepam (Valium, 5 mg/ml; Roche Pharmaceutivals, Nutley, NJ) and 7 mg/kg ketamine
(Vetamine, 100 mg/ml; Mallinckrodt Veterinary, Mundelein, IL), and then placed on a mixture
of halothane (Halocarbon Laboratries, Riveredge, NJ), oxygen (2.0 L/min) and nitrous oxide
gas (1.0 L/min) until bilateral ovariectomy was carried out through a mid-ventral incision.
Immediately after ovariectomy, ovaries of each ewe were placed in cold phosphate buffered
saline (PBS) and stored on ice until completion of the surgery. Follicles were dissected and
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granulosal cells were harvested. All animal procedures were approved by WVU Institutional
Animal Care and Use Committee (ACUC # 05-1205).

Culture of granulosal cells and treatments
Ovarian stroma was removed from 28 presumed preovulatory follicles (1.7 ± 0.8
follicles/ewe) and the diameter of each dissected follicle was recorded (9.2 ± 1.5 mm). Using a
22-gauge needle attached to 3 mL syringe, follicular fluid (FF) of each follicle was aspirated
and centrifuged at 400 × g at 4 C for 5 min and the supernatant stored at -20 C for subsequent
steroid determination by RIA; the remaining granulosal cells were added to those granulosal
cells obtained directly from the follicle (see below).
Each follicle was bisected under sterile conditions and granulosal cells were scraped gently
from the basement membrane with a spatula into F12 Nutrient Mixture (Ham’s F12) media
supplemented with sodium bicarbonate (0.01 M), antibiotics (1.5 mg of penicillin/mL and 2.5
mg of streptomycin/mL) and 19-OH androstenedione (1 M) (Jimenez-Krassel and Ireland,
2002). Granulosal cells were rinsed in cold Ham’s F12 supplemented medium, centrifuged at
400 × g for 5 min at 4 C and resuspended in 200 L of cold Ham’s F12 supplemented medium.
This last procedure was repeated twice. The number of cells and cell viability were estimated
using a hemocytometer and trypan blue exclusion dye, respectively. According to the number
of granulosal cells harvested from each follicle, additional volume of Ham’s F12 supplemented
medium was added to cell suspension. Approximately 5.9 ± 2.6 × 105 cells were cultured in
each well. Nevertheless, because differentiating viable and non-viable cells by the trypan blue
method was sometime difficult, steroid concentrations per well were normalized against total
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protein content per well and expressed as pg of steroid per g of protein per 24 h. Total protein
at end point of the incubation period was quantified by colorimetric method using the
Coomassie Protein Assay (Pierce Biotechnology, Inc., Rockford, IL).
Aliquots of 15 L of granulosal cell suspension obtained from each presumed preovulatory
follicle were cultured in 96-well plates containing a solution, previously equilibrated at 37 C,
of 185 L of Ham’s F12 supplemented medium and treatments (described in Table 1). Cultures
were incubated at 37 °C in a humidified atmosphere (5% CO2 and 95% air) for 24 h. Once
finished the incubation period, the medium was removed carefully from each well, centrifuged
(3000 × g for 1 min at room temperature) and stored at -20°C for subsequent steroid assays by
RIA. Cultured granulosal cells and the remaining volume of granulosal cells in suspension were
stored at -20°C.

Radioimmunoassays for LH, progesterone, and estradiol
Concentrations of P4 and E2 in FF and culture media, and LH concentrations in serum were
measured in duplicate by RIA as previously described (Sheffel et al., 1982; Tortonese et al.,
1990; Goodman et al., 2004). LH assay sensitivity averaged 0.54 ng/ml, and the intraassay
coefficient of variation was 15%. Intraassays coefficient of variation and sensitivities for P4 and
E2 in unextracted FF were 8.6%, and 34 pg/tube for P4 and 10.6%, and 32 pg/tube for E2,
respectively. For P4 and E2 in culture media, the inter- and intra-assay coefficient of variation
and sensitivities were P4, 12.3%, 14.4%, and 0.20 ng/ml; and E2, 13.0%, 14.9%, and 0.25
pg/ml.
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Treatments used to evaluate the role of END1 in steroid production by granulosal
cells from preovulatory follicles in sheep.

Table 1.

Treatments

Description

Doses

1

Control

Ham’s F12 (Sigma-Aldrich, Milwaukee, WI) supplemented
media

─

2

LH

Luteinizing hormone (LH, NIADDK-oLH-25 AFP 5551B;)

150 ng/mL

3

END1

Endothelin-1 peptide (END1; Bachem Bioscience Inc, King
of Prussia, PA)

100 nM

4

LH+ END1

5

ENDRAa

6

ENDRAa+LH+ END1

7

ENDRBa

8

ENDRBa +LH+END1

9

ENDRAa+ ENDRBa

10

ENDRAa+ENDRBa+
LH+END1

─
selective END receptor type A antagonist (ENDRA): BQ610 (Azepane-1-carbonyl-leu-D-Trp(For)-D-Trp-OH;
Bachem Bioscience Inc, King of Prussia, PA)

1500 nM

─
selective END receptor type B antagonist (ENDRB): BQ788 (N-cis-2,6-Dimethylpiperidinocarbonyl)-D-Nle-OH;
Bachem Bioscience Inc, King of Prussia, PA)

1000 nM

─
END receptor types A and B antagonist (ENDRA+B)

─
─

Statistical Analysis
Concentrations of P4 and E2 in culture media were evaluated by one-way analysis of
variance using the General Linear Model (GLM) procedure of SAS (SAS Institute; Cary, NC).
Differences among means were compared by the LSM procedure of SAS. Data were expressed
as mean ± SEM. Antral follicles with greater concentrations of P4 and androgens than E2 were
considered atretic (Morr et al., 1978; Ireland and Roche, 1982), and estrogen-inactive (P4>E2)
(Ireland and Roche, 1983) follicles were removed from the analysis. Estrogen-active follicles
(E2>P4) were categorized according to E2 concentration in FF into three groups (1:

250
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ng/ml; 2: > 250

350 ng/ml, and 3: > 350 ng/ml) and included as a discrete variable in the

statistical model. Two ewes had concentrations of LH greater than 180 ng/ml in samples
collected at 24 or 30 h after the second dose of PGF2 , and their follicles were excluded from
the analysis. The final number of follicles examined was 20, which were collected from 13
ewes. For 9 of these follicles, cells were cultured in duplicate and the average value was
utilized.
Results

Accumulation of E2 and P4 was not affected by either LH or END1 or the END receptor
blockers (Fig 7). Correlations between concentration of E2 in FF and E2 and P4 accumulation in
the culture media were 0.30 (P < 0.0001) and 0.26 (P < 0.0004), respectively. Granulosal cells
from follicles with the greatest concentration of E2 in FF produced on the average significantly
more E2 and P4 than follicles with lower concentrations of E2 in FF (Table 2). Treatments did
not affect accumulation of E2 and P4 in any of the categories of follicles considered (Fig 8).
However, for all treatments, granulosal cells from preovulatory follicles with the greatest
concentration of E2 in FF produced greater amounts of E2 and P4 than preovulatory follicles
with lower concentration of E2 in FF (Fig 8).
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Steroid accumulation in media from cultured granulosal cells according to
estradiol concentration in follicular fluid from preovulatory follicles

Table 2.

Concentration of E2 in follicular fluid (ng/ml)

Steroid

≤ 250

> 250 ≤ 350

0.75 ± 0.06 a

Estradiol

> 350

0.80 ± 0.08 a

145.0 ± 3.9 a

Progesterone

Significance
level

1.97 ± 0.07 b

170.8 ± 5.9 b

203.4 ± 7.6 c

a,b

P<0.0001

a,b,c

P<0.0001
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Figure 7. Effects of LH, END1, ENDRAa (BQ-610) and ENDRBa (BQ-788) on production of
estradiol and progesterone by ovine granulosal cells isolated from preovulatory follicles. Bars
represent mean ± SEM of estradiol (panel A) or progesterone (panel B) accumulation expressed
in pg/ g of protein in 24 h.
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Figure 8. Effects of LH, END1, ENDRAa (BQ-610) and ENDRBa (BQ-788) on production of
estradiol and progesterone by ovine granulosal cells isolated from preovulatory follicles.
According to concentration of estradiol in follicular fluid, preovulatory follicles were
categorized into three groups (1: 250 ng/ml; 2: > 250 350 ng/ml, and 3: 350 ng/ml). Bars
represent mean ± SEM of estradiol (panel A) and progesterone (panel B) accumulation
expressed in pg/ g of protein in 24 h. Values were statistically different between groups 1 and
2 versus group 3 ( P < 0.001) for estradiol (panel A) and between groups 1 and 3 ( P < 0.02) for
progesterone.
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Discussion
Granulosal cells from preovulatory follicles with greater concentrations of estradiol
produced more E2 and P4, most likely due to the greater steroidogenic capacity of these follicles
(Tian et al., 1995) compared to follicles with lower estrogenic production. Dominant follicles
expressed greater amounts of mRNA for LH receptor, P450scc, P450c17 and 3 HSD in thecal
cells and P450arom in granulosal cells than subordinate follicles (Xu et al., 1995b; Bao et al.,
1997a; Bao et al., 1997b). Moreover, follicular dominance was associated with onset of
expression of LH receptor and 3 HSD in granulosal cells (Bao et al., 1997a; Bao et al., 1997b;
Beg et al., 2001). Hence, in the preovulatory follicles collected in this study, greater steroid
production may be supported by a greater expression of LH receptor and steroidogenic
enzymes in the two populations of endocrine cells, theca and granulosa. It is clear that some
preovulatory follicles collected from either the same or different animals may have had
functional advantages over others with lower rank. Thus, granulosal cells from those follicles
reflected more steroidogenic capacity with greater accumulation of E2 and P4 after 24 h of
culture. In addition, given that the substrate for synthesis of estradiol was provided in culture
media, aromatization of androstenedione to estradiol by granulosal cells was carried out
rapidly.
Unexpectedly, LH did not induce an increase of either E2 or P4. Evidence indicated that LH
and FSH stimulated steroid production by granulosal cells in vitro and END1 prevented that
increment in other species (Iwai et al., 1991; Tedeschi et al., 1992; Kamada et al., 1993; Flores
et al., 1999). However, responsiveness of LH receptors in follicles exposed to sustained
activation by LH decreased progressively (Zor et al., 1976; Rao et al., 1977; Hunzicker-Dunn,
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1981), most likely because components of the downstream signaling pathway were disrupted
(Ekstrom and Hunzicker-Dunn, 1989; Gudermann et al., 1995). Aggregation of receptors and
receptor internalization are other mechanisms of agonist-induced desensitization of LH
receptors (Amsterdam et al., 1980; Ghinea et al., 1992; Gudermann et al., 1995). In this study
preovulatory follicles were collected at a specific follicular stage prior to LH surge, but were
exposed to increasing concentrations of LH over time (Karsch et al., 1983; Fortune and Hansel,
1985). In that circumstance, presence of elevated and sustained concentrations of LH in culture
media may have induced deactivation of LH receptors in granulosal cells, and prevented
stimulation of E2 and P4 production.
It was hypothesized that END1, via either ENDRA or ENDRB, would regulate follicular
steroid production and prevent premature luteinization of granulosal cells before the LH surge
in sheep, as suggested for other species (Tedeschi et al., 1992; Flores, 2000). In this
experiment, neither individual nor combined presence of LH and END1 in the culture medium
affected the patterns of E2 and P4 secretion by granulosal cells isolated from preovulatory
follicles. Hence, the hypothesis that END1 may modulate steroid production by granulosal cells
from preovulatory follicles was not supported. Although antisteroidogenic actions of END1
were demonstrated in follicles of rats (Tedeschi et al., 1992; 1994), pigs (Iwai et al., 1991;
Flores et al., 1992; Kamada et al., 1993) and human beings (Denkova et al., 2000; Yaneva et
al., 2003), such a role of END1 has not been reported in sheep. Attempts to identify END1 by
immunohistochemistry in follicles from days 2 to 6 of the estrous cycle in sheep were not
productive (Perea et al., unpublished data). However, in microdialyzed large bovine follicles,
END1 stimulated E2 secretion and inhibited P4 and androgen production (Acosta et al., 1998;
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1999). Moreover, LH increased END1 release from mature follicles (Acosta et al., 1998), and
the presence of ENDRA and ENDRB was detected in the theca of bovine follicles (Acosta et
al., 1999). Because the presence of END1 in preovulatory follicles was associated with other
vasoactive peptides such as angiotensin II and atrial natriuretic peptide in microdialyzed mature
follicles (Acosta et al., 1999), a role of END1 in modulating blood flow into the follicle may be
one of its functions.
In conclusion, these results did not demonstrate effects of END1 on LH-stimulated steroid
production by granulosal cells from preovulatory follicles. Future research is needed to clarify
whether END1 has a role of in follicular function in the sheep. Given that earlier in vitro
studies in pigs, FSH-simulated P4 production by granulosal cells collected from small- and
medium-sized follicles was inhibited by END1 (Kamada et al., 1993; Flores et al., 1992; 1999),
such future research should include preovulatory follicles collected earlier of and incorporation
of FSH and serum in culture media.
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Effects of blocking endothelin receptor type A during spontaneous and
PGF2 -induced luteolysis on morphological and functional characteristics of
the corpus luteum and length of the estrous cycle in the sheep
Introduction
After ovulation, the collapsed ovulatory follicle undergoes dramatic cellular and structural
changes that result in formation of the corpus luteum. The corpus luteum is a transient
endocrine gland that produces increasing amounts of P4 until the mid-luteal phase, at which
time P4 reaches steady state concentrations. Progesterone plays important roles modulating the
hypothalamic–hypophyseal axis and promoting appropriate uterine physiological conditions to
sustain development of the embryo/fetus during pregnancy. In the absence of an embryo in the
uterus, CL demise in function and a new estrous cycle is initiated a few days later.
Luteal regression involves two consecutive and complementary processes through which the
CL loses steroidogenic capacity without apparent changes in the structure of the tissue
(functional luteolysis), followed by degradation of all cellular and structural components of the
CL, with the concomitant reduction of luteal weight and size (structural luteolysis). Functional
luteolysis was associated with decline of circulating concentrations of P4 and a transient
increase followed by progressive reduction in blood flow to the CL (McCracken et al., 1970;
Niswender et al., 1975; 1976; Nett et al., 1976; Acosta et al., 2003). Once P4 decreases,
structural changes imply degradation of the cellular matrix and apoptosis of all cellular
components of the CL (Hoyer, 1998; Pate and Keyes, 2001; Smith et al., 2002; Stocco et al.,
2007). Luteolysis is a complex and orchestrated process initiated by uterine PGF2 at the end of
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the luteal phase, or after an injection of exogenous PGF2 during mid-luteal phase of the
estrous cycle (Zarco et al., 1988a; Niswender et al., 2000; Tsai et al., 2001). Luteolysis initiated
by uterine PGF2 is mediated by numerous local (intraluteal) factors such as NO (Jaroszewski
et al., 2003), angiotensin II (Shirasuna et al., 2004), TNF- , INF- , IL-1 (Neuvians et al.,
2004), and END1 (Girsh et al., 1996a; Hinckley and Milvae, 2001) secreted by different luteal
cells.
Substantial evidence demonstrated that END1 is a relevant mediator of luteolytic actions of
PGF2 (Girsh et al., 1996a; 1996b; Miyamoto et al., 1997; Ohtani et al., 1998; Hinckley and
Milvae, 2001; Keator et al., 2008). Endothelin 1, a 21-amino acid peptide, originally isolated
from porcine aortic endothelial cells as a potent vasoconstrictor (Yanagisawa et al., 1988), is
involved in a wide variety of physiologic and pathologic roles in numerous mammalian tissues
(Nussdorfer et al., 1999; Kedezierski and Yanagisawa, 2001). Two G protein-coupled receptors
have been described for END1 (Nussdorfer et al., 1999). Type A (ENDRA) mediated luteolytic
actions of PGF2 (Girsh et al., 1996b; Doerr et al., 2008; Keator et al., 2008). In the ruminant
CL, END1 reduced both basal and LH-stimulated P4 secretion in a dose-dependent manner
(Girsh et al., 1996a; Hinckley and Milvae, 2001), and the inhibitory effect was prevented by the
addition of a selective ENDRA receptor antagonist (Girsh et al., 1996a).
In recent years, data from various in vivo studies have confirmed and strengthened the
concept that END1 is an important mediator of PGF2 -induced luteal regression. Although
intraluteal injection of BQ-123 (an ENDRA antagonist) did not reverse completely the
luteolytic effect of PGF2 , intramuscular injection of both END1 (100 g) and PGF2 (7.5 mg)
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effectively reduced P4 concentrations by 48 h post-treatment, and shortened the length of the
cycle (Hinckley and Milvae, 2001). However, separate administration of either END1 or PGF2
at the same dosage, did not induce luteolysis in sheep (Hinckley and Milvae, 2001).
Intrauterine infusions of BQ-610, a highly specific ENDRA antagonist, every 12 h on d 16
through 18 of the estrous cycle in heifers delayed luteolysis for about 2 days (Keator et al.,
2008). Chronic administration of BQ-610 into the sheep CL through a minipump implanted in
the ovary during the mid-luteal phase allowed decreased serum P4 concentration throughout the
first 12 h after a single injection of PGF2 . However, P4 progressively increased during the next
36 h, attaining a concentration similar to the control group by 48 h after PGF2 (Doerr et al.,
2008). Apparently, a direct action of PGF2

decreased serum P4 during early luteolysis,

whereas END1 was required in later stages as indicated by the rise of P4 in BQ-610-treated
ewes beginning 12 h after PGF2 . In addition, blockade of ENDRA during PGF2 -induced
luteolysis in cows, prevented the increase of caspase 3 mRNA by 24 h compared with controls
(Watanabe et al., 2006). These findings indicate that END1 may participate in structural rather
than functional luteolysis, stimulating expression of pro-apoptotic factors.
Two experiments were carried out to study the effects of END1 on functional and structural
changes of the CL during either spontaneous or PGF2 -induced luteolysis in the sheep. In the
first experiment, the ENDRA antagonist BQ-610 was delivered into the CL through an osmotic
minipump to examine the expression of genes related with P4 production and structural
luteolysis at 6 and 24 h after exogenous PGF2 . It was hypothesized that sustained blockade of
ENDRA would prevent upregulation of genes stimulated by PGF2 during structural luteolysis.
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In the second experiment, the same approach was used to examine the effects of the
sustained blockade of ENDRA during spontaneous luteolysis on the length of the estrous cycle
and functional and structural characteristics of the CL. It was hypothesized that chronic
delivery of BQ-610 into the CL would prevent or delay the luteal regression induced by
endogenous PGF2 , increasing the length of estrous cycle.

Experiment 2: Effect of blocking endothelin receptor type A on gene
expression during PGF2 -induced luteolysis in sheep

Materials and methods

General experimental procedure
Forty five nonpregnant mixed-breed ewes with at least one previous estrous cycle of normal
length (15 to 19 days) were used in the experiment, conducted in fall of 2007 and 2008
(September-December) with ewes from the West Virginia University research flock. For
observation of estrus (12 h intervals), ewes were penned with a vasectomized ram bearing a
harness with a crayon in the area of the brisket; standing estrus was confirmed by teasing with
another vasectomized ram. Treatment was begun at day 7.5 to 9 of the estrous cycle (standing
estrus = day 0). Ewes were assigned randomly to receive one of the following treatments:
Alzet® mini-osmotic pump (model 2002; Durect Corporation, Cupertino, CA) loaded with
either vehicle (200

L of 2:1 methanol/saline solution) or 2.5 mg of END receptor A

antagonist, BQ-610 (Azepane-1-carbonyl-leu-D-Trp(For)-D-Trp-OH), diluted in 200

L of

vehicle. A third experimental group did not receive mini-osmotic pumps (control). The Alzet®
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mini-osmotic pumps (Bachem Bioscience Inc, King of Prussia, PA), designed to deliver 0.52 ±
0.02 L/h for approximately 14 days, were kept overnight in sterile 0.9% saline solution at
37 C until implantation in the ovarian pedicle. Thus, the expected delivered dosage was 6.25
g/h of BQ-610.
Ewes were initially anesthetized with 0.3 mg/kg diazepam (Valium, i.v., 5 mg/ml; Roche
Pharmaceuticals, Nutley, NJ) and 7 mg/kg ketavet (Ketamine HCL, i.v.,) and then placed on a
mixture of halothane, oxygen (2.0 L/min), and nitrous oxide gas (1.0 L/min) until mid-ventral
laparotomy was finished. Ovaries were examined carefully, and in the presence of multiple CL,
one was selected for implantation of the catheter connected to the mini pump. Additional CL in
the same ovary were enucleated and an absorbable gelatin sponge was placed inside the
remaining cavity (Gelfoam®, Pfizer Inc, New York, NY) as a hemostatic component. The
contralateral ovary was removed if it contained additional CL. Each minipump was positioned
in the mesoovarium and the attached catheter stabilized within the CL following the surgical
procedure previously described (Doerr et al., 2008). All ewes received a dose (i.m.) 3 × 10 6 IU
of penicillin G immediately after surgery.
A luteolytic dose of PGF2 (25 mg; Lutalyse®, Pfizer Animal Health, New York, NY) was
injected (i.m.) 48 h after surgery, and 6 or 24 h later ewes were euthanized, the correct position
of the pumps and catheters was verified, and ovaries were collected. Ewes in the control group
(no minipump implantation) received a saline injection (5 ml; i.m.) on day 9, 10 or 11 of the
estrous cycle, and 6 or 24 h later ovaries were removed by mid-ventral laparatomy as described
above. Jugular blood samples (8 ml) were collected at 3 h intervals from hour 0 to 6 (6-h
group) or 0 to 24 (24-h group) after PGF2

or saline injection (h 0) to monitor P4
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concentrations. Blood samples were refrigerated for 24 hours to allow them to clot, and then
centrifuged for 20 minutes at 2500 rpm. Serum was collected and stored at -20° C until
radioimmunoassay for P4. All animal procedures were approved by WVU Institutional Animal
Care and Use Committee (ACUC # 05-1205).
Once removed, ovaries were refrigerated in ice-cold PBS, transported to the laboratory, and
each CL was dissected, weighed, and sectioned into pieces that were weighed individually, then
frozen in liquid nitrogen and stored at -80°C. One piece of each CL was homogenized in PBS
(1 ml/100 mg of tissue), centrifuged, and supernatant stored at -20 °C until assayed for P4.
Number of ewes per treatment and times of tissue collection are shown in Table 3.

Table 3.

Numbers of ewes per treatment and time of tissue collection

Time of tissue
collection

Treatment
BQ-610

Vehicle

Control

6-h

9

6

6

24-h

10

7

7

Total

19

13

13

Real-Time RT-PCR
The relative expression of a group of genes associated with luteal function or involved in
functional and structural luteolysis, as reported elsewhere (Juengel et al., 2000; Tsai et al.,
2001; Diaz et al., 2002; Smith et al., 2002; Taniguchi et al., 2002; Kliem et al., 2007; 2009),
was quantified by real-time PCR. Total RNA was isolated from frozen luteal tissue using Trireagent (MRC, Cincinnati, OH) following the recommendations of the manufacturer. Once
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solubilized in RNAse-free water, the quality and quantity of each RNA sample were assessed
by 1% agarose gel electrophoresis and by spectrophotometry (Nano Drop Technologies,
Wilmington, DE), respectively. Purified RNA samples were treated with DNAse (Invitrogen,
Carlsbad, CA) to remove residual DNA contamination. To assure that low expression of a gene
was not negatively affecting the Ct values and confirming variability within replicates, the RTPCR was tested at total RNA concentrations of 0.5, 1.0 and 2.0 g/ L. The gene expression
data reported in this study were from the 2.0 g of total mRNA concentration.
To generate first-strand cDNA, total RNA was reverse transcribed in a reaction volume of
20 L containing sample RNA (2.0 g), dNTP mix (10 nM), oligo dT primer (450 ng) and
Superscript II reverse transcriptase (200 U) (Invitrogen, Carlsbad, CA). Real-time PCR was
carried out using the approach reported by Pfaffl (2001) and following the procedure described
by Goravanahally et al. (2009). Briefly, representative RNA samples from each treatment were
pooled and used to produce first-strand cDNA as described above. Five consecutive dilutions
(1:10) of cDNA were used to generate a standard curve to estimate the efficiency of the specific
primers for each gene. The optimum efficiency of the PCR reactions was standardized between
90 to 110%. Melting curve from optimization reactions of each set of primers assured the
absence of secondary products.
Oligonucleotide primers were designed with primer3 software (Rozen and Skaletsky, 2000)
based on the mRNA sequences of Ovis aries. In the event of mRNA sequences not previously
described in sheep, Bos taurus mRNA sequences were used. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was the reference gene to normalize the expression values of the
genes of interest. Table 4 shows the species, accession number, sequences and additional
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characteristics of each gene primer included in the study. Quantitative PCR reactions were
carried out in duplicate for each cDNA sample in an iCycler iQ Real-Time PCR Detection
System (Bio-Rad, Hercules, CA), using a total reaction volume of 25 L that included SYBR
Green Supermix (Bio-Rad, Hercules, CA), 1 M of each primer and non-diluted target cDNA
(2 L). Real-time PCR conditions were: 30 sec at 95 C followed for 40 cycles at 95 C for 30
sec to denature, 30 sec at 60 C to anneal, and 1 min at 72 C for extension.

Radioimmunoassays for progesterone
Concentrations of P4 in serum and luteal tissue were measured in duplicate by RIA as
previously described (Sheffel et al., 1982). Assay sensitivity averaged 0.15 ng/ml, and interand intraassay coefficients of variation were 13.8% and 13.0%, respectively.

Statistical Analysis
The effect of treatments on concentrations of serum and luteal P4 and luteal weight for each
time of tissue collection (6-h and 24-h groups) was evaluated by one-way analysis of variance
using the General Linear Model (GLM) procedure of SAS (SAS Institute; Cary, NC).
Differences among means were compared by the LSM procedure of SAS. To examine
differences in gene expression according to treatment, time, and treatment × time, a complete
block design was applied and analyzed by the GLM procedure of SAS. Differences among
means were compared by orthogonal contrasts. Contrasts tested were (a) PGF2 versus control
and (b) BQ-610 versus vehicle. Data were expressed as mean ± SEM.
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Table 4.

Gene

Characteristics of primers used in quantitative real-time RT-PCR

Accession
number

Species

StAR

NM_001009243

O. aries

3 HSD

NM_174343

20 HSD

Primer sequence

Product
size
(bp)

Annel.
Temp.
( C)

Slope
Standard
curve

F: 5’-TGCTGAGTAAAGTGATCCCTGA-3’
R: 5’-AGGACCTTGATCTCCTTGACAC-3’

148

60

-3.631

B. taurus

F: 5’-CCACACCAAAGCTACGATGA-3’
R: 3’-TGTAAATTGGACTGAGCAGGAA-3’

148

60

-3.419

XM_868164

B. taurus

F: 5’-CTGAACGCATTGCTGAGAAC-3’
R: 3’-AACTCCTCGTGAAAGGGGTAA-3’

148

60

-3.601

VEGF

NM_001025110

O. aries

F: 5’-TTGCTGCTCTACCTTCACCAT-3’
R: 5’-TCTGGGTACTCCTGGAAGATGT-3’

158

60

-3.370

eNOS

DQ015701

O. aries

F: 5’-TGTTGGATTCCCTGTACTATCTCA-3’
R: 5’-AACTTCTGGTCCAGTCTCTTATGG-3’

240

60

-3.262

TIMP-1

NM_001009319

O. aries

F: 5’-CCAGACATCCGATTCATCTACA-3’
R: 3’-GCAGAACTCATGCTGTTCCA-3’

167

60

-3.558

TIMP-2

NM_174472

B. taurus

F: 5’-AGTTCTTCGCCTGCATCAA-3’
R: 3’-AGCTGGACCAGTCTGAACTCTT-3’

159

60

-3.376

Bcl-2

DQ152929

O. aries

F: 5’-TGGATGACCGAGTACCTGAA-3’
R: 3’-CAGCCAGGAGAAATCAAACAG-3’

120

60

-3.314

Bax

AF163774

O. aries

F: 5’-GAAGCGCATTGGAGATGAA-3’
R: 3’-AAGTAGAAAAGGGCGACAACC-3’

159

60

-3.286

MMP-2

AF267159

O. aries

F: 5’-TTCATCTGGCGAACAGTGAC-3’
R: 3’-CAGTATTCGTTCCCTGCAAAG-3’

149

60

-3.264

MMP-14

AF267160

O. aries

F: 5’-TGAGAGGAAGGATGGCAAGT-3’
R: 3’-TCCAGAAGAGAGCAGCATCA-3’

149

60

-3.376

Fas-R

NM_001123003

O. aries

F: 5’-CGGAAGAATGGTATGGAGGA-3’
R: 3’-TGCAAGAGCTTTTGGGAGAT-3’

162

60

-3.375

Caspase 3

AF068837

O. aries

F: 5’-GGATTATCCTGAAATGGGTTTATG-3’
R: 3’-GATCGTTTTTAATCCTGACTTCGT-3’

155

60

-3.266

Caspase 8

NM_001045970

B. taurus

F: 5’-TGTCACAATCGCTTCCAGAG-3’
R: 3’-AGTATCCCCGAGGTTTGCTT-3’

126

60

-3.311

GAPDH

AF030943

O. aries

F: 5’-TCTCAAGGGCATTCTAGGCTAC-3’
R: 3’-TGTAGCCGAATTCATTGTCG-3’

155

60

-3.254

87

Results

Corpus luteum weight
The weights of the CL collected 6 h after injection of saline or PGF2 were not affected by
treatments. Apparently, treatment with BQ-610 did not prevent the luteolytic effect of
exogenous PGF2 , because CL from BQ-610-treated ewes were lighter (P < 0.02) than those
from control ewes 24-h after PGF2 or saline (Fig 9).

Serum and luteal progesterone
Given that control ewes had one or more CL in the ovaries, while treated ewes had only one
CL, concentrations of P4 for each collection time were compared as the change from hour 0
(time of PGF2 or saline injection). In ewes from which CL were removed at 6 h, change in
concentration of P4 3 h after PGF2 was less negative in control than in BQ-610- and vehicletreated ewes (P < 0.01). By 6 h, the P4 decrease was similar in all treatments (Fig 10). In
contrast, P4 concentrations in BQ-610-treated and vehicle-treated ewes from which CL were
removed at 24 h, declined progressively by greater than 0.5 ng/ml by 24 h after PGF2 , while in
control ewes P4 remained more than 0.5 ng/ml above the initial value throughout the sampling
period (Fig. 11). Six hours after onset of induced luteolysis, content of luteal P 4 in BQ-610treated and vehicle-treated ewes that received PGF2 had decreased by ~ 65% and ~ 61%,
respectively, with respect to luteal content of P4 in control ewes. By 24 h after PGF2 injection,
luteal content of P4 in BQ-610-treated and vehicle-treated ewes was around 1/9 and 1/3,
respectively, of the luteal content of P4 in control ewes (P < 0.0005; Fig. 12). In the 24-h group,
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one ewe had a secretion pattern of serum P4 similar to that reported by Doerr et al. (2008) in
sheep treated with BQ-610. In this responsive BQ-610-treated ewe, P4 concentration declined
progressively from 2.5 ng/ml at time 0 to 0.9 ng/ml 9 h after PGF2 injection, remained below 1
ng/ml until h 15 and then increased to 1.5 ng/ml by h 24 after PGF2 . Concentration of luteal P4
in this animal was 12.8 g/g and the luteal pattern of gene expression was similar to mid-cycle
CL from the control ewes.

Gene expression
Expression of StAR and 3 -HSD mRNA were affected by treatment (P = 0.05 and P <
0.0001, respectively), and the expression of each gene was lower in PGF2 -treated than in
control ewes (P < 0.03; P < 0.0001, respectively); but did not differ between BQ-610- and
vehicle-treated CL at any time (Fig 13). For 20 -HSD mRNA, there was an effect of treatment
(P < 0.0001), time (P < 0.01) and treatment × time (P < 0.0001), reflected in the upregulation of
this gene in PGF2 -treated compared with control animals (P < 0.02) and in BQ-610-treated
ewes compared with vehicle-treated animals (P < 0.02; Fig 13). Expression of VEGF mRNA
was affected by treatment (P < 0.0001), time (P < 0.01) and treatment × time (P < 0.04),
specifically being lower in PGF2 -treated than in control ewes (P < 0.0001; Fig 14). Treatment
(P < 0.0001) and treatment × time (P < 0.0001) affected mRNA expression of TIMP-1 (Fig 14),
which was lower in PGF2 -treated than in control ewes (P < 0.0001). In contrast, TIMP-2
mRNA at 6 and 24 h averaged 1.35 ± 0.28 and 1.03 ± 0.27, respectively, and did not differ with
treatment, time or the interaction.
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Expression of MMP-1 mRNA was affected by time, while the contrast BQ-610 versus
PGF2 only tended to be different (0.90 ± 0.20 versus 0.57 ± 0.20, respectively; P<0.10). For
MMP-14, treatment (P = 0.0002), time (P < 0.0001) and treatment × time (P = 0.0005) differed,
and its expression was lower in PGF2 -treated versus control ewes (P < 0.0001; Fig 15); and as
judged by least squares means, this transcript was greater in vehicle-treated than in BQ-610treated ewes followed by control animals at 24 h (P < 0.01). Time and treatment affected
expression of eNOS (Fig 15), which was lower in PGF2 -treated than in control ewes (1.03 ±
0.14 and 1.47 ± 0.13, respectively; P = 0.001).
In regard to the genes involved in structural luteolysis, Bcl-2 expression was affected by
treatment (P = 0.06) and time (P < 0.002; Fig 16), whereas its expression in PGF2 -treated ewes
was greater than in control ewes (1.22 ± 0.30 versus 0.63 ± 0.28, respectively; P < 0.03). Time
(P < 0.0001) and treatment × time (P < 0.005) affected Bax mRNA expression (Fig 16), with a
trend for a greater expression in BQ-610-treated than in vehicle-treated CL (0.86 ± 0.1 versus
0.68 ± 0.1; P < 0.09). The Bcl-2/Bax ratio at 6 h was greater in BQ-610-treated than in control
ewes (P < 0.01) (2.29 ± 0.38 versus 0.84 ± 0.38, respectively). In contrast, at 24 h, Bcl-2/Bax
ratio tended to be lower in BQ-610-treated ewes than in control ewes (P < 0.09) (0.79 ± 0.38
versus 1.70 ± 0.33, respectively). For Fas-R transcript, time (P < 0.0001) and treatment × time
(P = 0.001) differed, and treatment (P = 0.09) and PGF2 versus control tended to differ (P <
0.09; Fig 16). For caspases 3 and 8, mRNA expression was affected by treatment, time and
treatment × time (all P ≤ 0.01), and both contrasts, PGF2 versus control and BQ-610 versus
vehicle were significant. As judged by least squares means, mRNA expression in BQ-610-
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treated ewes for both caspases 3 and 8 was upregulated at 24 h compared to either vehicletreated or control animals with the effect already apparent at 6 h for caspase 3 (Fig 17).
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Figure 9. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis
on corpus luteum weight in sheep. Corpora lutea were collected 6 h or 24 h after PGF2 injection in BQ610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of
corpus luteum weight (g). Values differed among treatments (a,bP < 0.07; a,cP < 0.02; b,cNS ).
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Figure 10. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis
on changes in serum concentrations of progesterone in ewes from which CL were removed at 6 h.
Jugular blood samples were collected at 3-h intervals from hour 0 to 6 after PGF2 injection (time 0) in
BQ-610- (○) and vehicle-treated (■) ewes or after saline injection in control ewes (▲). Data points
represent differences in progesterone (ng/ml) from hour 0 (mean ± SEM). Values in control and PGF2 treated ewes were different ( P < 0.01) at hour 3.
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Figure 11. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis
on changes in serum concentration of progesterone in ewes from which CL were removed at 24 h.
Jugular blood samples were collected at 3-h intervals from hour 0 to 24 (24-h group) after PGF2
injection (time 0) in BQ-610- (○) and vehicle-treated (■) ewes or after saline injection in control ewes
(▲). Data points represent differences in progesterone (ng/ml) from hour 0 (mean ± SEM). Values in
control and PGF2 -treated ewes were statistically different ( P < 0.001).
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Figure 12. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis
on luteal content of progesterone in sheep. Corpora lutea were collected 6 h or 24 h after PGF2
injection in BQ-610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent
mean ± SEM of homogenized corpus luteum extracts ( g/g). Values differed among treatments (a,bP <
0.03; c,dP < 0.0005).
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Figure 13. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2 injection in BQ610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of
normalized mRNA expression for StAR (panel A), which was affected by treatment (P = 0.05) and the
contrast PGF2 versus control (a,bP < 0.03); 3 HSD (panel B), which varied with treatment (P < 0.0001),
and the contrast PGF2 versus control (a,bP < 0.0001); and 20 HSD (panel C), which varied with time (P
< 0.0001), treatment (P < 0.01), time × treatment (P < 0.0001), the contrasts PGF2 versus control and
and BQ-10 versus vehicle (P < 0.02); least squares means for treatments at 24 h differed (a,bP = 0.004;
a,c
P < 0.0001; b,cP < 0.01).
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Figure 14. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2 injection in BQ610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of
normalized mRNA expression for VEGF (panel A), which varied with time (P < 0.01), treatment (P <
0.0001), time × treatment (P < 0.04), and the contrast PGF2 versus control (a,bP < 0.0001), least squares
means for treatments differed (a,bP < 0.0001; a,cP < 0.003; b,cP < 0.0001); and TIMP-1 (panel B), which
was affected by treatment (P < 0.0001), time × treatment (P < 0.0001), and the contrast PGF2 versus
control (a,bP < 0.0001), least squares means for treatments differed (a,bP < 0.0001; b,cP < 0.0001; c,dP =
0.05).
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Figure 15. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2 injection in BQ610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of
normalized mRNA expression for MMP-14 (panel A), which was affected by time (P < 0.0001),
treatment (P = 0.0002), time × treatment (P = 0.0005), and the contrast PGF2 versus control (P <
0.0001), least squares means for treatments at 24 h differed (a,bP < 0.01; a,cP < 0.0001); and eNOS (panel
B), which varied with time (P < 0.0001), treatment (P < 0.005), and the contrast PGF2 versus control (P
= 0.001).
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Figure 16. Effects of chronic administration of either BQ-610 or vehicle during PGF2 -induced
luteolysis on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2 injection in BQ610- and vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of
normalized mRNA expression for Bcl-2 (panel A), which was affected by time (P = 0.002), and
treatment (P = 0.06); Bax (panel B), time (P < 0.0001), which was affected by time × treatment (P =
0.003), and the contrast BQ-610 versus vehicle (P < 0.09), least squares means for treatments differed
(a,eP < 0.0001; b,cP < 0.04; b,eP < 0.002; c,bP < 0.04; c,dP < 0.0001); and Fas-R (panel C), which varied
with time (P < 0.0001), and time × treatment (P = 0.001), least squares means for treatments differed
(a,cP ≤ 0.0002; a,dP ≤ 0.04).
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Figure 17. Effect of chronic administration of either BQ-610 or vehicle during PGF2 -induced luteolysis
on gene expression. Corpora lutea were collected 6 h and 24 h after PGF2 injection in BQ-610- and
vehicle-treated ewes or after saline injection in control ewes. Bars represent mean ± SEM of normalized
mRNA expression for caspase 3 (panel A), time (P = 0.001), which varied with treatment (P < 0.0001),
time × treatment (P = 0.01), the contrasts PGF2 versus control (P < 0.0005) and BQ-10 versus vehicle
(P < 0.0001), least squares means for treatments at 6 and 24 h differed ( a,b,c,dP<0.0005; b,cP<0.06; c,dNS);
and caspase 8 (panel B), which was affected by time (P < 0.01), treatment (P = 0.0001), time ×
treatment (P = 0.0005), the contrasts PGF2 versus control (P < 0.02) and BQ-10 versus vehicle (P =
0.0001), least squares means for treatments at 24 h differed (a,bP < 0.0001).
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Discussion

Data from serum and luteal concentrations of P4 (Fig. 10 and 11) as well as CL weight (Fig.
9) at 24 h indicated that BQ-610 did not prevent luteolysis in 90% (9/10) of the treated ewes.
Because control ewes had an average of 1.7 ± 0.5 and 1.8 ± 0.4 CL in 6-h and 24-h groups,
respectively, compared to only one CL in the treated ewes, data were presented as changes in
concentrations of P4 with respect to h 0. Accordingly, at 6 h, serum P4 had declined equally in
all groups of ewes with respect to h 0. In contrast, P4 concentrations decreased to sub-luteal
values by 24 h in both groups of PGF2 -treated ewes, while in control animals P4
concentrations rose more than 0.5 ng/ml with respect to h 0. Similarly, luteal P 4 in the 24-h
group was significantly lower in both groups of PGF2 -treated ewes than in control ewes. In
contrast to the present results, Doerr et al. (2008) reported that blocking ENDRA with BQ-610,
using a similar experimental approach, effectively reversed the decrease in concentrations of P 4
induced by exogenous PGF2 in all of 6 treated animals. In that study, P4 concentration in BQ610-treated ewes decreased rapidly after a luteolytic dose of PGF2 , and remained below 1
ng/ml until hour 12 after PGF2 , but increased thereafter, reaching similar concentrations to the
saline-injected ewes, around 48 h after PGF2 . Thus, it was suggested that during the first 12 h,
PGF2 exerted its antisteroidogenic actions independent of mediation by END1, whereas in
later stages END1 was required to suppress P4 production (Doerr et al., 2008). Nevertheless,
only one ewe had a similar pattern of P4 secretion at 24 h in this study. In that animal, luteal
concentration of P4 was 12.8

g/g, an amount considerably greater than mean luteal P4 in

vehicle-treated ewes 24 h after PGF2 (2.0 ± 2.1 g/g). Moreover, the overall pattern of gene
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expression in this responsive BQ-610-treated animal was similar to the control ewes. Hence,
the physiological response to the antagonist in the responsive BQ-610-treated animal indicated
that luteolysis was prevented and the functional status of the CL was like a saline-injected ewe.

Although CL weight did not differ among treatments at 6 h after PGF2 , luteal content of P4
was significantly lower in both groups of PGF2 -treated ewes with respect to control animals.
Consistent with the present findings, neither luteal volume nor CL weight decreased after 4 h of
PGF2 -induced luteolysis in mid-cycle bovine CL, whereas serum and luteal P4 concentrations
were significantly lower than in saline-injected cows (Tsai et al., 1998b). Judged by CL weight,
it seems that at least 24 h are required for PGF2 to induce structural changes in the luteal tissue
(Juengel et al., 1996; Tsai et al., 1998a). The first hours after PGF2 initiates luteal regression
are associated with rapid decreases of circulating concentrations of P4, concomitant with the
reduction of the luteal blood flow (Niswender et al., 1996; Wanatabe et al., 2006).
Nevertheless, a transient increase in blood flow was associated with PGF2 -stimulated release
of NO from vascular tissue (Acosta et al., 2002, 2008).

Loss of steroidogenic capacity occurs mostly by down regulation of enzymes and proteins
involved in P4 synthesis (Juengel et al., 1995; Tsai and Wiltbank, 1998; Tsai et al., 2001). It is
likely that PGF2 reduced synthesis of P4 and transport of cholesterol, because both StAR and
3 HSD were reduced equally by 6 h after PGF2 . However, as judged by the increment in the
expression of 20 HSD at 24 h, metabolism of P4 may have contributed to decrease circulating
and luteal concentrations of P4. Interestingly, treatment with BQ-610 upregulated even more
20 HSD transcripts than vehicle, supporting the fact that BQ-610 did not prevent luteolysis, as
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shown by concentrations of serum P4. Moreover, as indicated by luteal P4 and weight and some
other genes, the degree of luteolysis in BQ-610-treated ewes appeared to be greater than in
vehicle-treated animals. In bovine luteal tissue, mRNA expression for StAR and 3 HSD
decreased as early as 4 h after exogenous PGF2 (Tsai et al., 2001). Six hours after PGF2 is
likely too early to determine if BQ-610 was able or not to effectively prevent luteolysis. During
this early period, antisteroidogenic actions of PGF2 were independent of END1, as indicated
by the profile of P4 concentration in BQ-610-treated ewes reported by Doerr et al. (2008). Even
if structural luteolytic changes were induced by lower doses of PGF2 , (3 mg PGF2a/60 kg
body weight) removal of luteolytic stimulus allowed increased serum P4 concentrations and
reversed the effects of PGF2 in luteal tissue (Juengel et al., 2000).
Apart from 3 HSD and StAR, other genes that promote luteal function, VEGF and TIMP-1,
were downregulated by PGF2 in both 6 and 24-h groups. VEGF, an angiogenic and potent
mitogenic growth factor, was highly expressed during early luteal development and
downregulated at the end of the luteal phase (Schams and Berisha, 2004; Ribeiro et al., 2006;
2007). In agreement with these data, studies in ruminants indicated a reduction of VEGF
mRNA within 8 to 12 after exogenous PGF2 . (Neuvians et al., 2004b; Vonnahme et al., 2006).
TIMP family members are associated with the maintenance of the ECM stability by reducing
activity of MMP (Smith et al., 2002). TIMP-1 mRNA expression in ovine CL decreased 1 h
after PGF2 , increased by 4 and 6 h, and decreased again from 12 through 48 h of PGF2 induced luteolysis (Ricke et al., 2002); and as occurred in this study, TIMP-2 remained
unchanged from 6 through 48 h after PGF2 (Ricke et al., 2002a). In the light of this finding, it
seems that downregulation of the genes associated with stability of luteal function by PGF2 is
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required in order for structural changes to take place. In this experiment, only MMP-14 was
upregulated by PGF2 , and its expression increased from 6 to 24 h in all groups. In contrast,
MMP-2 was similar among treatments and declined over time. In ovine luteal tissue, MMP-2
transcript varied throughout the examined time after PGF2 with peaks of expression at 6 and
24 h (Ricke et al., 2002b); whereas MMP-14 was upregulated by PGF2 as early as 6 h and
remained unchanged over time. The lower expression of MMP-2 at 24 h than at 6 h in this
study might be associated with fluctuation of this gene as reported by Ricke et al. (2002b).
Once the antiluteolytic effect of P4 is withdrawn, PGF2 stimulates upregulation of factors
involving in degradation of cellular matrix (Smith et al., 2002). In the current study,
upregulation of MMP-14 is consistent with that concept, and with reports in ewes and cows that
monitored expression of this transcript during a period of time after PGF2 -induced luteolysis
(Ricke et al., 2002b; Kliem et al., 2007).
In general, the expression pattern of genes that stimulate synthesis of P 4 or inhibit its
metabolism tended to favor luteal function in control ewes, but not in the BQ-610-treated group
in which the ENDRA antagonist was expected to prevent luteolysis and maintain the functional
status of the CL, as reported elsewhere for PGF2 -treated ewes (Doerr et al., 2008) and seen in
spontaneous luteolysis (experiment 3). Moreover, BQ-610 appeared to promote the expression
of genes related with structural luteolysis, because at 24 h after PGF2 , expression of caspases 3
and caspases 8 were significantly greater in BQ-610-treated ewes than in vehicle-treated or
control ewes (Fig 16). Moreover, Bcl-2/Bax ratio decreased over time only in the BQ-610treated group. These factors are involved in apoptosis and are upregulated within a few hours
after PGF2 (Yadav et al., 2005; Kliem et al., 2009). Structural luteolysis follows the functional
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demise of the CL, and occurs as a consequence of degradation of luteal cellular and structural
components (Hoyer, 1998; Pate and Keyes, 2001; Smith et al., 2002; Stocco et al., 2007).
Upregulation of factors related with apoptosis, as shown for caspase 3 and 8 in this study, is an
integral part of luteolysis and follows functional demise of the CL.
A reasonable explanation why in this experiment BQ-610 treatment was ineffective to
inhibit the luteolytic actions of END1 in PGF2 -induced luteolysis in the majority of the
animals is not readily available. The experimental design of the current study was based on the
findings reported by Doerr et al. (2008). Because concentrations of luteal P4 were ~ 42% lower
in BQ-610/BQ-788-treated ewes (1 mg each) and approximately 26% lower in BQ-610-treated
ewes (2 mg) than in saline-injected animals (Doerr et al., 2008), it was evident that BQ-610
treatment in that concentration was not able to completely reverse the antisteroidogenic effects
of PGF2 mediated by END1. Therefore, on the basis of that finding, the amount of BQ-610
used in this study was increased from 2 to 2.5 mg/pump and the vehicle in which the antagonist
was totally solubilized was 1 to 2 saline/methanol. The proportion of methanol in the BQ-610
solution was considerably greater than (2.5 times) that reported by Doerr et al. (2008; 3 to 1
saline/methanol). As described in material and methods, in a few cases, technical problems
derived from catheter deattachment, presence of partial clots into the catheter or in the tissue
around the end of the catheter might have interfered with the delivery of the BQ-610 or vehicle
solution into the luteal tissue. At the moment of CL collection, 4 catheters (2 from 6-h vehicle,
1 from 6-h BQ-610 and 1 from 24-h BQ-610) were not attached to the treated CL. It was
considered that the manipulation of the reproductive tract inside of abdominal cavity during
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necropsy was probably the cause. In addition, in 6 ewes (2 in 6-h vehicle, 2 in 6-h BQ-610 and
2 in 24-h BQ-610) the end of the catheter attached to the treated CL was partially clotted.
Was the increased volume of methanol in the BQ-610 solution the cause of the
ineffectiveness of BQ-610 treatment to reverse the luteolytic effect of PGF2 mediated by
END1? Perhaps so, if only the data from serum and luteal P4 and CL weight are considered.
One can speculate that methanol, in that elevated concentration, was cytotoxic and supported
induction of luteal regression. Another possible mechanism is that methanol interfered with or
prevented binding of BQ-610 to ENDRA, and thus, luteal regression was a consequence of
exogenous PGF2 . Nevertheless, if either of the previous mechanisms caused or allowed luteal
regression in BQ-610-treated ewes, the effects on gene expression in BQ-610-treated ewes
should have been similar (as were the serum and luteal P4 and CL weight) to those in vehicletreated animals. However, that was not the case, particularly in the 24-h group in which the
genes related with apoptosis were upregulated more in BQ-610-treated than in vehicle-treated
ewes after PGF2 . So, it seems that instead of preventing luteolysis by acting as an antagonist,
the greater dosage of BQ-610 synergized with or enhanced the effect of PGF2 ; or alternatively,
elevated concentrations of methanol may have modified the molecular structure of BQ-610
making it able to activate ENDRA, because the expression of 20 HSD, caspase 3 and caspase
8 in BQ-610-treated ewes at 24 h, was considerably greater than in vehicle treated ewes. The
ratio Bcl-2/Bax in BQ-610-treated ewes changed from 2.29 in 6-h group to 0.79 in 24-h group;
and tended to be lower only in BQ-610-treated with respect to control ewes. Moreover, at 24 h
after PGF2 , CL weight was reduced significantly only in BQ-610-treated ewes compared to
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control animals; and reduction of CL mass is a reliable evidence of the cellular and structural
changes during luteolysis (Stocco et al., 2007).
From the previous argument a new question arises. Why did this hypothetical luteolytic
effect attributed to BQ-610 not occur in all animals of this experiment and experiment 3 or in
any animal of the Doerr et al. (2008) study? As mentioned earlier, in one ewe from this
experiment and in 3 from experiment 3, the evidence indicated that BQ-610 effectively
inhibited luteolysis. So, a combination of factors, including the presumptive ability of BQ-610
to act as an agonist, the greater amount of methanol in the BQ-610 solution and some other
factor derived from particular characteristics of the animals may explain this physiological
incongruence? One or more of these possibilities may be a reasonable physiological
explanation.
Binding of END1 to type A G-protein coupled receptor activates at least three classes of G
proteins (G q, G s, G i), each of them associated to a different signaling pathway (Aramori
and Nakanishi, 1992; Wang et al., 1992; Ono et al., 1994; Takigawa et al., 1995). Different
domains of the ENDRA structure are required for coupling to distinct G proteins (Nussdorfer
et al., 1999). In addition, there are at least two separable ligand interaction subdomains within
the ENDRA (Sakamoto et al., 1993); and ENDRA gene can give rise to at least three transcripts
by alternative RNA splicing (Miyamoto et al., 1996). Moreover, a single amino acid
substitution altered the three-dimensional structure of the ligand-binding domain of ENDRA
and significantly reduced the END1 binding activity (Juan, 2008). This complex molecular
scenario in combination with the experimental conditions mentioned above, might make it
plausible that BQ-610 activated the ENDRA, and consequently triggered downstream events
105

conducive to luteal regression. To support this interpretation, it was documented that
abosentan, a selective non-peptide ENDRA antagonist, stimulated p38 mitogen-activated
protein kinase (MAPK/ERK) phosphorylation mediated by ENDRA in mouse cardiac tissue
(Marchant et al., 2009). The ERK signaling pathway stimulated mRNA and protein expression
of early growth response 1 (EGR1), and during PGF2 -induced luteal regression in the cow
ERG1 induced expression of TGF 1, an important tissue remodeling protein also involved in
apoptosis (Hou et al., 2008).
Intraluteal injections of ENDRA antagonists in cows did not prevent antisteroidogenic
effects of PGF2 mediated by END1 (Watanabe et al., 2006; Keator et al., 2008) or did not
reverse completely the luteolytic effect of PGF2 in sheep (Hinckley and Milvae, 2001). As
reported by Watanabe et al. (2006), administration of 5 intraluteal injections of LU-13522 (an
ENDRA antagonist) at 2 h intervals in cows did not prevent the decrease in plasma P 4
concentration and the downregulation of mRNA for StAR and 3 HDS in response to a
luteolytic dosage of PGF2 , as occurred in the vehicle-treated group. In addition, blockade of
ENDRA upregulated expression of ppEND1 and ENDRB but did not affect ENDRA transcript
expression (Watanabe et al., 2006).
Administration of ENDRA antagonist by multiple intraluteal injections, delayed for about 2
d the decrease of CL volume and blood flow in the area adjacent to the CL compared with
vehicle-treated cows (Watanabe et al., 2006). The vasocontractive properties of END1 have
been previously reported (Clarke et al., 1989; Ivi et al., 1994; Skovgaard et al., 2008), and the
decrease of blood flow to the ovary at the end of the luteal phase was associated with luteal

106

demise (Wise et al., 1982). Likewise, reduced blood flow implies lower concentrations of
oxygen in the tissues, and hypoxic conditions in the bovine CL decreased P4 production
(Nishimura et al., 2006) and induced apoptosis by upregulating pro-apoptotic factors such as
caspase 3 and BNIP3 (Nishimura et al., 2008).
Interestingly, caspase 3 mRNA expression was significantly greater in vehicle-treated than
antagonist-treated cows at 24 h after PGF2 (Watanabe et al., 2006), indicating that the role of
END1 during luteolysis may be associated with structural rather than functional luteolysis. This
hypothesis is supported by the findings reported by Doerr et al., (2008) that the early
antisteroidogenic actions of PGF2 were independent of mediation by END1, whereas in later
stages of luteolysis END1 was required to effectively induce demise of the CL. In experiment
3, the delay of endogenous luteolysis for more than 5 days in 3 of 12 ewes by blocking
ENDRA did not prevent the upregulation of genes related with apoptosis and structural
luteolysis. Apparently, the elevated concentrations of P4 in the responsive BQ-610-treated
animals exerted a protective effect, most likely by reducing the activity of apoptotic proteins.
The protective and antiapoptotic effect of P4 on luteal function has been widely documented
(Rueda et al., 2000; Goyeneche et al., 2003; Okuda et al., 2004; Nishimura et al., 2008). The
assumption that in this experiment BQ-610 activated ENDRA and upregulated apoptosisrelated genes fits with the concept that actions of END1 during luteolysis are directly
(inhibiting P4 production and stimulating apoptosis) and indirectly (via reduction of luteal
blood flow) associated to structural luteolysis (Watanabe et al., 2006; Doerr et al., 2008;
experiment 3).
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In conclusion, data from serum and luteal P4 and CL weight indicated that PGF2 induced
luteolysis in both vehicle-treated and BQ-610-treated ewes. The pattern of gene expression
further confirmed the luteolytic effect of PGF2 in both treated groups. But, interestingly,
upregulation of genes related to apoptosis and structural luteolysis was greater in BQ-610treated than vehicle-treated ewes, indicating that instead of blocking actions of endogenous
END1, BQ-610 might have stimulated actions ascribed to stimulation of ENDRA by END1
(Watanabe et al., 2006; Doerr et al., 2008). This unexpected finding indicates that BQ-610 or
its combination with a greater concentration of methanol may have activated ENDRA and
therefore, induced over expression of these apoptotic factors. If so, these findings would
confirm that END1 via ENDRA in luteal cells is associated with structural luteolysis as
previously reported (Watanabe et al., 2006; Doerr et al., 2008).

Experiment 3: Effect of chronic administration of an endothelin receptor
type A antagonist on length of estrous cycle and functional characteristics of
the corpus luteum during spontaneous luteolysis in sheep

Materials and methods
General experimental procedure
Twenty one nonpregnant Suffolk ewes with at least one previous estrous cycle of normal
length (15 to 19 days) were used in the experiment, conducted in winter (January-February)
and fall (September-November) of 2008 with ewes from the West Virginia University research
flock. For observation of estrus (12 h intervals) ewes were penned with a vasectomized ram
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bearing a harness with a crayon in the area of the brisket; standing estrus was confirmed by
teasing with another vasectomized ram. On day 9 of the estrous cycle (standing estrus = day 0)
ewes were assigned randomly to receive one of the following treatments: Alzet® mini-osmotic
pump (model 2002; Durect Corporation, Cupertino, CA) loaded with either vehicle (200 L 2:1
methanol:saline solution; n = 9), or 2.5 mg of END receptor A antagonist (n = 12), BQ-610
(Azepane-1-carbonyl-leu-D-Trp(For)-D-Trp-OH), diluted in 200 L of vehicle. The Alzet®
mini-osmotic pumps (Bachem Bioscience Inc, King of Prussia, PA) designed to deliver 0.52 ±
0.02 L/h for approximately 14 days, were kept overnight in sterile 0.9% saline solution at
37 C previous to implantation in the ovary. Thus, the expected delivered dosage was 6.25 g/h
of BQ-610.
Minipumps were implanted surgically as described in experiment 2. Twenty four h after
surgery, ewes were penned with a vasectomized ram bearing a harness with a crayon in the area
of the brisket, and estrous detection was performed as described above. Blood samples were
collected (8 ml) by jugular venipuncture at 6 h intervals from day 11 until estrus or until day 21
of the estrous cycle in ewes that did not return to estrus. Blood samples were refrigerated for 24
h to allow them to clot, and then centrifuged for 20 minutes at 2500 rpm. Serum was collected
and kept at -20° C until radioimmunoassay for P4. Approximately 12 h after estrous detection
or in the afternoon of day 21, ewes were euthanized, the correct position of the pumps and
catheters were verified, and ovaries were collected. All animal procedures were approved by
WVU Institutional Animal Care and Use Committee (ACUC # 05-1205).
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Luteal tissue processing
Ovaries were refrigerated in ice-cold PBS, transported to the lab within 2 to 3 h after
surgery, and each CL was dissected, weighed, sectioned into 5 pieces that were weighed
individually and 3 of them were frozen in liquid nitrogen and stored at -80°C. One piece of
each CL was homogenized in PBS (1 ml/100 mg of tissue), centrifuged, and supernatant stored
at -20 °C, for determination of luteal P4. A second fragment was placed in Bouin’s fixative for
at least 24 h, and processed later to assess cellular morphology and apoptosis.
Bouin’s fixative was removed by rinsing luteal tissue successively in 70% alcohol. Pieces of
tissue were embedded in paraffin and cut into 10 μm sections, then mounted about 8 to 14
sections on each microscope slide. After deparaffinization with xylene and rehydration through
descending grades of alcohol, tissue specimens were stained with the terminal deoxynucleotide
transferase-mediated deoxy-UTP nick labeling method (TUNEL) for detection of apoptotic
cells by immunohistochemistry (APO-BRDU-IHC; Phoenix Flow Systems, San Diego, CA).
Briefly, the procedure was performed as follows: (1) permeabilization of specimen with
proteinase K (20 min at room temperature); (2) inactivation of endogenous peroxidases with
30% H2O2 diluted 1:10 in methanol (5 min at room temperature); (3) equilibration reaction with
1X reaction buffer followed by a labeling reaction in humid chamber (at 37 C for 90 min)
using bromolated deoxyuridine triphosphate nucleotides (Br-dUTP) and the enzyme terminal
deoxynucleotidyl transferase (TdT); in the next reaction (4) an anti-BrdU antibody directly
conjugated to biotin was attached to the Br-dUTP’s (in darkness, for 1-1.5 hours at room
temperature) followed by (5) the attachment of peroxidase-conjugated avidin to the biotin
labeled Br-dUTP’s; finally, (6) a DAB-H2O2-Urea stain reaction was performed to label the
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incorporated Br-dUTP’s. Slides were observed under an Olympus PROVIS AX70 microscope
to identify specific brown color in the cellular nuclei indicative of apoptosis. Three fields-ofview from two different sections, at least 100 μm apart, were evaluated to quantify the number
of apoptotic cells, and to estimate the rate of apoptosis for each treatment.

Assessing gene expression
To corroborate the functional status of the CL, expression of genes involved in progesterone
production or structural luteolysis was determined by quantitative RT-PCR, applying a
transverse-transcription real-time PCR procedure identical to that described in experiment 2. In
addition to tissue from BQ-610 and vehicle ewes, luteal tissue from control ewes (no
minipump; saline injection; day 10-11 of estrous cycle) obtained in experiment 2 was used.
Accession number, sequence, animal source and additional characteristics of each gene primer
are indicated in Table 5.
Radioimmunoassays for progesterone
Concentrations of P4 in serum and luteal tissue were measured in duplicate by RIA as
previously described (Sheffel et al., 1982). Assay sensitivity averaged 0.18 ng/ml, and interand intraassay coefficients of variation were 9.5% and 9.8%, respectively.

Statistical Analysis
Differences in concentrations of serum and luteal P4, luteal weight, length of estrous cycle,
cellular apoptosis and gene expression among treatments were evaluated by one-way analysis
of variance using the General Linear Model (GLM) procedure of SAS (SAS Institute; Cary,
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NC). Differences among means were compared by the LSM procedure of SAS. Data were
expressed as mean ± SEM. Proportions of ewes in which the length of the estrous cycle was
prolonged beyond 20 d were analyzed by Chi-square method of SAS.

Table 5.

Gene

Characteristics of primers used in quantitative real-time RT-PCR

Accession
number

Specie

StAR

NM_001009243

O. aries

3 HSD

NM_174343

PPEND1

Primer sequence

Product
size (bp)

Annel.
Temp.
( C)

Slope
Standard
curve

F: 5’-TGCTGAGTAAAGTGATCCCTGA-3’
R: 5’-AGGACCTTGATCTCCTTGACAC-3’

148

60

-3.631

B. taurus

F: 5’-CCACACCAAAGCTACGATGA-3’
R: 3’-TGTAAATTGGACTGAGCAGGAA-3’

148

60

-3.419

NM_001009810

O. aries

F: 5’-TCTGCAAGTTGTTCCCCTTT-3’
R: 3’-ATCTCAATGGCTGTGACCAAC-3’

148

60

-3.331

ENDAR

NM_001009433

O. aries

F: 5’-TCTGCAAGTTGTTCCCCTTT-3’
R: 3’-ATCTCAATGGCTGTGACCAAC-3’

148

60

-3.208

Bcl-2

DQ152929

O. aries

F: 5’-TGGATGACCGAGTACCTGAA-3’
R: 3’-CAGCCAGGAGAAATCAAACAG-3’

120

60

-3.314

Bax

AF163774

O. aries

F: 5’-GAAGCGCATTGGAGATGAA-3’
R: 3’-AAGTAGAAAAGGGCGACAACC-3’

159

60

-3.286

Fas-R

NM_001123003

O. aries

F: 5’-CGGAAGAATGGTATGGAGGA-3’
R: 3’-TGCAAGAGCTTTTGGGAGAT-3’

162

60

-3.375

Caspase 3

AF068837

O. aries

F: 5’-GGATTATCCTGAAATGGGTTTATG-3’
R: 3’-GATCGTTTTTAATCCTGACTTCGT-3’

155

60

-3.266

TIMP-1

NM_001009319

O. aries

F: 5’-CCAGACATCCGATTCATCTACA-3’
R: 3’-GCAGAACTCATGCTGTTCCA-3’

167

60

-3.558

GAPDH

AF030943

O. aries

F: 5’-TCTCAAGGGCATTCTAGGCTAC-3’
R: 3’-TGTAGCCGAATTCATTGTCG-3’

155

60

-3.254
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Results

Length of the estrous cycle and corpus luteum morphology
Three of 12 (25%) ewes treated with BQ-610 (in the successive named responsive BQ-610treated ewes) did not show estrus before d 21 compared to 0 of 9 (0%) vehicle-treated ewes (P
= 0.33); the remaining nine BQ-610 ewes had cycles averaging 15.3 ± 0.2 d. Estrous cycles in
the responsive BQ-610-treated ewes were at least 5.5 d longer than in vehicle-treated ewes (>
21 d vs. 15.5 ± 0.2 d, respectively; P<0.0001). Differences in size, color and weight of the CL
were important aspects to assess the effect of blocking ENDRA (Fig. 18 and 19) during
spontaneous luteolysis in sheep. Corpora lutea from the three responsive BQ-treated ewes were
approximately 1.6 times heavier and had 2.4 times more volume than CL from vehicle-treated
ewes. In addition, CL from responsive BQ-610-treated ewes were pink while CL from control
ewes had pallid color.

Serum and luteal progesterone
Serum concentrations of P4 in the three responsive BQ-610-treated ewes remained above 1.5
ng/ml through d 21 of the cycle (P < 0.01). In this group, P4 concentration averaged 2.97 ± 0.08
ng/ml from d 11 through d 16 and decreased to 1.91 ± 0.10 ng/ml from d 17 to d 21 of the cycle
(P<0.0001). In non-responsive BQ-610-treated ewes, initial concentration of P4 was 1.75 ng/ml
and decreased gradually to minimal values by d 15 of the estrous cycle. In vehicle-treated ewes,
P4 concentration remained above 2 ng/ml from d 11 to d 13 and then decreased progressively
until d 15 of the estrous cycle (Fig 20). Luteal content of P4 was 16 fold greater in responsive
BQ-610-treated than in vehicle-treated ewes (Fig 21).
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Cellular morphology
Luteal tissue in responsive BQ-610-treated ewes appeared normal with 53.3 ± 5.8% of
apoptotic cells, whereas luteal tissue in vehicle-treated ewes was markedly disorganized and in
an advanced stage of structural regression (Fig 22). In this tissue it was not possible to detect
apoptotic cells.

Gene expression
To examine functional status of the CL, expression of genes involved in progesterone
production or structural luteolysis was determined in ewes treated with BQ-610 or vehicle and
in mid-phase CL (n = 3 per group; Table 6). Although StAR mRNA expression was about 3 to
5 times greater in mid-phase CL and responsive BQ-610-treated ewes than in vehicle-treated
ewes, differences were not significant. Also, luteal tissue from responsive BQ-610-treated ewes
and mid-phase CL had greater expression of transcript for 3 HSD and TIMP-1 than vehicletreated group. In regressed CL, both ppEND1 and ENDRA mRNA expression were greater (P
≤ 0.05) than mid-phase CL or responsive BQ-610-treated CL. The expression of Bcl-2 was not
affected by treatments; nevertheless, it was 3.9 and 1.7 times greater in mid-phase CL than in
CL from responsive BQ-610-treated or vehicle-treated ewes, respectively. Bax mRNA
expression was significantly lower in responsive BQ-610-treated and mid-phase CL than in the
vehicle-treated group. The Bcl-2:Bax ratios were 2.25, 0.69 and 0.64 for mid-phase CL,
responsive BQ-610-treated and vehicle-treated ewes, respectively (P > 0.05). There was no
significant effect of treatment on the expression of Fas-R. In contrast, mid-phase CL had lower
expression of caspase 3 than either BQ-610-treated or vehicle-treated CL.
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BQ-610

Vehicle

Figure 18. Representative picture of macroscopic characteristics of corpora lutea collected 12 h
after onset of estrus in vehicle-treated ewes, or on the afternoon of d 21 in BQ-610-treated
ewes. Corpus luteum from vehicle-treated ewe was smaller and pallid with respect to BQ-610
treated ewes.
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Figure 19. Effect of chronic administration of either BQ-610 (n = 3) or vehicle (n = 9) during
spontaneous luteolysis on corpus luteum weight in sheep. Bars represent mean weight (g) ±
SEM of corpora lutea collected 12 h after onset of estrus in vehicle-treated ewes, or on the
afternoon of d 21 in BQ-610-treated ewes. Values are statistically different (a,bP<0.002).
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Figure 20. Effect of chronic administration of either BQ-610 or vehicle during spontaneous
luteolysis on serum concentrations of progesterone in sheep. Blood samples were collected by
jugular venipuncture at 6 h intervals from d 11 until estrus or until d 21 of the estrous cycle in
ewes that did not return to estrus. Data points represent mean (± SEM) serum progesterone
(ng/ml) per time of sampling for responsive BQ-610-treated (n = 3; ○), non-responsive BQ610-treated (n = 9; ▲) and vehicle-treatted (n = 9; ■) ewes. Values are statistically different
between treatments at designated time point ( P<0.01).
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Figure 21. Effect of chronic administration of either BQ-610 (n = 3) or vehicle (n = 9) during
expected spontaneous luteolysis on luteal content of progesterone in sheep. Bars represent
mean (± SEM) concentrations ( g/g) of progesterone in homogenized corpus luteum extracts.
Values are statistically different (a,bP<0.0001).
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Figure 22. Representative examples of cellular morphology and apoptosis in luteal tissue after
chronic administration of either (A) BQ-610 (n = 3) or vehicle (n = 9) during spontaneous
luteolysis in sheep. In responsive BQ-610-treated ewes luteal tissue appeared normal with 53.3
± 5.8% of apoptotic cells, whereas it was markedly disorganized and in an advanced stage of
structural regression in vehicle-treated ewes.

Table 6. Effect of chronic administration of either BQ-610 or vehicle during expected
spontaneous luteolysis on expression of genes involved in progesterone production or structural
luteolysis in sheep.
Level of

Treatments
Gene

significance

Mid-phase CL

BQ-610

Vehicle

StAR

1.80 ± 1.15 a

2.49 ± 1.15 a

0.47 ± 1.15 a

3 HSD

0.55 ± 0.08 a

1.22 ± 0.08 b

0.01 ± 0.08 c

a,b,c

P < 0.01

TIMP-1

1.06 ± 0.11 a

0.81 ± 0.11 a

0.28 ± 0.11 b

a,b

P < 0.01

b

c

a,c

P < 0.04; b,c P < 0.01

a,b

P < 0.01

a,b

ppEND1

0.69 ± 0.27

0.97 ± 0.27

ENDRA

0.40 ± 0.39 a

0.56 ± 0.39 a

3.24 ± 0.48 b

Bcl-2

2.90 ± 0.86 a

0.76 ± 0.86 a

1.67 ± 1.48 a

a

a

b

1.26 ± 0.23

1.96 ± 0.27

Bax

1.29 ± 0.23

2.61 ± 0.30

Fas-R

0.77 ± 0.18 a

1.16 ± 0.18 a

0.95 ± 0.32 a

Caspase 3

1.47 ± 0.53 a

3.16 ± 0.53 b,c

3.91 ± 0.65 c

P > 0.05

P > 0.05
a,b

P < 0.02

P > 0.05
a,b

P < 0.08; a,c P < 0.04

Three samples per treatment. Data are expressed as mean ± SEM.
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Discussion
In this study, blocking of ENDRA prevented endogenous luteolysis for more than 5 days in
only 25% of 12 BQ-treated ewes, compared with none of the 9 ewes treated with vehicle. Data
on macroscopic characteristics of the CL, serum and luteal concentration of P4 and gene
expression supported this observation, and confirmed previously published in vivo studies in
ruminants about the role of END1 in mediating luteolytic actions of PGF2 (Hinckley and
Milvae, 2001; Doerr et al., 2008; Keator et al., 2008). Although intraluteal injection of BQ-123
(an ENDRA antagonist) did not reverse completely the luteolytic effect of PGF2 ,
intramuscular injection of both END1 (100

g) and PGF2 (7.5 mg) effectively reduced P4

concentrations by 48 h post-treatment, and shortened the length of the cycle (Hinckley and
Milvae, 2001).
A large body of evidence indicates that END1, a 21-amino acid peptide that regulates
vascular function in different tissues, participates in the luteolytic cascade initiated by uterine
PGF2 at the end of the luteal phase. In ruminants, a greater ppEND1 and ENDRA mRNA
expression was observed at the end of estrous cycle near the time of luteolysis (Mamluk et al.,
1999; Girsh et al., 1996b) and after exogenous PGF2 during mid-luteal phase (Levy et al.,
2000; Hinckley and Milvae, 2001; Choudhary et al., 2004). In addition, END1 reduced both
basal and LH-stimulated production of P4 and this anti-steroidogenic effect was reversed by the
addition of a selective ENDRA antagonist (Girsh et al., 1996a; Hinckley and Milvae, 2001;
Doerr et al., 2008). In concordance with the previous reports, expression of ppEND1 and
ENDRA mRNA in vehicle-treated ewes was greater by the time of estrus than in mid-cycle CL
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and responsive BQ-treated CL, which further supports the relevance of the END system in
mediating luteal regression in ruminants.
Different methods for administration or delivery of ENDRA antagonists in vivo have been
applied to test the role of END1 in luteal regression. Apparently, intraluteal injection of a
selective ENDRA antagonist (BQ-610 or LU-13522) was ineffective to reverse the decline of
P4 production induced by PGF2 in cows (Watanabe et al., 2006; Keator et al., 2008). In
contrast, intrauterine infusions of 500 g of BQ-610 every 12 h from d 16 through 18 of the
estrous cycle delayed spontaneous luteolysis in heifers for about 2 days. Moreover, BQ-610
chronically delivered into the CL by means of an osmotic mini-pump effectively reversed the
luteolytic effect of PGF2 12 h after its administration, allowing concentrations of serum P4
attain similar values to the control group by 48 h after PGF2 (Doerr et al., 2008). Apparently, a
direct action of PGF2 decreased serum P4 during early luteolysis, whereas END1 was required
in later stages, indicating that END1 might participate in structural more than functional
luteolysis.
This study followed the same experimental approach utilized by Doerr et al. (2008), but the
greater dosage of BQ-610 prevented spontaneous luteolysis and lengthened the estrous cycle in
only 3 of 12 (25%) ewes. Endogenous PGF2 starts to be secreted from the uterus in increased
amounts around day 11 to 13 of the sheep estrous cycle (Silvia et al., 1984; Zarco et al. 1988b).
The sustained delivery of BQ-610 for more than 8 days after the beginning of endogenous
PGF2 secretion effectively blocked endogenous END1 in those 3 ewes.
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Different methods to assess the functional features in luteal tissue treated with BQ-610 or
vehicle were used in this experiment: macroscopic and histological characteristic, steroidogenic
capacity and expression of genes related to P4 synthesis and structural luteolysis. Thus, data
from this experiment evaluated both functional and structural aspects of luteolysis.
Functional regression of the CL is characterized by a rapid decrease of P 4 production by
luteal steroidogenic cells coincident with a transient increased followed by a diminution of
blood flow to the CL (Niswender et al., 1975; Nett et al., 1976). During this short period
synthesis and secretion of P4 is inhibited, mostly by interrupting mobilization of cholesterol
throughout the cytoplasm and outer mitochondrial membrane (Murdoch, 1996; Juengel et al.,
2000; Tsai et al., 2001). Thus, lacking the substrate to synthesize P4, steroidogenic enzyme
activity declines and less P4 is secreted by large and small luteal cells. Although differences in
mRNA expression for StAR were not significant, probably due to the large variation among
samples (and few samples per treatment), values from responsive BQ-610 and mid-cycle CL
were 5.3 and 3.8 times greater than in CL of vehicle-treated ewes. Transcript concentration for
3 HSD was greater in responsive BQ-treated and mid-cycle CL than in vehicle-treated CL.
Hence, there were greater serum and luteal concentrations of P4 in responsive BQ-610-treated
ewes. These data, together with similar expression values for StAR and 3 HDS transcripts in
mid-cycle CL and responsive BQ-610-treated CL, strongly indicate the cellular metabolic
machinery to synthesize P4 by luteal steroidogenic cells was completely operative in responsive
BQ-610-treated ewes at day 21 of the estrous cycle.
In vehicle-treated ewes, luteal weight 12 h after estrus was 0.39 ± 0.03 g, about 37% lighter
than CL from responsive BQ-610-treated ewes (0.62 ± 0.05 g) on day 21 of the cycle.
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Moreover, judged by color, CL from the three responsive BQ-610-treated ewes were larger and
appeared healthier than those collected from vehicle-treated ewes. As seen by Braden et al.
(1988), Juengel et al. (1996) and Tsai et al. (1998a), CL weight significantly decreased 30 to
50% by 24 to 36 h after exogenous PGF2 in sheep. The decrease in CL weight represents clear
evidence that luteal regression has been already induced and implies death and phagocytosis of
cellular components, mostly endothelial and steroidogenic luteal cells, and degradation of
cellular matrix as well (Braden et al., 1988; Sawyer et al., 1990; Pate and Keyes, 2001; Smith et
al., 2002). However, morphological alterations were not evident until 24 to 36 h after initial
exposure to PGF2 (Sawyer et al., 1990).
The expression pattern of genes related with structural luteolysis appeared to be less clear.
Although the expression of Bax mRNA was significantly lower in BQ-610 and mid-cycle CL
compared with vehicle CL, Bcl-2 and Fas-R expression did not differ among treatments.
Moreover, the ratio between Bcl-2 and Bax mRNA was around 3.5 times greater in mid-cycle
CL than in CL of either responsive BQ-610-treated or vehicle-treated ewes. Bcl-2 and Bax are
proteins that prevent and promote apoptosis, respectively, and their relative abundance at a
specific luteal stage could favor or oppose apoptosis (Tilly et al., 1996). While Bcl-2 prevents
apoptosis by regulating mechanisms related to Ca2+ homeostasis and oxidative stress (Kane et
al., 1993; Pinton et al., 2001), Bax promotes apoptosis by antagonizing anti-apoptotic actions of
Bcl-2 (Nutt et al., 2002; Chami et al., 2004). Concentrations of Bax but not Bcl-2 mRNA and
protein increased after PGF2 -induced luteolysis in ruminants (Rueda et al., 1997; Yadav et al.,
2005); this change was reflected in Bax/Bcl-2 ratio for both mRNA and protein that was
significantly greater at 4 h than immediately before PGF2 injection (Yadav et al., 2005). In
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addition, both protein and activity of caspases 3 and 9 increased after PGF2 (Yadav et al.,
2005). Thus, it is evident that PGF2 upregulates proteins that induce apoptosis in luteal cells.
Interestingly, PGF2 significantly increased the expression of caspase 3 in vehicle-treated
animals as well as in BQ-610-treated ewes compared with mid-cycle CL. This finding agrees
with the fact that luteal tissue from the three responsive BQ-610-treated ewes had 53.3 ± 5.8%
of apoptotic cells and that serum concentrations of P4 in this group were about 36% lower from
day 16 through 21 of the cycle compared with the previous days. Nevertheless, luteal
concentrations of P4 were elevated, indicating that CL from responsive BQ-610-treated ewes
were completely active. To provide a physiological explanation for this discrepancy it is
important to consider two aspects. First, BQ-610 blocks ENDRA but does not prevent PGF2
from binding to its receptor. In pregnant ewes (Nett et al., 1976; Lewis et al., 1977; Vincent and
Inskeep, 1986), secretion of uterine PGF2 around d 21 post estrus is still elevated to mid range,
and consequently PGF2 may be inducing intracellular changes at mRNA or even protein levels
by different pathways than END1 utilizes to mediate PGF2 -induced luteolysis. Second, antiapoptotic and protective effects of P4 on luteal function have been documented (Rueda et al.,
2000; Goyeneche et al., 2003; Okuda et al., 2004; Nishimura et al., 2008). Thus, elevated
concentrations of P4 in BQ-610-treted ewes may counteract the luteolytic actions of PGF2 by
inhibiting or reducing activity of pro-apoptotic factors.
In summary, chronic delivery of BQ-610 into the CL during mid- to late-luteal phase
prevented natural luteolysis and prolonged the estrous cycle for more than 5 days in only 3 of
12 ewes. Macroscopic and functional characteristics of those responsive BQ-610-treated CL
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were similar to mid-phase CL. Overall this study indicates that END1 might plays mediatory
role during spontaneous luteolysis in the ewe.

General discussion
Immediately after the LH surge, the pattern of steroid secretion from the preovulatory
follicle in known to change abruptly (Murdoch and Dunn, 1982; Fortune and Hansel, 1985)
from estrogen to P4 dominance. It was postulated that END1, a 21-amino acid peptide with
recognized anti-steroidogenic properties, might modulate steroid production preventing
premature luteinization of granulosal and thecal cells (Tedeschi et al., 1992; Flores, 2000). In
experiment 1, the protocol designed for collection of large preovulatory follicles was successful
and granulosal cells from 20 of 28 follicles were cultured and challenged to 10 different
treatments, resultant from combinations of LH, END1, ENDRA and ENDRB. However, neither
E2 nor P4 accumulation in the culture media was affected by treatments after 24 h of incubation.
To interpret these findings, it is important consider three aspects. First, granulosal cells from
large preovulatory follicles were exposed to greater concentrations of endogenous LH for
several hours and thereafter to supplemented LH during in vitro incubation. Second, removing
granulosal cells in this particular follicular developmental stage and culturing them in a serum
free culture medium may have triggered their luteinization; as judged by greater concentrations
of P4 than E2 in the culture media. Third, as occurs during luteolysis, END1 may act in
conjunction with other locally produced ovarian mediators regulating follicular steroid
production, and therefore, the absence of these factors in the culture media may have allowed
luteinization of granulosal cells. Apparently, a more appropriate culture system would be
necessary to test the role of END1 in steroid production by granulosal cells in large
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preovulatory follicles in sheep. Alternatively, collection of preovulatory follicles earlier, and
incorporation of FSH and serum in culture media, may allow elucidation of the role of END1 in
modulating steroid production by granulosal cells prior to ovulation in sheep. In earlier in vitro
studies, FSH-simulated P4 production by granulosal cells collected from small- and mediumsized swine follicles was inhibited by END1 (Kamada et al., 1993; Flores et al., 1992; 1999).
However, END1 also reduced production of LH-stimulated P4 by granulosal cells isolated from
medium-sized follicles in pigs (Iwai et al., 1991).

A large body of evidence indicates that END1 plays an important role in luteal regression
(Girsh et al., 1996a; 1996b; Miyamoto et al., 1997; Ohtani et al., 1998; Hinckley and Milvae,
2001; Doerr et al., 2008; Keator et al., 2008). In experiment 2, the role of END1 in structural
luteolysis was not elucidated, as judged by concentrations of serum and luteal P4 and CL
weight, as well as the over expression of the genes 3 -HSD and caspases 3 and 8 in BQ-610treated compared to vehicle-treated luteal tissue. Apparently, the increased rate of delivery of
BQ-610 into the CL in combination with greater concentrations of methanol and individual
animal features might have interfered with the binding ability or modified the molecular
structure of BQ-610. Also, blockade of ENDRA by BQ-610 may have allowed END1 to bind
ENDRB and trigger downstream signaling through this receptor contributing to an increase in
the luteolytic signal. In the cow, ENDRB mRNA expression was greater at the end of luteal
phase, during luteal regression (Berisha et al., 2002) and after an exogenous dose of PGF2
(Schams et al., 2003; Watanabe et al., 2006) indicating a putative role of this receptor during
luteolysis.

However, concentrations of ENDRB mRNA in luteal cells were minimal during

PGF2 -induced luteolysis in sheep (Doerr et al., 2008). In addition, the luteolytic effect of
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PGF2 was reversed by blocking ENDRA but not ENDRB (Doerr et al., 2008) in the ovine CL.
The ENDRB is more abundant in vascular endothelial cells and its activation by END1
stimulated releases of NO (Ishiguro et al., 2001; Hirata et al., 1993), which is an important
inhibitor of luteal P4 production. It was proposed that NO acts as a local mediator of PGF2 induced regression in bovine CL (Jaroszewski and Hansel, 2000; Jaroszewski et al., 2003).
Thus, the greater availability of endogenous END1 during induced and spontaneous luteolysis
in experiments 2 and 3, respectively, as well as the hypothetical increased concentrations of
ENDRB at that time, may have induced direct and/or indirect luteolytic signals that caused over
expression of pro-apoptotic factors in those animals in which luteolysis was not prevented.

Under the experimental conditions described above, blockage of ENDRA in experiments 1
and 2 prevented luteolysis in only 10 and 25% of the treated animals, compared to 100% in the
earlier study by Doerr et al. (2008). Pharmacological dosage of PGF2 in experiment 1 versus
physiological secretion of uterine PGF2 in experiment 2 may account for the 15 percentage
point difference. In addition to the increased concentrations of methanol in the vehicle,
placement of the catheter into the CL may have disrupted the functional capacity of the CL
treated with BQ-610. Therefore, secretion of lower amounts of progesterone was unable to
counteract the direct and indirect luteolytic actions of PGF2 ., and as a consequence, luteolysis
was not prevented. Perhaps lower luteal damage and greater steroidogenic capacity of the CL in
those BQ-610 responsive animals during natural luteolysis might explain why BQ-610
effectively prevented luteolysis in 25% of the treated animals compared with only 10% of the
animals in experiment 2, in which luteolysis was induced by a pharmacological dose of PGF2 .
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